23-11-2018

10:00 - 11:30 Type: Opening session Hall 406

Title: Opening & Keynote
Chair: Josep Tabernero, ES

10:00 - 10:10 Opening

10:10 - 10:15 Welcome address by the ESMO President

J. Tabernero, ES

10:15 - 10:25 Welcome address by the Senior Minister of State in the Ministry of Health and
the Ministry of Transport
L.P. Min, SG

10:25 - 10:30 Welcome address by the President of the Singapore Society of Oncology
S.P. Choo, SG

10:30 - 10:50 Presentation of Token of Appreciation to the Endorsing National Oncology

Societies
J. Tabernero, ES

10:50 - 11:00 Scientific address

T.S.K. Mok1, S. Banerjee2; 1HK, 2GB

11:00 - 11:30 ESMO Presidential Address

J. Tabernero, ES

11:45 - 12:30 Type: Challenge Your Expert session Hall 405

Title: Treatment of node positive bladder
Chair: Ji Youl Lee, KR; Ben Tran, AU

11:45 - 12:05 Treatment of node positive bladder

J.Y. Lee1, B. Tran2; 1KR, 2AU

12:05 - 12:30 Discussion led by

J.Y. Lee1, B. Tran2; 1KR, 2AU

Last update: 09-11-2018 [Link]pm

11:45 - 12:30 Type: Challenge Your Expert session Hall
Title: Treatment for stage IIb cervical cancer: Surgery or 404
chemoradiation?
Chair: Andres Maria Poveda Velasco, ES

11:45 - 12:00 Treatment for stage IIb cervical cancer: Surgery or chemoradiation?
J.-W. Kim, KR

12:00 - 12:30 Discussion led by

A.M. Poveda Velasco, ES

11:45 - 12:30 Type: Challenge Your Expert session Hall 407

Title: Management of early breast cancer in young women
Chair: Binghe Xu, CN

11:45 - 12:00 Management of early breast cancer in young women

L. Del Mastro, IT

12:00 - 12:30 Discussion led by

B. Xu, CN

11:45 - 12:30 Type: Challenge Your Expert session Room 324

Title: Skull base tumours
Chair: Lisa Licitra, IT

11:45 - 12:00 Skull base tumours

P. Pai, IN

12:00 - 12:30 Discussion led by

L. Licitra, IT

11:45 - 12:30 Type: Challenge Your Expert session Room

Title: What is the optimal first-line chemotherapy for advanced soft- 311
tissue sarcoma?
Chair: Herbert Loong, HK

11:45 - 12:00 What is the optimal first-line chemotherapy for advanced soft-tissue sarcoma?
A. Le Cesne, CEDEX/FR

12:00 - 12:30 Discussion led by

H. Loong, HK

12:45 - 14:15 Type: Industry Satellite Symposium Hall 405

Title: Industry Satellite Symposium

Last update: 09-11-2018 [Link]pm

12:45 - 14:15 Type: Industry Satellite Symposium Hall 404
Title: Industry Satellite Symposium
12:45 - 14:15 Type: Industry Satellite Symposium Hall 407
Title: Industry Satellite Symposium
12:45 - 14:15 Type: Industry Satellite Symposium Room 324
Title: Industry Satellite Symposium
12:45 - 14:15 Type: ESMO Colloquium Room
Title: ESMO COLLOQUIUM - Immunotherapy of lung cancer: Alone or 311
in combination?

12:45 - 12:50 Introduction

T. Mitsudomi, JP

12:50 - 13:10 1st line immunotherapy options for patients without an oncogene driver
R. Soo, SG

13:10 - 13:30 What is the biological rationale for combining chemotherapy with immune
checkpoints inhibitors?
M. Garassino, IT

13:30 - 13:50 Are ICPs better as single agent, doublet ICPs or combined with Chemo +/- anti-
angiogenics?
S. Peters, CH

13:50 - 14:10 What’s new in the guidelines for immune therapy of metastatic NSCLC?
D. Planchard, FR

14:10 - 14:15 Conclusions

T. Mitsudomi, JP

Last update: 09-11-2018 [Link]pm

14:30 - 16:00 Type: Educational session Hall 405
Title: Controversies in lung cancer immuno-oncology
Chair: Raffaele Califano, GB; Ross Soo, SG

14:30 - 14:55 Immuno checkpoint blockade for advanced NSCLC: What is the role in the
elderly and patients with PS2?
R. Califano, GB

14:55 - 15:20 Immuno checkpoint blockade for oncogene-addicted NSCLC

R. Soo, SG

15:20 - 15:45 Immuno checkpoint blockade in patients with brain metastases

S. Ekman, SE

15:45 - 16:00 Discussion

14:30 - 16:00 Type: Educational session Hall

Title: Immunotherapy in GI cancers: Current status & future 404
perspectives
Chair: Claus-Henning Koehne, DE; Yung-Jue Bang, KR

14:30 - 14:45 Biomarkers for immunotherapy

B. Ma, HK

14:45 - 15:05 Immunotherapy in gastric cancer

Y.-J. Bang, KR

15:05 - 15:25 Immunotherapy in hepatocellular carcinoma (HCC)

T. Okusaka, JP

15:25 - 15:45 Immunotherapy in other GI cancers

C.-H. Koehne, DE

15:45 - 16:00 Discussion

Last update: 09-11-2018 [Link]pm

14:30 - 16:00 Type: Proffered Paper session Hall 407
Title: Proffered Paper session 1

14:30 - 14:42 39O - Ribociclib (RIB) + non-steroidal aromatase inhibitor (NSAI) + goserelin in
premenopausal Asian women with hormone-receptor-positive (HR+), HER2-
negative (HER2–) advanced breast cancer (ABC): Results from the randomized
Phase III MONALEESA-7 study

S.-A. Im1, J. Sohn1, D. Tripathy2, L. Chow3, K.S. Lee1, K.H. Jung1, G. Babu4, Y.-H. Im1, N.
El Saghir5, M.-C. Liu6, I. Diaz-Padilla7, J. Alam8, O. Kong8, M. Miller8, Y.-S. Lu6; 1KR,
2TX/US, 3HK, 4IN, 5LB, 6TW, 7CH, 8NJ/US

14:42 - 14:52 Invited discussant

M. Toi, JP

14:52 - 15:04 69O - Larotrectinib efficacy and safety in TRK fusion cancer: an expanded
clinical dataset showing consistency in an age and tumor agnostic approach

D.S.W. Tan1, U. Lassen2, C. Albert3, S. Kummar4, C. van Tilburg5, S. Dubois6, B.

Geoerger7, L. Mascarenhas8, N. Federman8, A. Basu-Mallick9, F. Doz7, J. Berlin10, D.-Y.
Oh11, S. Bielack5, R. McDermott12, S. Cruickshank8, N. Ku8, M. Cox8, A. Drilon13, D.
Hong14; 1SG, 2DK, 3WA/US, 4US, 5DE, 6MA/US, 7FR, 8CA/US, 9PA/US, 10TN/US, 11KR,
12Belgard Square North/IE, 13NY/US, 14TX/US

15:04 - 15:16 LBA4 - Efficacy and safety of entrectinib in patients with NTRK fusion-positive
tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001

G.D. Demetri1, L. Paz-Ares2, A. Farago3, S.V. Liu3, S. Chawla4, D. Tosi3, E. Kim5, C.

Blakely4, J. Krauss6, D. Sigal4, L. Bazhenova4, T. John7, B. Besse8, J. Wolf9, T. Seto10, E.
Chow-Maneval4, P. Multani4, A. Johnson4, B. Simmons3, R. Doebele11; 1GB, 2ES, 3US,
4CA/US, 5NC/US, 6MI/US, 7AU, 8CEDEX/FR, 9DE, 10Fukuoka/JP, 11CO/US

15:16 - 15:31 Invited discussant

T. Yap, Surrey/US

15:31 - 15:43 252O - MMR deficiency(d) in an unselected cohort of endometrial cancer (EC)
patients, the Royal Marsden experience
C. Orbegoso Aguilar, K. Vroobel, A. Attygalle, S. Lalondrelle, A. Taylor, M. Nobbenhuis, S.
Banerjee, A. George; GB

15:43 - 15:53 Invited discussant

C. Scott, AU

Last update: 09-11-2018 [Link]pm

14:30 - 16:00 Type: Special Session Room 324
Title: Skin toxicity
Chair: Carsten Bokemeyer, DE

14:30 - 14:35 Introduction

C. Bokemeyer, DE

14:35 - 14:55 Hair loss and management

F. Boyle, AU

14:55 - 15:15 EGFR associated skin toxicities

C. Bokemeyer, DE

15:15 - 15:35 Immuno-related skin reactions

15:35 - 15:55 Hand-foot syndrome

Y.S. Yap, SG

15:55 - 16:00 Conclusion

14:30 - 16:00 Type: Special Session Room 311

Title: Controversial cases of melanomas and sarcomas
Chair: Axel Le Cesne, FR; Akira Kawai, JP; Richard Quek, SG

14:30 - 14:35 Presentation of case/condition

A. Le Cesne, CEDEX/FR

14:35 - 14:55 A 32-year old woman presenting with a large right thigh mass (high risk synovial
sarcoma)
A. Kawai, JP

14:55 - 15:15 A 32-year old man presenting with gastrointestinal bleeding (intra-abdominal
clear cell sarcoma)
A. Le Cesne, CEDEX/FR

15:15 - 15:35 A 32-years old man with an acral lentiginous melanoma of the big toe with
popliteal lymph node involvement
R. Quek, SG

15:35 - 16:00 General discussion

Last update: 09-11-2018 [Link]pm

14:30 - 16:00 Type: Educational session Room
Title: The challenges of cancer care in low and middle-income 310
countries
Chair: Soe Aung, MM

14:30 - 14:55 Education and training in low and middle-income countries: How can ESMO
foster regional collaboration among Asian regional institutions?
K. Sharma, IN

14:55 - 15:20 How to build capacity to perform clinical trials and cancer research in LMICs
B. Gyawali, Aichi/US

15:20 - 15:45 Strategies for managing cancer treatment and palliative care with limited
resources
G.S. Bhattacharyya, West Bengal/IN

15:45 - 16:00 General discussion

16:00 - 16:30 Type: Young Oncologist session Exhibition area

Title: Meet your mentor
16:30 - 18:00 Type: Multidisciplinary tumour board Hall 405
Title: Recurrent cervical cancer
Chair: Keiichi Fujiwara, JP; Jae-Weon Kim, KR

16:30 - 16:40 Presentation of case of recurrent cervical cancer

J.-W. Kim, KR

16:40 - 17:00 Prognostic and predictive factors including human papillomavirus (HPV)
H.Y.-S. Ngan, HK

17:00 - 17:20 Surgical considerations

M.-C. Lim, KR

17:20 - 17:40 Advances in systemic therapy

A. Oaknin, ES

17:40 - 18:00 General discussion and conclusions

K. Fujiwara, JP

Last update: 09-11-2018 [Link]pm

16:30 - 18:00 Type: ESMO Colloquium Hall 404
Title: ESMO COLLOQUIUM - Oncology biosimilars in Asia

16:30 - 16:35 Introduction

J. Tabernero, ES

16:35 - 16:45 Existing challenges for uptake of oncology biosimilars in Asia

J. Tabernero, ES

16:45 - 17:00 ESMO survey on biosimilars in oncology - results

M. Vyas, BE

17:00 - 17:15 India: Tackling the rising demand for medicines with locally developed
biosimilars
G.S. Bhattacharyya, West Bengal/IN

17:15 - 17:30 One year on – state of play in the APAC region on oncology biosimilars
S. Magaz, SG

17:30 - 17:50 Panel Discussion with industry representatives

17:50 - 17:55 Conclusions

J. Tabernero, ES

Last update: 09-11-2018 [Link]pm

16:30 - 18:00 Type: Proffered Paper session Hall 407
Title: Proffered Paper session 2

16:30 - 16:45 LBA7 - Afatinib followed by osimertinib in patients with EGFR mutation-positive
advanced NSCLC: A real-world study (GioTag)

M. Hochmair1, A. Morabito2, D. Hao3, C.-T. Yang 4, R. Soo5, J. Yang4, R. Gucalp6, B.

Halmos6, L. Wang4, A. Golembesky7, A. Märten7, T. Cufer8; 1AT, 2IT, 3AB/CA, 4TW, 5SG,
6AL/US, 7DE, 8SI

16:45 - 17:00 LBA8 - Mechanisms of acquired resistance to first-line osimertinib: Preliminary

data from the phase III FLAURA study

B.C. Cho1, Y. Cheng2, C. Zhou3, Y. Ohe4, F. Imamura4, M.-C. Lin5, M. Majem6, R. Shah7,
Y. Rukazenkov8, A. Todd8, A. Markovets9, C. Barrett9, J. Chmielecki9, J. Gray10, S.
Ramalingam11; 1KR, 2Jilin/CN, 3CN, 4JP, 5TW, 6ES, 7Kent/GB, 8GB, 9ME/US, 10FL/US,
11US

17:00 - 17:15 Invited discussant

S. Ekman, SE

17:15 - 17:30 LBA9 - IMpower150: An exploratory analysis of efficacy outcomes in patients

with EGFR mutations

T.S.K. Mok1, M. Socinski2, M. Reck3, R. Jotte2, D. Lim4, F. Cappuzzo5, F.J. Orlandi6, D.

Stroyakovskiy7, N. Nogami8, D. Rodríguez-Abreu9, D. Moro-Siblot10, C. Thomas11, F.
Barlesi12, G. Finley13, A. Lee14, G. Shankar2, W. Yu2, M. Kowanetz2, W. Lin2, M. Nishio8;
1HK, 2US, 3DE, 4SG, 5IT, 6CL, 7Krasnogorski District/RU, 8JP, 9ES, 10FR, 11ME/US,
12CEDEX 20/FR, 13PA/US, 14CA/US

17:30 - 17:40 Invited discussant

S. Lu, CN

17:40 - 17:55 547O - Stereotactic Ablative Radiotherapy for oligometastatic cancers: Efficacy
and Toxicity Results from the randomized SABR-COMET Trial

S. Senan1, R. Olson2, S. Harrow3, S. Gaede4, A. Louie4, C. Haasbeek1, L. Mulroy5, M.

Lock4, G. Rodrigues4, B. Yaremko4, D. Schellenberg5, B. Ahmad4, G. Griffioen1, S.
Senthi6, M. Liu7, K. Moore3, S. Currie3, G. Bauman4, A. Warner4, D. Palma4; 1NL,
2BC/CA, 3GB, 4ON/CA, 5AB/CA, 6ACT/AU, 7CA

17:55 - 18:05 Invited discussant

M.L.K. Chua, SG

Last update: 09-11-2018 [Link]pm

16:30 - 18:00 Type: Educational session Room 324
Title: Rational development of immuno-oncology combinations
Chair: Daniel Shao Weng Tan, SG

16:30 - 16:55 Non-clinical models (including immunoavatars) for development of immuno-

oncology combinations
R. Stripecke, DE

16:55 - 17:20 Lessons learned from immuno-oncology combinations in the clinic

T. Yap, Surrey/US

17:20 - 17:45 Clinical trial designs, biomarkers and endpoints for immuno-oncology
combinations
S.-B. Kim, KR

17:45 - 18:00 Cancer evolution and immuno escape

N. McGranahan, GB

16:30 - 18:00 Type: Multidisciplinary tumour board Room 311

Title: Oligometastatic prostate cancer
Chair: Ravindran Kanesvaran, SG; Shigeo Horie, JP; Ji Youl Lee, KR; Yuji Miura, JP

16:30 - 16:35 Presentation of case/condition

S. Horie, JP

16:35 - 16:55 Cutting edge science of oligometastatic

R. Kanesvaran, SG

16:55 - 17:15 Role of surgery in oligometastatic prostate cancer

J.Y. Lee, KR

17:15 - 17:35 ADT and chemotherapy in oligometastatic prostate cancer

Y. Miura, JP

17:35 - 18:00 Discussion

Last update: 09-11-2018 [Link]pm

16:30 - 17:30 Type: Special Session Room
Title: Caring for AYA with cancer in Europe and Asia: Different 310
challenges, same Goals
Chair: Jean-Yves Douillard, CH; Chi-kong Li, CN

16:30 - 16:35 Introduction

J.-Y. Douillard , CH

16:35 - 16:50 The current situation in Europe: Challenges and opportunities

G. Mountzios, GR

16:50 - 17:05 The current situation in Asia: Challenges and opportunities

C.-K. Li, CN

17:05 - 17:25 Results of the Joint ESMO/SIOPE/SIOP Asia survey on AYA with cancer
R. Dalvi, IN

17:25 - 17:30 Conclusions

C.-K. Li, CN

Last update: 09-11-2018 [Link]pm

 24-11-2018
09:00 - 10:30 Type: Educational session Hall 405
Title: Impact of germline genetics on current care of breast cancer
Chair: Suzette Delaloge, FR; Giuseppe Curigliano, IT

09:00 - 09:25 Landscape of somatic and germline mutation in patients with breast cancer in
Asia
P. Yuan, CN

09:25 - 09:50 Management of patients with BRCA1 and BRCA2 mutated early breast cancer
S. Delaloge, FR

09:50 - 10:15 Targeting BRCA mutations and BRCAness in patients with metastatic breast
cancer: Evidences from clinical trials
Y.-H. Im, KR

10:15 - 10:30 Discussion

09:00 - 10:30 Type: ESMO Clinical Practice Guidelines session Hall 406
Title: ESMO Clinical Practice Guidelines
Chair: George Pentheroudakis, GR; Andrés Cervantes, ES

09:00 - 09:05 Introduction

G. Pentheroudakis, GR

09:05 - 09:25 Hepatoma Case Presentation

C.-H. Koehne, DE

09:25 - 09:45 Hepatoma Case Discussion

S.P. Choo, SG

09:45 - 10:05 BRCA-related cancer syndromes: prevention, follow up, counselling Case
Presentation
A. Trainer, AU

10:05 - 10:25 BRCA-related cancer syndromes: prevention, follow up, counselling Case
Discussion
S.Y. Yoon, MY

10:25 - 10:30 Conclusions

A. Cervantes, ES

Last update: 09-11-2018 [Link]pm

09:00 - 10:30 Type: Multidisciplinary tumour board Hall 407
Title: Challenges in the management of ALK positive stage III NSCLC
Chair: Benjamin Solomon, AU; Suresh Senan, NL; Masahiro Tsuboi, JP

09:00 - 09:05 Presentation of case/condition

B. Solomon, VIC/AU

09:05 - 09:25 Medical oncologist’s perspective

B. Solomon, VIC/AU

09:25 - 09:45 Radiation oncologist’s perspective

S. Senan, NL

09:45 - 10:05 Thoracic surgeon’s perspective

M. Tsuboi, Chiba/JP

10:05 - 10:30 Discussion

Last update: 09-11-2018 [Link]pm

09:00 - 10:30 Type: Young Oncologist session Room 324
Title: Unusual challenges in clinical oncology: case discussions
Chair: Susana Banerjee, GB; Guillem Argilés Martinez, ES

09:00 - 09:05 Introduction

09:05 - 09:10 YO1 - Pulmonary Metastases From Anaplastic Meningioma Presenting with Non-
Islet-Cell Tumour Hypoglycemia (NICTH) : A Case Report

N. Salimin1, G.F. Ho2; 1MY, 2Wilayah Persukutuan/MY

09:10 - 09:20 Q&A

09:20 - 09:25 YO2 - Response to panitumumb monotherapy in patient with metastatic

colorectal cancer harbouring novel KRAS p.A59T and NRAS p.A59T missense
substitutions
R. Tan, S.J. Ong, M.H. Tan, M. Ng; SG

09:25 - 09:35 Q&A

09:35 - 09:40 YO3 - Hyperprogression after Immunotherapy in Non-clear cell RCC patient
T. Ruchakorn, TH

09:40 - 09:50 Q&A

09:50 - 09:55 Summary

Last update: 09-11-2018 [Link]pm

09:00 - 09:45 Type: Mini Oral session Room 311
Title: Mini Oral - Supportive and palliative care
Chair: Kirsty Lee, HK; Carsten Bokemeyer, DE

09:00 - 09:05 358O - Evaluation Of Functional Decline In Elderly Breast Cancer Patients
Receiving First Line Chemotherapy
Y. Khamis, A. Darwish, N. Lotfy, S. Abou-Raya, S.-E. Abdelmoneim; EG

09:05 - 09:10 420O - The rate of Hepatitis B virus screening before systemic anticancer
therapy among patients in Japan
S. Yazaki, T. Yamauchi, T. Higashi; JP

09:10 - 09:15 421O - Assessment and comparison of CISNE model versus MASCC model in
clinically stable febrile neutropenia patients

D. Koppaka1, L.C. Kuntegowdanahalli2, D. Lokanath1, K. Govind Babu1, L. Jacob1, M.

Suresh Babu1, K.N. Lokesh2, A. Rudresha2, L. Rajeev1, S. Smitha1, A. Anand1, V. Asati1,
R. Chethan1, R. Patidar1, T. Chaudhuri1, A. Kasturi1; 1IN, 2Karnatka/IN

09:15 - 09:20 422O - A prospective phase III randomized study to evaluate the efficacy of
olanzapine for prevention of nausea and vomiting in patients receiving highly
emetogenic chemotherapy (HEC).

J. PEHALAJANI1, K. Govind Babu1, D. Lokanatha1, L. Jacob1, M. Suresh Babu1, K.N.

Lokesh2, A. Rudresha2, L. Rajeev1, S. Smitha1, G. Giri1; 1IN, 2Karnatka/IN

09:20 - 09:25 423O - Study of Psycho-social Profile of Caregivers In Teenage and Yound Adult
(TYA) Cancer Patients: Indian Perspective

D. Yadlapalli1, P. Chitalkar2, A. Punia1, S. Runu1, B. Ankit1; 1IN, 2MP/IN

09:25 - 09:45 Discussion

K. Lee1, C. Bokemeyer2; 1NSW/HK, 2DE

Last update: 09-11-2018 [Link]pm

09:00 - 09:45 Type: Mini Oral session Room 310
Title: Mini Oral - Public policy
Chair: Deme Karikios, AU; Bishal Gyawali, US

09:00 - 09:05 396O - A multi-center, randomized, double-blind, parallel, two-group Phase III
trial on the efficacy and safety of QL1101 or bevacizumab in combination with
paclitaxel and carboplatin in first-line treatment of non-squamous non-small cell
lung cancer
B. Han, K. Li, T. Chu, M. Bi, H. Zhang, Y. Yu, J. Shi, X. Zhang, Z. Chen, C. Han, T. Bai; CN

09:05 - 09:10 397O - Adolescents and Young Adults with Cancer Care in Asia: The Joint
ESMO/SIOPE/SIOP ASIA survey

R. Dalvi1, C.-K. Li2, K. Yonemori3, H. Ariffin4, C.J. Lyu5, M. Farid6, J.R.N. Gonzales-
Santos7, Q. Zhou2, S. Bielack8, L. Brugieres9, A. Blondeel10, S. Essiaf10, F. Peccatori11, S.
Jezdic12, D. Stark13, J.-Y. Douillard 12, E. Saloustros14, G. Mountzios14; 1IN, 2CN, 3JP, 4MY,
5KR, 6SG, 7PH, 8DE, 9FR, 10BE, 11IT, 12CH, 13GB, 14GR

09:10 - 09:15 398O - The Prevalence of Breast Tumor: An Indonesia Non Communicable
Disease Survey
S. Idaiani, D. Delima; ID

09:15 - 09:20 399O - Analysis of the Current Status of Multidisciplinary Team (MDT) Care for
Cancer Patients in Korea
C.H. Maeng, H.K. Ahn, S.Y. Oh, B.-S. Kim, S. Lim, D.Y. Kim; KR

09:20 - 09:40 Discussion

D. Karikios1, B. Gyawali2; 1NSW/AU, 2Aichi/US

Last update: 09-11-2018 [Link]pm

09:55 - 10:45 Type: Mini Oral session Room 311
Title: Mini Oral - Gastrointestinal tumours
Chair: David Goldstein, AU; Brigette Ma, HK

09:55 - 10:00 87O - mFOLFOXIRI versus mFOLFOX6 as neoadjuvant chemotherapy in locally

advanced rectal cancer: A Propensity Score Analysis from two prospective trials
J. Zhang, H. Hu, Z. Wu, Y. Cai, J. Ling, J. Xiao, Y.-H. Deng; CN

10:00 - 10:05 88O - Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based
chemotherapy in metastatic colorectal cancer (mCRC): A preplanned analysis of
the phase III AXEPT trial

R. Xu1, K. Muro2, T.W. Kim3, Y.S. Park3, W. Wang4, S.-W. Han 3, M. Kotaka5, Y.-H. Deng4,
J.B. Ahn3, M. Nakamura6, Y. Ba4, S.-H. Cho3, T. Kato6, T. Zhang4, K.-W. Lee 3, H.
Matsuoka6, W.-J. Fang4, S. Morita6, S. Iwasa6, S. Junichi6; 1Guangdong/CN, 2Aichi/JP,
3KR, 4CN, 5Hyogo/JP, 6JP

10:05 - 10:15 Discussion

D. Goldstein, NSW/AU

10:15 - 10:20 153O - M7824 (MSB0011359C), a bifunctional fusion protein targeting

transforming growth factor β (TGF-β) and PD-L1, in Asian patients with
pretreated biliary tract cancer (BTC): Efficacy by BTC subtype

C. Yoo1, D.-Y. Oh 2, H.J. Choi2, M. Kudo3, M. Ueno3, S. Kondo3, L.-T. Chen 4, M. Osada3, C.
Helwig5, I. Dussault6, M. Ikeda3; 1Songpa-gu/KR, 2KR, 3JP, 4TW, 5DE, 6MA/US

10:20 - 10:25 154O - Atezolizumab monotherapy in Chinese patients with locally advanced or
metastatic solid tumours
L. Shen, L. Zhang, X. Hu, H. Pan, T. Liu, Y. Bai, Y.-C. Chen, J. Huang, T. Xu, W. Hsu, J. Shi;
CN

10:25 - 10:30 155O - Efficacy of TAS-120, an Irreversible Fibroblast Growth Factor Receptor
Inhibitor (FGFRi), in Patients With Cholangiocarcinoma and FGFR Pathway
Alterations Previously Treated With Chemotherapy and Other FGFRi’s

B. Tran1, F. Meric-Bernstam2, H.-T. Arkenau 3, R. Bahleda4, R. Kelley5, C. Hierro6, D.

Ahn7, A. Zhu7, M. Javle2, R. Winkler8, H. He9, J. Huang9, L. Goyal10; 1AU, 2TX/US, 3GB,
4FR, 5CA/US, 6ES, 7US, 8AL/US, 9NJ/US, 10MA/US

10:30 - 10:45 Discussion

B. Ma, HK

Last update: 09-11-2018 [Link]pm

09:55 - 10:50 Type: Mini Oral session Room 310
Title: Mini Oral - Developmental and precision medicine
Chair: Miguel Quintela-Fandino, ES; Daniel Shao Weng Tan, SG; Timothy Yap, US;
Nicholas McGranahan, GB

09:55 - 10:00 70O - Relationships between lenvatinib plasma concentration and toxicity in
Japanese cancer patients
R. Makihara, S. Narita, N. Yamamoto, J. Sato, S. Murakami, Y. Goto, S. Kanda, Y.
Fujiwara, H. Horinouchi, T. Tsukamoto, H. Hashimoto, Y. Makino, Y. Ohe, M. Yamaguchi;
JP

10:00 - 10:05 71O - Phase 1 extension study of ETC-159 an oral PORCN inhibitor administered
with bone protective treatment, in patients with advanced solid tumours.

D. Tan1, M. Ng1, V. Subbiah2, W. Messersmith3, V. Teneggi4, V. Diermayr1, K. Ethirajulu1,

P. Yeo1, B.H. Gan1, L.H. Lee1, S. Blanchard1, R. Nellore1, M. Yasin1, D. Umrani1, M.A.
Lee1, J. Hill1, B. Madan1, D. Virshup1, A. Matter1; 1SG, 2TX/US, 3CO/US, 4Singapore/SG

10:05 - 10:10 72O - Addition of durvalumab (Dur) upon progression to bevacizumab (Bev)
maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): safety,
efficacy and biomarkers.

M. Quintela-Fandino1, L. Manso Sànchez1, E. Holgado Martín1, M. Moreno1, S. Morales

Murillo2, B. Bermejo De Las Heras3, D. Malon Gimenez1, R. Colomer Bosch1, L. Gonzalez
Cortijo4, J. Hornedo1, S. Mouron1, M. Muñoz1, S. Escudero1, R. Blanco1, S. Mañes1; 1ES,
2NA, 3Valencia/ES, 4Madrid/ES

10:10 - 10:20 Discussion

D.S.W. Tan1, T. Yap2; 1SG, 2Surrey/US

10:20 - 10:25 367O - Parallel identification and profiling of tumour antigen-specific T cells for
biomarker discovery by mass cytometry
F. Michael, E. Newell; SG

10:25 - 10:30 368O - Tumor mutation index as biomarker for responsive stratification on
multi-targeted TKI Anlotinib: an ALTER-0303 companion diagnostic study
J. Lu, W. Zhang, B. Yan, H. Li, L. Zhang, Y. Dong, J. Qian, S. Wang, B. Zhang, J. Wu, X.
Zhao, Y. Zhao, B. Han; CN

10:30 - 10:35 369O - Biomarker-integrated study of single agent targeting molecular

alterations of PI3KCA, MET, ALK, ROS1, KRAS, NRAS or BRAF in advanced
NSCLC: Ph2 umbrella trial in China (CTONG1505)

Q. Zhou1, X.-C. Zhang2, H.-Y. Tu 2, B. Gan2, B.-C. Wang2, C.-R. Xu2, H.-J. Chen2, M.-Y.
Zheng2, Z. Wang2, X.-Y. Bai 2, Y.-L. Sun2, A. Myers2, X. Lv2, Y. Chakrabcorti3, S. Zhao2, J.-
J. Yang2, Y.-L. Wu2; 1Guangdong/CN, 2CN, 3IN

10:35 - 10:45 Discussion

M. Quintela-Fandino1, N. McGranahan2; 1ES, 2GB

Last update: 09-11-2018 [Link]pm

10:30 - 11:00 Type: Young Oncologist session Exhibition area
Title: Meet your mentor
11:00 - 12:30 Type: Proffered Paper session Hall 406
Title: Presidential Symposium
Chair: Josep Tabernero, ES; Andrés Cervantes, ES

11:00 - 11:15 LBA1 - IMpower133: Primary efficacy and safety + CNS-related adverse events in
a phase I/III study of first-line (1L) atezolizumab + carboplatin + etoposide in
extensive-stage SCLC (ES-SCLC)

T.S.K. Mok1, M. Reck2, L. Horn3, S. Lam4, D. Shames4, J. Liu5, F. Kabbinavar4, W. Lin4, A.

Sandler6, S. Liu7; 1HK, 2DE, 3TN/US, 4US, 5CN, 6OR/US, 7DC/US

11:15 - 11:30 Invited discussant

P. Garrido Lopez, ES

11:30 - 11:45 LBA2 - Primary results of ALESIA: phase III, randomised open-label study of
alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve
ALK+ advanced non-small-cell lung cancer (NSCLC)

C. Zhou1, Y. Lu2, S.-W. Kim 3, T. Reungwetwattana4, J. Zhou1, Y. Zhang1, J. He1, J.-J. Yang1,
Y. Cheng5, S.H. Lee3, L. Bu1, T. Xu1, L. Yang1, C. Wang1, P. Morcos6, E. Mitry7, Z. Li8;
1CN, 2Sichuan/CN, 3KR, 4TH, 5Jilin/CN, 6NY/US, 7CH, 8Guangdong/CN

11:45 - 12:00 Invited discussant

R. Soo, SG

12:00 - 12:15 LBA3 - Maintenance olaparib following platinum-based chemotherapy in newly

diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2
mutation (BRCAm): Phase III SOLO1 trial

M. Friedlander1, K. Moore2, N. Colombo3, G. Scambia3, B.-G. Kim4, A. Oaknin5, A.

Lisyanskaya6, A. Floquet7, A. Leary8, G. Sonke9, C. Gourley10, S. Banerjee10, A. Oza11, A.
González-Martín5, C. Aghajanian12, W. Bradley13, E. Lowe14, R. Bloomfield10, P.
Disilvestro15; 1NSW/AU, 2US, 3IT, 4KR, 5ES, 6RU, 7CEDEX/FR, 8FR, 9NL, 10GB,
11Ontario/CA, 12NY/US, 13WI/US, 14MD/US, 15RI/US

12:15 - 12:30 Invited discussant

A.M. Poveda Velasco, ES

12:45 - 14:15 Type: Industry Satellite Symposium Hall 405

Title: Industry Satellite Symposium
12:45 - 14:15 Type: Industry Satellite Symposium Hall 404
Title: Industry Satellite Symposium
12:45 - 14:15 Type: Industry Satellite Symposium Hall 407
Title: Industry Satellite Symposium

Last update: 09-11-2018 [Link]pm

12:45 - 14:15 Type: ESMO Colloquium Room
Title: ESMO COLLOQUIUM - Updated therapeutic approach of 324
castration-resistant prostate cancer

12:45 - 12:50 Welcome introduction

R. de Wit, NL

12:50 - 13:05 Definition and peculiarities of CRPC: M0 vs M1

M. De Santis, DE

13:05 - 13:20 Chemotherapy in mCRPC: Is it still relevant?

B. Tran, AU

13:20 - 13:35 Hormonal therapies in mCRPC: Where are we now?

R. de Wit, NL

13:35 - 13:50 Is there an optimal sequencing strategy in mCRPC?

M. De Santis, DE

13:50 - 14:05 Immunotherapy in mCRPC: Moving beyond Sip-T

T. Powles, GB

14:05 - 14:15 Conclusion and wrap up

B. Tran, AU

12:45 - 14:15 Type: Industry Satellite Symposium Room 311

Title: Industry Satellite Symposium
14:30 - 16:00 Type: Educational session Hall 405
Title: Latest developments in urological cancers
Chair: Ronald de Wit, NL

14:30 - 14:55 Metastatic prostate cancer: Optimal use of the currently available agents
R. de Wit, NL

14:55 - 15:20 Renal cell cancer: Optimising systemic treatment in an era of emerging
treatment paradigms
M. Lolkema, NL

15:20 - 15:45 Integration of immunotherapy in bladder cancer: Who and when to treat?
M. De Santis, DE

15:45 - 16:00 Discussion

Last update: 09-11-2018 [Link]pm

14:30 - 16:00 Type: Joint Symposium Hall 404
Title: ESMO-AACR: PD1/PDL1: From discovery to clinical use
Chair: Solange Peters, CH; Thomas Powles, GB

14:30 - 14:35 Introduction

T. Powles, GB

14:35 - 14:55 Discovery of immune checkpoint as a mechanism of immune suppression

P. Romero, CH

14:55 - 15:15 Predictive biomarker of efficacy for the use of immune checkpoint inhibitors
T. Powles, GB

15:15 - 15:35 Development in the use of immune checkpoint inhibitors: Lung cancer as a
paradigm shift
S. Peters, CH

15:35 - 15:55 Should immune checkpoint inhibitors be considered as agnostic drugs?

J. Larkin, GB

15:55 - 16:00 Conclusions

S. Peters, CH

14:30 - 16:00 Type: Multidisciplinary tumour board Hall 407

Title: Multidisciplinary approach to resectable gastric cancer
Chair: Florian Lordick, DE; Masanori Terashima, JP

14:30 - 14:35 Presentation of case/condition

F. Lordick, DE

14:35 - 14:55 Surgical treatment perspectives

M. Terashima, Shizuoka/JP

14:55 - 15:15 Medical oncology perspectives

S.P. Choo, SG

15:15 - 15:35 Is there a role for radiotherapy?

T. Leong, AU

15:35 - 16:00 General discussion

Last update: 09-11-2018 [Link]pm

14:30 - 16:00 Type: Multidisciplinary tumour board Room 324
Title: Issues for cancer care in the elderly
Chair: Dorothy Keefe, AU; Christopher Steer, AU

14:30 - 14:40 Case presentation

U. Wedding, DE

14:40 - 15:00 Assessment by onco-geriatrician

U. Wedding, DE

15:00 - 15:20 Balancing between treatment and toxicity

C. Steer, VIC/AU

15:20 - 15:40 Managing the financial implication

D. Keefe, SA/AU

15:40 - 16:00 Conclusions

Last update: 09-11-2018 [Link]pm

14:30 - 15:15 Type: Mini Oral session Room 311
Title: Mini Oral - Breast cancer
Chair: Giuseppe Curigliano, IT; Binghe Xu, CN

14:30 - 14:35 1O - Differences in Prognosis and Efficacy of Chemotherapy by p53 Expression in

Triple Negative Breast Cancer
S.Y. Bae, S.P. Jung, K.B.C.S. Korean Breast Cancer Society, S.J. Nam, Y. Jung, B.W. Park,
W. Lim, S.H. Jung, H.K. Kim, J.-Y. You, S.B. Lee; KR

14:35 - 14:40 23O - Implications of Plasma Deoxyribonucleic Acid Topoisomerase 2 Beta Level
in Breast Cancer Patients receiving Doxorubicin-Based Chemotherapy
T. Win, T.T. Naing, T.T. Win, K.K. Aung, Y.Y. Htun; MM

14:40 - 14:45 40O - Biomarker analyses of Asian women with hormone receptor-positive
(HR+), HER2-negative (HER2–) advanced breast cancer (ABC) receiving
ribociclib (RIB) + endocrine therapy (ET)

Y.S. Yap1, N. Masuda2, Y. Ito2, T. Ishikawa2, S.J. Kim2, T. Aruga2, T. Toyama2, T. Saeki2, T.
Yamanaka2, M. Saito2, J. Watanabe2, M. Takahashi2, S. Nakamura2, K. Inoue2, J. Suarez-
Vizcarra3, W. He3, N. Solovieff3, F. Su3, J. Chiu4; 1SG, 2JP, 3NJ/US, 4HK

14:45 - 14:50 41O - Decreased mortality strongly correlated with the upregulation of BCR in
breast cancer metastasis to bone

S.N. Mai1, H. Vu1, X.T. Hoang1, V.T. Than1, T. Nguyen2, M.T. Le3, P.-L. Luu4, H. Tran1,
M.N. Nguyen5; 1VN, 2WA/AU, 3KR, 4ACT/AU, 5US

14:50 - 15:15 Discussion led by moderators

14:30 - 16:00 Type: Educational session Room 310

Title: The reality of accessing cancer care in Asia and Asia/Pacific
Chair: Sumitra Thongprasert, TH; Alexandru Eniu, RO

14:30 - 14:55 Cancer medicines: What is available and is it effective enough?

A. Eniu, RO

14:55 - 15:20 Financial toxicity of cancer treatment in Asia and Asia-Pacific

M. Bertram, CH

15:20 - 15:45 Strategies to improve accessibility and availability of cancer medicines in LMICs
S. Thongprasert, Muang/TH

15:45 - 16:00 Discussion

Last update: 09-11-2018 [Link]pm

15:30 - 16:20 Type: Mini Oral session Room 311
Title: Mini Oral - Head and neck cancers
Chair: Anthony Chan, HK; Joseph Wee, SG

15:30 - 15:35 304O - Relationship of Circulating Tumor Cells to Progression-Free Survival and
Tumor Response in Patients with Metastatic Nasopharyngeal Carcinoma: A
Prospective Cohort Study

R. You1, M. Chen2, Y.-P. Liu1, Y.-N. Zhang1, P.-Y. Huang 1; 1CN, 2Guangdong/CN

15:35 - 15:40 305O - Surgery for Isolated Regional Failure in Nasopharyngeal Carcinoma after
Radiation: Selective or Comprehensive Neck Dissection

L. You-Ping1, R. You1, M. Chen2, H. Li1; 1CN, 2Guangdong/CN

15:40 - 15:50 Discussion

15:50 - 15:55 307O - Randomized, double-blind, placebo-controlled trial of probiotics to

reduce radiation and chemotherapy induced oral mucositis for nasopharyngeal
cancer patients
C. Jiang, H. Xie, L. Zeng, T. Chen, J. Li; CN

15:55 - 16:05 Discussion led by moderators

16:00 - 16:30 Type: Young Oncologist session Exhibition area

Title: Meet your mentor

Last update: 09-11-2018 [Link]pm

16:30 - 18:00 Type: ESMO Clinical Practice Guidelines session Hall 405
Title: Adaptation of ESMO guidelines in Asia
Chair: Josep Tabernero, ES; Takayuki Yoshino, JP

16:30 - 16:40 Welcome and Introduction

T. Yoshino1, J. Tabernero2; 1JP, 2ES

16:40 - 16:55 Case presentation: Metastatic oeso-gastric cancer

T. Nakajima, JP

16:55 - 17:10 Pan Asia Adapted metastatic Oeso-Gastric cancer Guidelines: results
K. Muro, Aichi/JP

17:10 - 17:25 Case presentation: Metastatic Non-Small Cell Lung Cancer

H. Sun, CN

17:25 - 17:40 Pan Asia Adapted metastatic NSCLC cancer Guidelines: results
Y.-L. Wu, CN

17:40 - 18:00 The way forward: other ESMO guidelines to adapt in 2019 Perspective and
Challenges (panel), moderated by George Pentheroudakis
G. Pentheroudakis, GR

16:30 - 18:00 Type: Special Session Hall

Title: In collaboration with ATEP: Pulmonary ground glass opacities 404
(GGOs): Emerging challenge, evolving management
Chair: Tetsuya Mitsudomi, JP

16:30 - 16:45 GGO Management: Are current guidelines adequate?

T. Mitsudomi, JP

16:45 - 17:05 Advances in clinical and molecular profiling of GGOs

17:05 - 17:25 Resection of GGOs: Are surgeons being too aggressive … or not aggressive
enough?
S. Cho, KR

17:25 - 17:45 Advances in techniques and technologies for GGO surgery

A.D.L. Sihoe, HK

17:45 - 18:00 Discussion and Conclusions

Last update: 09-11-2018 [Link]pm

16:30 - 18:00 Type: Educational session Hall 407
Title: Neurotoxicity: A problem to remember
Chair: Dorothy Keefe, AU; Kirsty Lee, HK

16:30 - 16:55 Peripheral neuropathy

G. Cavaletti, IT

16:55 - 17:20 Lost in the fog: What is chemobrain?

F. Boyle, AU

17:20 - 17:45 Acute central neurotoxicity

K.A. Griffith, US

17:45 - 18:00 Discussion

16:30 - 19:00 Type: Special Session Room 324

Title: Radiation oncology
Chair: Françoise Mornex, FR; Suresh Senan, NL

16:30 - 16:42 Stage III NSCLC and the immuno-oncology paradigm: Immunotherapy
R. Soo, SG

16:42 - 16:54 Stage III NSCLC and the immuno-oncology paradigm: Radiotherapy
considerations
F. Mornex, CEDEX/FR

16:54 - 17:00 Q&A

17:00 - 17:12 Approaches towards inoperable HCC: Systemic treatment of HCC

S.P. Choo, SG

17:12 - 17:24 Approaches towards inoperable HCC: Role of external beam radiotherapy
evidence and comparison with other local treatment
J. Seong, KR

17:24 - 17:30 Q&A

17:30 - 17:42 Evolving radiotherapy strategies in early-stage breast cancer: The role of surgery
and new surgical approaches in early breast cancer
C.W. Chan, SG

Last update: 09-11-2018 [Link]pm

17:42 - 17:54 Evolving radiotherapy strategies in early-stage breast cancer: The role of
radiotherapy and new technical approaches
F. Lim, SG

17:54 - 18:00 Q&A

18:00 - 18:12 Oesophagus and Oeso-gastric junction carcinomas: Role of systemic treatment
F. Lordick, DE

18:12 - 18:24 Oesophagus and Oeso-gastric junction carcinomas: The radiation oncologist
point of view
T. Leong, AU

18:24 - 18:30 Q&A

18:30 - 18:42 Oligometastatic prostate cancer - Management options: Initial neo-adjuvant

systemic treatment
R. Kanesvaran, SG

18:42 - 18:54 Oligometastatic prostate cancer - Management options: The radiation oncologist
point of view
M.L.K. Chua, SG

18:54 - 19:00 Q&A

Last update: 09-11-2018 [Link]pm

16:30 - 17:15 Type: Mini Oral session Room 311
Title: Mini Oral - Genitourinary tumours
Chair: Shigeo Horie, JP; James Larkin, GB

16:30 - 16:35 212O - United in Fight against prOstate cancer registry (UFO): treatment
patterns and quality of life from a large, multi-center, longitudinal cohort study
in Asia

R. Kanesvaran1, H. Uemura2, D. Ye3, E. Chiong1, B. Lojanapiwat4, Y.-S. Pu5, S. Kumar

Rawal6, A.H.A. Razack7, H. Zeng3, B.H. Chung8, Y.-S. Tsai5, M.Y. Noor Ashani7, Y. Liu9,
M. Asinas-Tan 1, W. Liu3, G.K.M. Low1, M. van Kooten Losio10; 1SG, 2JP, 3CN, 4TH, 5TW,
6IN, 7MY, 8KR, 9NJ/US, 10ACT/AU

16:35 - 16:40 213O - Efficacy and Safety of Apalutamide (APA) in Patients (pts) With
Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) From SPARTAN:
Asian Subpopulation

P. Mainwaring1, E. Small2, H. Uemura3, J.Y. Lee4, S.-T. Pang 4, G. Marx1, T.G. Kwon4, T.
Satoh3, A. Bhaumik5, S. Cheng5, A. Londhe6, A. Lopez-Gitlitz2, M. Smith7; 1ACT/AU,
2CA/US, 3JP, 4KR, 5NJ/US, 6PA/US, 7US

16:40 - 16:45 214O - The change in expression of prostate-specific membrane antigen in

circulating tumor cells during treatments for castration-resistant prostate
cancer
N. Nagaya, M. Kanayama, M. Nagata, S. Horie; JP

16:45 - 16:50 232O - Pharmacokinetics of Cabozantinib in Asian and Non-Asian Populations

F. Benzaghou1, T.X.Q. Nguyen1, S. Lacy2; 1FR, 2CA/US

16:50 - 16:55 233O - Real World Practice and Outcomes for Metastatic Renal Cell Carcinoma:
What Can We Learn from Real World Data Analysis in the US?

F. Benzaghou1, A. Ren2, M. del Pilar Schneider1, J. Dinet1, E. Pham1; 1FR, 2MA/US

16:55 - 17:15 Discussion led by moderators

Last update: 09-11-2018 [Link]pm

16:30 - 17:30 Type: Special Session Room
Title: Summary of the ESMO-ESGO consensus conference on ovarian 310
cancer
Chair: Jae-Weon Kim, KR

16:30 - 16:45 The pathology, molecular biology and management of early ovarian cancer
S. Banerjee, GB

16:45 - 17:00 The management of advanced and recurrent ovarian cancer

J. Ledermann, London/GB

17:00 - 17:15 The Asian perspective

D. Tan, SG

17:15 - 17:30 Discussion / Q&A

17:30 - 18:15 Type: Mini Oral session Room 311

Title: Mini Oral - Gynaecological cancers
Chair: Keiichi Fujiwara, JP; Sudeep Gupta, IN

17:30 - 17:35 253O - Long-term results of treatment of patients with locally advanced cervical
cancer after pelvic exenteration
N. Zakhirova, M. Tillashaykhov, O. Ahmedov, S. Djanklich, Y. Ten; UZ

17:35 - 17:40 254O - Dysgerminoma Ovary : Clinical Features and Treatment Outcome
P. Nair, A. Kumar, S. Mathews, J. Joseph, S. Suchetha, J. Krishna, F. James; IN

17:40 - 17:45 255O - Achievement of complete response (CR) in metastatic or recurrent

cervical cancer (MRCC): Does it matter?
J.F. Grau Béjar, V. Rodriguez Freixinos, L. Fariñas Madrid, G. Villacampa, A. Gil, R.
Verges, M.A. Perez Benavente, A. García, R. Dienstmann, A. Oaknin; ES

17:45 - 17:50 256O - Barriers to early diagnostics of cervical cancer in Uzbekistan

V. Saidakhmedova, N. Zakhirova, E. Osmanova, O. Akhmedov, B. Yusupov, S. Djanklich, D.
Egamberdiev; UZ

17:50 - 18:10 Discussion led by moderators

18:00 - 19:00 Type: Poster Display Exhibition area

Title: Poster display - Cocktail

18:00 - 18:00 Breast cancer, early stage

Last update: 09-11-2018 [Link]pm

18:00 - 18:00 3P - HER2 positive rates in Invasive Lobular Breast Carcinoma : A study amongst
1,095 consecutive Asian patients
G.J. Kee, R. Tan, R. Sultana, M.W.W. Zaw, W. Lian, K.T.B. Tan, R. Dent, F.Y. Wong, G.E. Lee;
SG

18:00 - 18:00 4P - CanAssist-breast -an immunohistochemistry based test for risk of

recurrence prediction for early stage breast cancer patients: a cost-effective and
accurate solution for Asia
M. Bakre, Karnatala/IN

18:00 - 18:00 5P - Topical silymarin administration for prevention of radiodermatitis in breast

cancer patients: a randomized, double-blind, placebo-controlled clinical trial

S. Elyasi1, H. Karbasforushan1, S. Hosseini2, A. Fani Pakdel1; 1IR, 2Khorasan Razavi/IR

18:00 - 18:00 6P - Comparison of interstitial brachytherapy with volumetric modulated arc

therapy for tumour bed boost following breast conservative surgery
K. Periasamy, S. Cholayil, G. Karunanithi, K. Dharanipragada, V. Neelakandan; IN

18:00 - 18:00 7P - Triple Negative Breast Cancer and Platinum-based Systemic Treatment:
Meta-analysis and Systematic Review
J.G. Pandy, J. Balolong-Garcia, M.V. Cruz-Ordinario, F.V. Que; PH

18:00 - 18:00 8P - Longitudinal study on incidences of obesity and weight changes in Chinese
patients with early-stage breast cancer
W. Yeo, Y. Lei, A. Cheng, C. Kwok, K. Cheung, R. Lee, I. Lee, Y. He, S. Ho; HK

18:00 - 18:00 9P - Effect of combined CYP2C19 and CYP2D6 genotype on tamoxifen treatment
outcome in breast cancer indicates endogenous and exogenous interplay
H. Xie, J. Lövrot, J. Lindh, J. Bergh, S. Sim; SE

18:00 - 18:00 10P - A novel nipple aleolar complex involvement predictive index (NACPI) for
indicating nipple sparing mastectomy in breast cancer
H. Seki, T. Sakurai, K. Shimizu; JP

18:00 - 18:00 11P - Multicenter Trial for Safety and Toxicity of Nanoxel®M in Breast Cancer
T.H. Kim, G. Gwak, M.S. Chung, J.I. Kim, I. Park, E. Um, J.W. Han, A. Lee; KR

18:00 - 18:00 12P - Implication of PET-CT to improve negative predictive value for axillary
lymph node metastasis in early breast cancer
O. Cho, Y.-T. Oh; KR

18:00 - 18:00 13P - Upgrade of Low Grade Ductal Carcinoma in situ (DCIS): multimodality
approach in a 10-year single institution study
A. Chu, J.M. Chang, W.K. Moon; KR

Last update: 09-11-2018 [Link]pm

18:00 - 18:00 14P - Correlation between circulating tumor cells and the aromatase inhibitors
therapy in postoperative patients with early breast cancer
Y. Shi, G. Zhang, Y. Wang, C. Ren, L. Wen, L. Guo, N. Liao; CN

18:00 - 18:00 15P - A Pilot Study of Single Pegfilgrastim Compared with Intermittent Every
Other Days of 5 Shot-filgrastim in Breast Cancer Patients Receiving Adjuvant
Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) Chemotherapy (G-CSF 105
trial: NCT02685111)
J. Jeong, B.S. Sohn, J.-H. Ahn, K.H. Jung, J.E. Kim, J. Oh, H. Lee, J.H. Sohn, S.-J. Koh, J.H.
Seo, K.S. Lee, S.-B. Kim; KR

18:00 - 18:00 17P - Painful scalp during chemotherapy induced hair loss is associated to
permanent alopecia in breast cancer patients
N. Mejri, M. Saadi, F. Guermazi, H. El Benna, N. Daoud, S. Labidi, H. Boussen; TN

18:00 - 18:00 18P - Breast cancer survival analysis in East Azerbaijan: five years cancer
registry data in Iran

S. Pashaei1, R. Dolatkhah1, Z. Sanaat2, P. Jabbaripour1, G. de Bock3; 1IR, 2East

Azarbaijan/IR, 3NL

18:00 - 18:00 19P - Is sarcopenia associated with increased toxicity of neoadjuvant/adjuvant

chemotherapy for breast cancer?
A. Ueno, K. Yamaguchi, M. Sudo, S. Imai; JP

18:00 - 18:00 20P - A Study on possibility of High Sensitivity C - reactive protein (hs-CRP) and
Circulating Interluekin-6 (IL-6) as biomarker in Breast Cancer Patients
M.S.J.R. Shahi, M. Dey, A. Chowdhury; BD

18:00 - 18:00 21P - Correlation Between Expression of Topoisomerase II Alpha with Ki-67 and
Tumor Size in Luminal B-Like Indonesian Breast Cancer Patients
H. Putri, M. Kristina, D. Widjaja, B. Baskoro, E. Kristiani; ID

18:00 - 18:00 22P - Association of Serum Vitamin D Level and Vitamin D Receptor
Polymorphism (Apa 1) And Breast Cancer

S. Gohar1, S. Al-Hassanin2, B. Montaser2, S. Soliman2; 1Menoufia Governorate/EG, 2EG

18:00 - 18:00 Breast cancer, locally advanced

18:00 - 18:00 24P - Prognostic Nomograms for Predicting Overall and Cancer-Specific Survival
in Breast Cancer Patients Not Achieving Pathological Complete Response After
Neoadjuvant Chemotherapy
J. Lai, Z. Pan, H. Deng, J. Peng, P. Chen, G. Ye, F. Yu, K. Chen, F. Su; CN

18:00 - 18:00 25P - Prognostic Nomogram Based on Lymph Node Ratio to Predict Survival in
Node-Positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy
J. Lai, J. Peng, H. Deng, P. Chen, G. Ye, F. Yu, F. Su, K. Chen, Z. Pan; CN

Last update: 09-11-2018 [Link]pm

18:00 - 18:00 26P - Breast tumor associated exosomes mediate loss of antitumor immune
response by arresting cytotoxic T cell functions in the tumor microenvironment
S. Chatterjee, A. Chatterjee, S. Jana, H. Roy, N. Nargis, A. Bhattacharyya; IN

18:00 - 18:00 27P - Hormonal therapy confers clinically relevant benefit in women with low
estrogen receptor-positive breast tumor
T. Zhang, B. Ho, P. Chan, E.Y. Tan; SG

18:00 - 18:00 28P - Breast board comined with a thermoplastic head mask immobilization can
improve the reproducibility of the treatment setup for breast cancer patients
who received whole breast and supraclavicular nodal region irradiation
M.W. Ma, S. Wang, S. Qin; CN

18:00 - 18:00 29P - Imaging-proven Venous Thromboembolism Breast Cancer in a Tertiary

Hospital in the Philippines
A.T. Gerona, PH

18:00 - 18:00 30P - Tumor-infiltrating lymphocytes and pathologic complete response among
the patients with HER2 positive breast cancer receiving neoadjuvant docetaxel,
carboplatin, trastuzumab and pertuzumab (TCHP) : Single center experience
J. Ha, J.E. Kim, J.H. Jeong, J.-H. Ahn, K.H. Jung, H.J. Lee, G. Gong, E.Y. Chae, H.H. Kim,
I.Y. Chung, B.S. Ko, S.-B. Kim; KR

18:00 - 18:00 31P - PD-L1 expression on circulating monocytes in patients with breast cancer
M. Nagano, K. Saito, Y. Kozuka, M. Shibusawa, N. Imai, A. Noro, Y. Kageyama, T. Mizuno,
T. Ogawa, N. Katayama; JP

18:00 - 18:00 32P - Dosimetric plan evaluation of hypofractionated 3-Dimensional Conformal

Radiotherapy (3DCRT) and 2-Dimensional (2D) simulator planning in whole
breast irradiation after breast conserving surgery
M. Roy, B. Goswami, S. Goswami, A. Jadhav, S. Agarwal; IN

18:00 - 18:00 33P - IQGAP3 Overexpression Correlates with Poor Prognosis and Radiation
Therapy Resistance in Breast Cancer
H. Lin, X. Hua, Z. Long, W. Zhang, C. Lin, X. Sun, W. Wen, Z. Lu, N. Guo, Z. He, L. Song,
L. Guo; CN

18:00 - 18:00 34P - A reliable nomogram for predicting overall survival in patients with triple-
negative breast cancer
M.W. Ma, N. Jing, S. Gao; CN

18:00 - 18:00 35P - Dose distribution in coronary arteries in left-sided breast cancer treated
with Radiotherapy
U. Velu, P. Alurkar; IN

Last update: 09-11-2018 [Link]pm

18:00 - 18:00 36P - Metabolic Syndrome in Luminal-Type Non-Metastatic Breast Cancer during
Hormonal Treatment Does it really have impact on prognosis?
K. Taroeno-Hariadi, M. Hardianti, J. Kurnianda, Y. Putra, T. Aryandono; ID

18:00 - 18:00 37P - High Eosinophils Lymphocyte Ratio (ELR) Related With Subtype of Breast
Cancer in Sanglah General Hospital, Bali
A.A. Lestari, I.P. Prabawa, S. Wiranata, I.G.P. Supadmanaba; ID

18:00 - 18:00 YO4 - Breast ecchymotic purpura: a rare presentation of a locally advanced
breast carcinoma
C. Dabiri, K. Wehbe, O. Hu, P. Soibinet Oudot; FR

18:00 - 18:00 Breast cancer, metastatic

18:00 - 18:00 42P - Ribociclib (RIB) + endocrine therapy (ET) in Japanese women with
hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast
cancer (ABC)

N. Masuda1, S. Noguchi1, T. Ishikawa1, T. Aruga1, S.J. Kim1, T. Toyama1, T. Saeki1, M.

Saito1, T. Yamanaka1, J. Watanabe1, S. Nakamura1, M. Takahashi1, K. Inoue1, I.
Gounaris2, Y. Han2, T. Samant2, M. Gazdoiu2, Y. Ito1; 1JP, 2NJ/US

18:00 - 18:00 43P - Osteopontin Level and Promoter Polymorphism is Associated with
Aggressiveness in Breast Cancer

M. Elbaiomy1, M. El-Ghonemy2, R. Elhelaly2, R. Elzehery2; 1Mansura/EG, 2EG

18:00 - 18:00 44P - Global Clinical Trials Validating Bioequivalence with China-Manufactured
Trastuzumab Biosimilar, HLX02, and Herceptin®

Q. Zhang1, B. Xu1, Q. Zhang1, T. Sun1, W. Li1, Y. Teng1, X. Hu1, I. Bondarenko2, H.

Adamchuk2, L. Zhang1, D. Trukhin2, S. Wang1, H. Zheng1, Z. Tong1, X. Zhang1, E. Liu1,
W. Jiang1, S. Liu1, A. LUK1; 1CN, 2UA

18:00 - 18:00 45P - Circular RNA NCAPG promotes breast cancer metastasis through acting as
the sponge of miR-200s
Y. He, J. Tang; CN

18:00 - 18:00 46P - Repeat biopsy a must in recurrent breast cancer: A study from tertiary
cancer centre in India.

A. Anand1, L. Jacob1, K.C. Lakshmaiah1, K. Govind Babu1, D. Lokanatha1, M. Suresh

Babu1, K.N. Lokesh2, A.H. Rudresha1, L. Rajeev1, S. Saldanha1, G. Giri1, R. Patidar1, V.
Asati1, R. Chethan1, T. Chaudhuri1, D. Koppaka1, D. Panwar1, R. Kumar1; 1IN,
2Karnatka/IN

18:00 - 18:00 47P - Meta-analysis of four Phase 3 RCTs of tamoxifen, versus 3rd generation
aromatase inhibitors as 1st Line Endocrine Therapy for HR+ Advanced Breast
Cancer

Last update: 09-11-2018 [Link]pm

 J. Robertson1, C. Campbell1, J. Bogaerts2, R. Parideans2, J. Lichfield1; 1GB, 2BE

18:00 - 18:00 48P - Estimation of efficacy and safety of Genexol-PM, a Cremophor-free,

polymeric micelle formulation of paclitaxel, in recurrent or metastatic breast
cancer patients
S.S. Kang, KR

18:00 - 18:00 49P - The adipocyte suppresses the inhibitory role of hsa_circ_0000190 in the
metastasis of breast cancer cells
X. Chen, J. Tang; CN

18:00 - 18:00 50P - CircASS1 suppressed the invasion and metastasis ability of breast cancer
cell line by targeting gene ASS1 and harboring miR-4443
J. Hou, J. Tang; CN

18:00 - 18:00 51P - Ex-vivo drug sensitivity of primary breast cancer stems cell populations to
potentiate therapeutic strategy for treatment resistant breast cancer
S. Nandi, R. Bhattacharya, T. Roychowdhury, U. Roy, S. Chattopadhyay, A.
Mukhopadhyay; IN

18:00 - 18:00 52P - Molecular Tumor Board (MTB): development of clinical pathways for
precision medicine. Experiences of Center for Breast cancer at National cancer
center, Korea
I.H. Park, C. Park, W. Jang, H. Yang, K. An, Y. Kwon, K.S. Lee, S.H. Sim, S.Y. Kong; KR

18:00 - 18:00 53P - MicroRNA based immune response signature identifies poor prognostic
subgroup within ER negative breast cancers
S. Rajarajan, J. Prabhu, A. Korlimarla, M. Nair, A. Alexander, R. Kaluve, H. Ps, U. Raja, R.
Ramesh, S. Patil, S. Bs, S. Ts; IN

18:00 - 18:00 54P - The clinical efficacy of apatinib combined with Xeloda in advanced triple
negative breast cancer
Y. Li, Y. Wang; CN

18:00 - 18:00 55P - Quality of life and psychosocial needs of metastatic breast cancer patients
T. Mehmood, PK

18:00 - 18:00 56P - TC-1 mediate the TBC1D3 oncogene induced migration of MCF-7 breast
cancer cells
Y. Shen, L. Zhang, H. Zhao, C.-L. Shen; CN

18:00 - 18:00 57P - RelB facilitates cell migration and invasion in breast cancer via MMP1
upregulation
M. Wang, J. Tang; CN

18:00 - 18:00 58P - Re-challenging eribulin in patients with ER+HER2- metastatic breast
cancer: A single-institution experience

Last update: 09-11-2018 [Link]pm

 J. Watanabe1, S. Nakamoto2; 1Shizuoka/JP, 2JP

18:00 - 18:00 59P - Proteolysis-Targeting Chimera (PROTAC) Compounds to Degrade S100A4

and Inhibit Breast Cancer Metastasis
M. Du, G. Wang, T. Ismail, R. Crick, R. Barraclough, B. Daimark, G. Nixon, P. Rudland; GB

18:00 - 18:00 CNS tumours

18:00 - 18:00 60P - Most clinically approved anti-EGFR antibodies fail to neutralize EGFRvIII,
leading to lack of anti-tumour efficacy in high grade glioma

S. Greenall1, T. Adams2, T. Johns3; 1AU, 2VIC/AU, 3WA/AU

18:00 - 18:00 61P - Regulation of Programmed cell death 10 (PDCD10) by FAT1 gene in human
glioblastoma
N. Malik, P. Chattopadhyay, C. Sarkar, A. Suri, S. Sinha, K. Chosdol; IN

18:00 - 18:00 62P - Overall survival of elderly glioblastoma patient treated with concurrent
chemoradiotherapy: A retrospective review with comparison to non-elderly
counterpart
A. Das, BD

18:00 - 18:00 64P - Association of MTHFR gene polymorphisms with glioma and meningioma
patients in Indian population
R. Kumawat, S. Gowda, E. Debnath, S. Rashid, R. Niwas, A. Suri, C. Sarkar, S. Sinha, K.
Chosdol; IN

18:00 - 18:00 66P - A phase II trial of response adapted whole brain radiotherapy after high
dose Methotrexate based chemotherapy in patients with newly diagnosed
primary central nervous system lymphoma
N. Adhikari, A. Biswas; IN

18:00 - 18:00 67P - Association between altered expression of key enzymes involved in
kynurenine pathway with clinical outcome in patients with different grades of
astrocytoma

D. Mohania1, P. Kumar2, D. Goyal1, R. Acharya1, S. Kalra1, S. Jain1, S. Bhalla1, S. Misra1,

A. Kumar1; 1IN, 2AL/US

18:00 - 18:00 68P - Triple intrathecal chemotherapy for leptomeningeal carcinomatosis in

solid tumours

V. Srinivasalu1, N. Subramaniam1, A. Philip2, W. Jose3, K. Pavithran3; 1IN, 2Tamil

Nadu/IN, 3Kerala/IN

18:00 - 18:00 YO5 - Pleural metastasis from anaplastic meningioma

T. Patimarattananan, T. Ativitavas; TH

Last update: 09-11-2018 [Link]pm

18:00 - 18:00 YO6 - Pituitary and pineal germinoma with peritoneal metastasis
C. Ngokngarm, C. Bandidwattanawong, A. Suthepwanon, K. Runglodvatana; TH

18:00 - 18:00 YO7 - Pulmonary metastases in recurrent intracranial meningioma: Case Report
A.A. Sulaiman Shah, F. Ismail; MY

18:00 - 18:00 Developmental therapeutics

18:00 - 18:00 73P - Ganoderic acids BT-01, a galectin-1 inhibitor, suppresses ovarian cancer
growth in humanized mouse xenograft model.
C.-P. Huang, S.-Y. Chen, H.-H. Lai, Y.-H. Lin, C.-T. Su, S.-J. Wu, C.-H. Chang, C.-C. Tsao, Y.-
C. Chen, S.-C. Wang, Y.-H. Liu, S.-B. Lin, T.-H. Chen; TW

18:00 - 18:00 77P - SMA-tDodSNO improves the potency of doxorubicin in breast cancer
evidence for the involvement of oxidative stress

H. Alimoradi1, A. Barzegarfallah1, K. Giresh2; 1NZ, 2BH

18:00 - 18:00 78P - Selective killing of circulating tumor cells prevents metastasis and extends
survival
Y.R. Kim, J.W. Choi; KR

18:00 - 18:00 79P - CXCR4 antagonist mediated targeting of cancer cells using nanoparticles
S. Ansari, M. Mudassir, B. Vijayalekshmi, P. Chattopadhyay; IN

18:00 - 18:00 80P - Emodin Sensitizes Ovarian Cancer Cells to Carboplatin through
Suppression of Mitochondrial Respiration
Y. Ge, Y. Chen, W. Wang, D. Wu, F. Cao, X. Zhou, J. Gao, Z. Cao, X. Zheng, W. Li, J. Li; CN

18:00 - 18:00 81P - NKG2D enhances chemosensitivity to cisplatin in patients with extensive
small cell lung cancer by up-regulating NF-κβ2
R. Si, G. Yang, X. Tang; CN

18:00 - 18:00 82P - Anticancer activity of Moringa Oliefera mediated Silver Nanoparticles
(AgNps) on Human Lymphocyte Cells
S. Mahalakshmi, IN

18:00 - 18:00 83P - Phase 1 Investigator’s Perceptions to ‘Supersized Seamless Trials in

Oncology'

B. Ma1, N. van der Velden2, F. Mo1, H. Loong1, L. Siu3, B. Goh4, Y.-J. Bang5, C.-C. Lin6, J.
Desai7, M. Lolkema2; 1HK, 2NL, 3Ontario/CA, 4SG, 5KR, 6TW, 7VIC/AU

18:00 - 18:00 84P - Real World Experience of adverse events with immunotherapy using PD1
inhibitors- Single center experience from India

A. Rauthan1, P. Patil1, S.P. Somashekhar1, S. Zaveri2; 1IN, 2Karnataka/IN

Last update: 09-11-2018 [Link]pm

18:00 - 18:00 85TiP - A Phase 1 trial of the safety and pharmacokinetics of cemiplimab, a
human monoclonal antibody to programmed death-1, in Japanese patients with
advanced malignancies, including expansion cohorts for patients with non-small-
cell lung cancer

S. Kitano1, T. Shimizu1, T. Koyama1, T. Ebata1, S. Iwasa1, S. Kondo1, A. Shimomura1, Y.

Fujiwara1, N. Yamamoto1, C. Baum2, S. Li3, P. Rietschel2, T. Sims2; 1JP, 2NY/US, 3NJ/US

18:00 - 18:00 Gastrointestinal tumours, colorectal

D. Goldstein, NSW/AU

18:00 - 18:00 89P - Prevention and Management of Low Rectal Anastomotic Leakage in The
Robotic Era: A Propensity Score Matched Study
J. Xu, W. Chang, Y. Wei, T. Liu; CN

18:00 - 18:00 90P - Robot-assisted versus laparoscopic surgery for colorectal Cancer: short-
term outcome of a retrospective comparative study
L. li, X. Yang, X. Zhu, W. Zhang, L. Feng, B. Du; CN

18:00 - 18:00 91P - Surgery versus Combined Surgery and Chemotherapy: Survival Patterns
among Patients with Stage II Colorectal Adenocarcinoma
A. Shaltout, N. Sayed, A. Abobakr, R. Elemam, I. Uthman; EG

18:00 - 18:00 92P - NORTH/HGCSG1003 : A phase II study evaluating the safety and efficacy of
FOLFOX as adjuvant chemotherapy for patients with stage III colon cancer :
Comparison with medical oncologists and surgeons.

I. Iwanaga1, S. Yuki2, Y. Kawamoto1, H. Nakatsumi1, N. Takahashi1, T. Shichinohe1, H.

Okuda2, A. Ishiguro1, K. Harada1, K. Hatanaka2, K. Oomori1, M. Nakamura1, N.
Senmaru1, K. Iwai1, M. Koike1, Y. Ito1, A. Taketomi1, S. Hirano1, N. Sakamoto1, Y.
Komatsu2; 1JP, 2Hokkaido/JP

18:00 - 18:00 93P - Maintenance therapy with monthly tegafur-uracil for improving disease-
free survival of patients with ypStage III rectal cancer
Y.H. Kuo, TW

18:00 - 18:00 94P - Phase II trial of capecitabine plus oxaliplatin (CAPOX) as perioperative
therapy for locally advanced rectal cancer
J. Hasegawa, T. Kato, J. Nishimura, S. Yoshioka, S. Noura, Y. Kagawa, M. Yasui, M.
Ikenaga, K. Murata, T. Hata, C. Matsuda, T. Mizushima, H. Yamamoto, Y. Doki, M. Mori;
JP

18:00 - 18:00 95P - Long term outcomes of preoperative concurrent CapeOx/RT in locally
advanced rectal cancer
E. Sirachainan, C. Sitathanee, W. Suwanthanma, N. Larbcharoensub, S. Lukrak, N.
Sripaiboonkit Thokanit, S. Phongkitkarun, K. Sumboonnanonda; TH

Last update: 09-11-2018 [Link]pm

18:00 - 18:00 96P - Efficacy and safety of S‑1‑based chemotherapy as first-line treatment in
colorectal cancer: a meta-analysis of randomized controlled trials
Z. Wang, Y. Zang, X. Liu, G. Zhang, G. Cheng; CN

18:00 - 18:00 97P - Is right-sided (sRt) BRAF mutated (mBRAF) metastatic colorectal cancer
(mCRC) unresponsive to the 1st-line antiEGFR antibody treatment?
R. Kudo, JP

18:00 - 18:00 98P - The role of perioperative radiotherapy for patients with local recurrence of
rectal cancer

H. Karasawa1, S. Ohnuma1, H. Suzuki1, A. Kohyama1, K. Watanabe1, T. Kamei1, T.

Naitoh1, M. Unno2; 1JP, 2Miyagi/JP

18:00 - 18:00 99P - Comparative study: Side effects of Folfox4 and Folfiri for Colorectal Cancer
Chemotherapy regiment in Margono Soekarjo Hospital, Purwokerto
I.N.A. Wiratama, W. Djatmiko, I. Ardiansyah, M. Salipi, A. Ilmi, N. Maharani; ID

18:00 - 18:00 100P - Phase 2 KEYNOTE-164 Study of Pembrolizumab (pembro) Monotherapy

for Patients (pts) With Previously Treated, Mismatch Repair–Deficient (dMMR)
Advanced Colorectal Cancer (CRC): Primary and Japan Subgroup Analyses

H. Hara1, T. Yoshino1, H. Taniguchi2, K. Akagi1, K. Shitara1, T. Masuishi2, Y. Kuboki1, T.

Shimamoto1, K. Ueki1, S.R. Han1, K. Noguchi3, L. Diaz4; 1JP, 2Aichi/JP, 3Chiyoda-ku/JP,
4MD/US

18:00 - 18:00 101P - Effect On Oxaliplatin-Free Interval For Successful Rechallenge Of

Oxaliplatin In Colorectal Cancer Patients Who Had Experienced An Oxaliplatin–
Related Hypersensitivity Reaction.

S. Horasawa1, A. Kaneko1, D. Kotani2, S. Nakashima1, H. Bando1, T. Yoshino1; 1JP,

2Chiba/JP

18:00 - 18:00 102P - HGCSG1503 : A retrospective cohort study evaluating the safety and
efficacy of TAS-102 in patients with metastatic colorectal cancer : Analysis of
GERCOR index.

K. Suzuki1, S. Yuki2, S. Nakano1, Y. Kawamoto1, H. Nakatsumi1, K. Hatanaka2, T. Ando1,

K. Furukawa1, A. Ishiguro1, T. Ohta1, K. Eto1, J. Nakajima1, M. Nakamura1, S. Sogabe1,
K. Kato1, M. Tateyama1, S. Kato1, M. Sekiguchi1, Y. Sakata3, Y. Komatsu2; 1JP,
2Hokkaido/JP, 3Aomori/JP

18:00 - 18:00 103P - HGCSG1503 : A retrospective cohort study evaluating the safety and
efficacy of TAS-102 in patients with metastatic colorectal cancer : Analysis of
cases of prior regorafenib.

Y. Tsuji1, S. Yuki1, K. Sawada2, T. Muranaka1, Y. Kobayashi1, H. Okuda1, K. Ogawa2, S.

Minami2, T. Honda2, M. Dazai1, T. Kato2, T. Sasaki2, Y. Shindo2, S. Ota2, A. Sato2, A.
Ueda2, S. Saitoh2, H. Nagai2, Y. Sakata3, Y. Komatsu1; 1Hokkaido/JP, 2JP, 3Aomori/JP

18:00 - 18:00 104P - Efficacy of Ramucirumab in combination with second-line or salvage-line

FOLFIRI in patients with metastatic colorectal cancer.

Last update: 09-11-2018 [Link]pm

 Y. Katata, T. Nagasaka, H. Tanioka, A. Nyuya, T. Toshima, Y. Mori, K. Shigeyasu, M.
Okawaki, M. Yamamura, A. Tsuruta, T. Ueno, Y. Yamaguchi; JP

18:00 - 18:00 105P - A China-Manufactured Bevacizumab Biosimilar, HLX04, Matches

Avastin® Sourced from China, USA and European Union
Y. Ding, T. Yu, J. Sun, M. Wu, Q. Chen, H. Qian, L. Xie, X. Zhang, E. Liu, W. Jiang, S. Liu, A.
LUK; CN

18:00 - 18:00 106P - Safety and efficacy of trifluridine/tipiracil (TAS-102) plus bevacizumab in
clinical practice for patients with refractory metastatic colorectal cancer

D. Kotani1, Y. Kuboki2, K. Yasuda2, Y. Nakamura2, A. Kawazoe2, H. Bando2, H.

Taniguchi2, K. Shitara2, T. Yoshino2; 1Chiba/JP, 2JP

18:00 - 18:00 107P - Phase Ib/ II study of biweekly TAS-102 with bevacizumab combination for
patients with metastatic colorectal cancer refractory to standard therapies (BiTS
study): phase Ib results

Y. Kagawa1, H. Satake2, T. Kato1, K. Oba1, H. Yasui1, M. Nakamura1, T. Watanabe1, K.

Hirata1, K. Muro3, Y. Komatsu4, T. Yoshino1, K. Yamazaki5, H. Mishima3, M. Kotaka2, A.
Tsuji1, Y. Kakeji1, E. Oki6, N. Nagata7, S. Junichi1; 1JP, 2Hyogo/JP, 3Aichi/JP, 4Hokkaido/JP,
5Shizuoka/JP, 6Fukuoka/JP, 7Hukuoka/JP

18:00 - 18:00 108P - A pilot case-control study of second or third line treatment with
cetuximab-containing chemotherapy (Cetux-chemo) in patients (pts) with
metastatic colorectal cancer (mCRC) who were previously treated with Cetux-
chemo
C.S. Ho, A. Cheng, L. Li, W. Ho, E. Hui, K.F. To, J. Tong, B. Ma; HK

18:00 - 18:00 109P - Real-world evidence of the safety and effectiveness of regorafenib in
patients with metastatic colorectal cancer (mCRC) from Taiwan: A subgroup
analysis from the prospective, observational CORRELATE study

K.-H. Yeh1, T.-S. Yang1, T.-C. Hsu1, W.T.-L. Chen1, H.-H. Chen1, H.-W. Teng 1, B.-W. Lin 1, F.-
C. Kuan1, F.-F. Chiang1, C.-W. Duann 1, Y.-S. Li1, S. Fiala-Buskies2, M. Ducreux3, J.-Y.
Wang1; 1TW, 2DE, 3FR

18:00 - 18:00 110P - HGCSG1401 : A retrospective cohort study evaluating the safety and
efficacy of regorafenib in patients with metastatic colorectal cancer : Analysis of
risk factors for liver dysfunction.

A. Ishiguro1, S. Yuki2, S. Nakano1, Y. Kawamoto1, K. Sawada1, Y. Tsuji2, T. Honda1, T.

Miyagishima1, S. Yoshida1, K. Hatanaka2, T. Sasaki1, O. Muto1, H. Ohnuma1, S. Kato1, A.
Sato1, M. Abe1, K. Kato1, T. Amano2, Y. Sakata3, Y. Komatsu2; 1JP, 2Hokkaido/JP,
3Aomori/JP

18:00 - 18:00 111P - TAS-102 Followed by Regorafenib or the Reverse Sequence in Advanced
Colorectal Cancer

Y. NAKATANI1, S. Ueda1, Y. Tsuboguchi1, Y. Yoshii1, K. Akiyoshi1, A. Tsuya1, S. Okazaki2,

S. Tokunaga1, H. Daga1; 1JP, 2Fushimi-ku/JP

Last update: 09-11-2018 [Link]pm

18:00 - 18:00 112P - Efficacy of regorafenib in metastatic colorectal cancer: a multi-
institutional retrospective study

M.S. Bazarbashi1, M. Elshenawy2, M. Kandil1, M. Zahir1, A. Shaheen1, A. Gad3, O.

Alshaer1, A. Alzahrani1, A. Eldali1, A. Aljubran1; 1SA, 2Menoufia Governorate/EG, 3EG

18:00 - 18:00 113P - Real world experience with Regorafenib in dose escalation schedule in
metastatic colorectal cancer in Indian patients

A. Rauthan1, P. Patil1, S.P. Somashekhar1, S. Zaveri2; 1IN, 2Karnataka/IN

18:00 - 18:00 114P - Role of consolidative radiation therapy after surgery in patients with
stage IV rectal cancer
T. Mehmood, PK

18:00 - 18:00 115P - HGCSG1301 : A Multicenter, Double-Blind, Randomized control phase II

trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients
with metastatic colorectal cancer under IRIS/Bev second-line treatment.

M. Dazai1, S. Yuki1, K. Sawada2, T. Muranaka1, Y. Kawamoto2, H. Nakatsumi2, S.

Nakano2, A. Ishiguro2, M. Tateyama2, A. Sato2, Y. Kobayashi1, M. Nakamura2, H.
Okuda1, Y. Takahashi1, K. Eto2, S. Muto2, K. Hatanaka1, T. Amano1, Y. Sakata3, Y.
Komatsu1; 1Hokkaido/JP, 2JP, 3Aomori/JP

18:00 - 18:00 116P - Retrospective Analysis of Outcome in GIST patients on Imatinib in

Sarawak General Hospital: A Single Institution Experience
Y.Y. Sum, U. Nagaswara, S.K. Kho, C.J. Lim, Y.-Y. Junie Khoo; MY

18:00 - 18:00 117P - Immunoscore feasibility study in routine postsurgical pathologic review
for early-stage colon cancer (CC) cases risk-assessment

K. Belaloui1, E. Malifarge1, J. Bohm2, C. Bossard1, R. Dienstmann3, S. Garcia4, C.

Geppert5, I. Gogenur6, A. Hartmann5, D. Hatzibougias7, S. Landolfi3, M. Mishaeli8, D.
Paez3, P. Patel9, M. Rodriguez-Justo10, J. Szafranska3, M. van den Eynde11, E.
Zavadova12, S. Turcan1, F. Hermitte1; 1FR, 2FI, 3ES, 4CEDEX 20/FR, 5DE, 6DK, 7GR, 8IL,
9IN, 10GB, 11BE, 12CZ

18:00 - 18:00 118P - The Impact of Universal Immunohistochemistry on Lynch Syndrome

Diagnosis in an Australian Colorectal Cancer Cohort

Z. Loh1, D. Williams2, L. Salmon2, E. Dow2, T. John2; 1AU, 2VIC/AU

18:00 - 18:00 119P - Poor-prognosis Locally Advanced Rectal Cancer is Defined by a

Molecularly Distinct Subtype
J. Zhang, L. Shen, Y. Wang, Y. Deng, L. Yang, J. Wan, Z. Zhang; CN

18:00 - 18:00 120P - Comparison of incidence and survival outcomes in mucinous and signet-
ring cell colorectal cancers with classical adenocarcinoma: A SEER analysis
T. Mehmood, PK

Last update: 09-11-2018 [Link]pm

18:00 - 18:00 121P - Prognosis of Three Histological Subtypes of Colorectal Adenocarcinoma:
A Retrospective Analysis of 8005 Chinese Patients
C. Li, H. Zheng, D. Huang, S. Cai, J. Zhu; CN

18:00 - 18:00 122P - Impact of tumor regression grade as a major prognostic factor in
pathological stage II and III rectal cancer after neoadjuvant chemoradiotherapy

J.-S. Kim1, C. Song2, S.-B. Kang2, H.S. Lee2, K.-W. Lee 2; 1Gyeonggi-do/KR, 2KR

18:00 - 18:00 123P - Development of a Nomogram for Predicting Survival in Microsatellite

Stable Patients with Resected Colorectal Cancer
Y. Li, J. Peng, D. Huang, X. Ma, S. Cai; CN

18:00 - 18:00 124P - Targeted sequencing of germline colorectal cancer predisposition genes
in young Asians
J. Chiang, M.R. Toh, J. Ngeow; SG

18:00 - 18:00 125P - A SEER analysis of increasing disparities in age-related cause specific
survival (CSS) among patients with colorectal cancer
T. Mehmood, PK

18:00 - 18:00 126P - STING, an immune biomarker for colorectal cancer

H. Chon, D. Kim, C. Kim; KR

18:00 - 18:00 127P - A model based on a new inflammation–nutrition score and TNM stage for
predicting overall survival of patients with colorectal cancer
S. Fujino, N. Miyoshi, K. Saso, M. Sasaki, S. Ishikawa, Y. Takahashi, M. Yasui, M. Ohue, T.
Hata, C. Matsuda, T. Mizushima, Y. Doki, M. Mori; JP

18:00 - 18:00 129P - Prevalence of Vitamin D deficiency in Chinese Patients with Early Stage
Colorectal Cancer
D. Ng, R. Tan, R. Sultana, M. Ang, W. Lim, D. Chong, C. Cwl, S.-L. Koo, S. Seet, Z. Tan, I.
Tan; SG

18:00 - 18:00 130P - Liquid Biopsy has a potential to predict the colorectal cancer patients
with destiny for recurrence after curative surgery

T. Toshima1, A. Nyuya1, U. Umeda1, K. Yasui1, K. Yoshida1, T. Fujiwara1, A. Goel2, T.

Nagasaka1; 1JP, 2US

18:00 - 18:00 131P - Novel drug discovery for cancer invasion and metastasis
H.J. Na, S.Y. Park, S.J. Lee, Y.R. Kim, J.W. Choi; KR

18:00 - 18:00 133P - Molecular characterization of cancer associated fibroblasts in colorectal

cancer

T. Aizawa1, H. Karasawa1, H. Suzuki1, A. Yamamura1, S. Ohnuma1, T. Kamei1, T. Naitoh1,

M. Unno2; 1JP, 2Miyagi/JP

Last update: 09-11-2018 [Link]pm

18:00 - 18:00 134P - A retrospective analysis of the association between perioperative
carcinoembryonic antigen level and prognosis in stage III colorectal cancer

R. Kozuki1, E. Shinozaki1, H. Osumi1, T. Wakatsuki1, M. Suenaga1, T. Ichimura1, M.

Ogura1, T. Suzuki1, Y. Ota1, I. Nakayama1, D. Takahari2, K. Chin1, T. Nagasaki1, T.
Akiyoshi1, T. Konishi1, Y. Fujimoto1, S. Nagayama1, Y. Fukunaga1, M. Ueno1, K.
Yamaguchi1; 1JP, 2Aichi/JP

18:00 - 18:00 135P - Association of preoperative CEA with recurrence in high risk of
recurrence groups with Stage2 and 3 colorectal cancer patients received by
CapeOX adjuvant chemotherapy
H. Osawa, JP

18:00 - 18:00 137P - Prognostic value of staging FDG PET/CT in patients with metastatic
colorectal cancer
E.K. Choi, J.K. Oh, Y.-A. Chung; KR

18:00 - 18:00 138P - Natural killer NKG2A and NKG2D serum levels in patients with colorectal
cancer
G. Refaat, A. Mohamed, W. Zaki, M. Adel, M. Amin, M. Deeb, M. Rushdy, N. Safwat; EG

18:00 - 18:00 139P - Prognostic value of high EZH2 expression in patients with colorectal
cancer in East Azerbaijan, Iran

Z. Sanaat1, R. Dolatkhah2, N. Gholami2; 1East Azarbaijan/IR, 2IR

18:00 - 18:00 140P - DCLK1 as part of EMT feedback-loop promotes colorectal cancer cell
proliferation, invasion, and 5-Fu resistance

Y. Ge1, N. Weygant2, D. Qu2, C.W. Houchen3; 1CN, 2OK/US, 3AL/US

18:00 - 18:00 141P - Tumor-Associated Carbohydrate Antigens – Tn Antigen Expression and

Contribution in Human Colorectal Cancer
Y. Jiang, T. Wen; CN

18:00 - 18:00 142P - Biological characteristics predict outcome of rectal cancer patients: Data
from tertiary care hospital in a low economic country
A. zaki, S. Hirani, S. Sawani, S. Sarwar, M. Moosajee; PK

18:00 - 18:00 143P - The role of molecular biomarker CDKN-2A in early diagnosis of colorectal
cancer
Y. Ten, M. Tiilashaykhov, S. Abdujapparov, H. Islamov, Y. Ziyaev; UZ

18:00 - 18:00 144P - The Impact of Bone Fracture on Prognosis of Colorectal Cancer Patients
Receiving Chemotherapy.
Y. Sakai, T. Sone, T. Murai, K. Itaya, Y. Ono, M. Nakamura; JP

18:00 - 18:00 145P - pregnancy had no significant impact on young colorectal cancer patients
J. Zhu, J. Wang; CN

Last update: 09-11-2018 [Link]pm

18:00 - 18:00 146TiP - A multicenter, multicohort, phase 2 study of trastuzumab deruxtecan
(DS-8201a) in subjects with HER2-expressing metastatic colorectal cancer

T. Yoshino1, S. Siena2, R. Dalal3, Y. Okuda1, E. Yamamoto1, A. Grothey4; 1JP, 2IT, 3US,

4TN/US

18:00 - 18:00 147TiP - Impact of the Immunoscore® assay on adjuvant chemotherapy decision
making in patients with resected stage II-III colon cancer: A prospective,
multicenter study (PROSCORE)
D. Malka, C. Mollevi, F. Hermitte, A. Catteau, N. LACHAUX, C. Jouffroy; FR

18:00 - 18:00 YO8 - Delayed perforation after stent placement for sigmoid colon cancer
obstruction
S. Fukai, K. Mizokami; JP

18:00 - 18:00 YO9 - Durable response to cetuximab plus FOXFOX in metastatic unresectable
sigmoid colon cancer
D. Ratanapichayachai, TH

18:00 - 18:00 YO10 - Rectal Adenocarcinoma and Ileocecal Tuberculosis: a simple coincidence
or a pathologic co-existence?
J.M.J. Lomanta, C.D. Uy, J. Ignacio, R. Berba; PH

18:00 - 18:00 Gastrointestinal tumours, non-colorectal

18:00 - 18:00 156P - TCOG T1308 Study: The Final Results of a Phase II Trial of modified
Gemcitabine plus S-1 combination as the First-line Treatment in Patients with
Advanced Biliary Tract Cancer

N.-J. Chiang1, L.-T. Chen 1, J.-S. Chen1, S.-H. Yang1, C. Hsu1, Y.-S. Shan1, C.-J. Yen2, M.-H.
Chen1, H.-H. Tsou1; 1TW, 2CN

18:00 - 18:00 157P - Epidemiological parameters and survival outcome of Gall bladder cancer:
An North West India based institution study

S. Narayan1, P. Pareek2; 1Rajasthan/IN, 2IN

18:00 - 18:00 158P - Impact on gemcitabine plus cisplatin in unresectable hilar

cholangiocarcinoma patients according to effective bile drainage
K. Min Jae, J.-H. Hwang, J.-C. Lee, D.W. Shin, S.Y. Yang; KR

18:00 - 18:00 159P - Clinical prognostic factors and treatment outcomes for survival of
patients with cholangiocarcinoma
C. Charonpongsuntorn, P. Piyasatit, P. Chonmaitree, P. Muangnoi, D. Muntham; TH

18:00 - 18:00 160P - Common Chromosomal Abnormalities in Gastric Cancer Cell Lines and
Ascetic Fluids of Metastatic Gastric Cancer Patients

Last update: 09-11-2018 [Link]pm

 M. Yaghmaie, T. Nayebbagher, H. Pashaiefar, K. Alimoghaddam, M. Jalili, M. Esfandbod,
M. Saberian, H. Behroozi, M. Izadifard, A. Ghavamzadeh; IR

18:00 - 18:00 161P - Efficacy and safety of modified ECF regimen as first-line chemotherapy in
metastatic gastric adenocarcinoma: A phase II study
T. Chaudhuri, K.G. Babu, K.C. Lakshmaiah, L. Dasappa, L. Jacob, M.C.S. Babu, K.N.
Lokesh, A.H. Rudresha, L.K. Rajeev, R. Patidar, V. Asati, R. Chethan, D. Koppaka, A.
Anand; IN

18:00 - 18:00 162P - A population-based outcomes study of patients with metastatic gastric
cancer receiving second-line chemotherapy: A nationwide health insurance
database study

K.-W. Lee 1, I.S. Choi2, J.H. Kim1; 1Gyeonggi-do/KR, 2KR

18:00 - 18:00 163P - mFLOT versus EOX in first line treatment of metastatic carcinoma of
stomach

V. Srinivasalu1, N. Subramaniam1, W. Jose2, A. Philip3, K. Pavithran2; 1IN, 2Kerala/IN,

3Tamil Nadu/IN

18:00 - 18:00 164P - Gastric Adenocarcinoma Incidence And Mortality Trends In Asian-
American Population
M. Gad, A. Saad, M. Al-Husseini; EG

18:00 - 18:00 165P - Prognostic Significance of CT-determined Sarcopenia in Patients with

Advanced Gastric Cancer Treated with Chemotherapy
Y.S. Kim, E.Y. Kim, H.K. Ahn, I. Park, S.-C. Lee, I.G. Hwang, S.J. Sym, D.B. Shin; KR

18:00 - 18:00 166P - Assessment of molecular classification of gastric cancer by

immunohistochemistry and in situ hybridization: a validation study in the
chinese population
Y. Sun, W. Yu, W. Guan, M. Qiao, L. Zheng, R. Jiang, R. Wang, L. Wang; CN

18:00 - 18:00 167P - Pattern of gastric cancer in young(GCY) : A retrospective study from a
tertiary cancer care centre in Indian subcontinent.
S. Kumar, K. Gupta, T. Murali, K. Dharma, A. Anand, M. Bhandare, V. Chaudhary, S.
Shrikhande; IN

18:00 - 18:00 168P - Optimal time interval between surgery and adjuvant chemotherapy of
gastric cancer
G.T. Ahn, S.K. Baek, S.-Y. Kim, J.J. Han, H.-J. Yoon, C.H. Maeng; KR

18:00 - 18:00 169P - Apatinib reverses resistance of paclitaxel-containing regimens in

advanced gastric cancer: a phase II study
R. Lin, N. Fan, H. Li, J. Liu, S. Zhao, J. Yu; CN

Last update: 09-11-2018 [Link]pm

18:00 - 18:00 170P - Early Results of Pegvorhyaluronidase Alfa (PEGPH20; PVHA) +
Pembrolizumab Therapy in Patients (Pts) with Relapsed/Refractory
Gastric/Gastroesophageal Junction (GEJ) Adenocarcinoma

R.D. Harvey1, A. Murphy2, E. Kim3, M. Tejani4, W. Wu3, E. Pham5, M. Muhsin5; 1AL/US,

2MD/US, 3CA/US, 4NY/US, 5US

18:00 - 18:00 171P - A novel method of measuring exosomal HER2 to assist in selecting
advanced gastric cancer patients benefiting from anti-HER2 therapy

Q. Li1, X. Xu1, Y. Yu1, W. Li1, L. Liang1, J. Song1, X. Zhao1, S. Cai1, T. Liu2; 1CN,
2Changning/CN

18:00 - 18:00 172P - CT image features of peritoneal metastasis and outcomes of the advanced
gastric cancer patients receiving 2nd-line chemotherapy
S. Kita, A. Takashima, H. Hirano, M. Aoki, H. Imazeki, M. Ishikawa, H. Shoji, Y. Honma, S.
Iwasa, N. Okita, K. Kato, K. Nagashima, N. Boku; JP

18:00 - 18:00 173P - How can we predict the possibility of advanced gastric cancer patients to
receive third-line chemotherapy in the real-world setting?
M. Ueno, A. Doi, H. Mouri, M. Mizuno; JP

18:00 - 18:00 174P - EMT markers gene expression in BPIFB2 overexpressed gastric cancer
cell lines
Z. Karim, N.A. Zulkifli, S.H. Sheikh Abdul Kadir, K. Abd Khalil, M. Musa; MY

18:00 - 18:00 175P - Overall Survival Results From a Phase 3 Trial of Trifluridine/Tipiracil
(FTD/TPI) vs Placebo in Patients (Pts) with Metastatic Gastric Cancer Refractory
to Standard Therapies (TAGS)

K. Shitara1, J. Tabernero2, M. Dvorkin3, W. Mansoor4, H.-T. Arkenau 4, A. Prokharau5, M.

Alsina2, M. Ghidini6, C. Faustino7, V. Gorbunova3, E. Zhavrid5, K. Nishikawa1, A.
Hosokawa1, D. Ganea8, Ş. Yalçın9, K. Fujitani1, G. Beretta6, R. Winkler10, T. Doi1, D.
Ilson10; 1JP, 2ES, 3RU, 4GB, 5BY, 6IT, 7PT, 8RO, 9TR, 10AL/US

18:00 - 18:00 176P - Superior antitumor efficacy of interferon incorporated hydrogels

combined with CIK and radiation against gastric cancer
Q. Liu, D. Zhang, H. Qian, B. Liu; CN

18:00 - 18:00 177P - Long-term results of conversion therapy for initially unresectable gastric
cancer: analysis of 122 patients at the National Cancer Center in China
T. Wang, N. Wang, H. Ren, H. Zhou, A. Zhou, J. Jin, Y. Chen, D. Zhao; CN

18:00 - 18:00 178P - FOXO3 inhibits human gastric adenocarcinoma (AGS) cell growth by
promoting autophagy in an acidic microenvironment
Y. Gao, CN

18:00 - 18:00 179P - Efficacy and Safety of Regorafenib after Progression on Sorafenib in
Korean Patients with Advanced Hepatocellular Carcinoma (HCC)

Last update: 09-11-2018 [Link]pm

 C. Yoo1, J.-W. Park 2, Y.J. Kim2, D.Y. Kim2, S.J. Yu2, T.S. Lim2, B.-Y. Ryoo 2, S.J. Lee2, H.-Y.
Lim2; 1Songpa-gu/KR, 2KR

18:00 - 18:00 180P - Prognostic Factors affecting the survival of hepatocellular carcinoma
patients undergoing different surgical techniques
S. Ahmed, M. Morsi, I. Uthman; EG

18:00 - 18:00 181P - GNMT negatively regulates MAPK Pathway and suppresses the growth
and metastasis of Hepatocellular cancer cells
S. Jiang, F. Jingyuan; CN

18:00 - 18:00 182P - Lenvatinib acts as the salvage therapy for advanced hepatocellular
carcinoma
M.-C. Hsieh, Y.-L. Su, Y.-Y. Chen, C.-T. Liu, Y.-H. Chen, T.-J. Chiu, S.-N. Pei, C.-C. Wu, K.-M.
Rau; TW

18:00 - 18:00 183P - Response to Multi-Targeted Kinase Inhibitor (MKI) after Immune
Checkpoint Inhibitor (ICI) in Patients with Hepatocellular Carcinoma (HCC)
S. Chng, S. Tan, J. Lee, S.P. Choo; SG

18:00 - 18:00 184P - Continued Value of the Serum Alpha-Fetoprotein in Surveilling At-Risk
Populations for Hepatocellular Carcinoma
J.H. Shim, J. An, B. Oh, J. Song, Y.J. Oh; KR

18:00 - 18:00 185P - Role of Tie2, CD14, angiopoietin as angiogenetic markers in

hepatocellular carcinoma complicating hepatitis C virus infection in Egyptian
patients
E.-Z. Meghezel, H. Abdelhfez Ahmed, A. Askar, E.E. Hassan, A. Elyamany; EG

18:00 - 18:00 186P - Phase 2 trial of tepotinib vs sorafenib for treatment-naïve advanced
hepatocellular carcinoma (HCC) in Asian patients

B.-Y. Ryoo 1, Z. Ren2, T.-Y. Kim 1, H. Pan3, K.-M. Rau2, H.J. Choi1, J.-W. Park 1, J.H. Kim4, C.-
J. Yen2, B.-H. Kim1, D. Zhou2, J. Straub5, C. Zhao6, S. Qin2; 1KR, 2CN, 3Zhejiang/CN,
4Gyeonggi-do/KR, 5DE, 6MA/US

18:00 - 18:00 187P - Outcome of induction chemotherapy consisting of docetaxel, cisplatin,

and S-1 (DCS) followed by esophagectomy for cT4 esophageal cancer in
comparison with chemoradiotherapy
H. Shimoji, T. Nishimaki, H. Karimata, Y. Nakamura; JP

18:00 - 18:00 188P - Outcome of Small Cell Carcinoma of Esophagus: An Institutional

Experience from North-East India

P. Roy1, B. Saikia2, M. Hazarika2, C. Bhuyan2, G. Kumar2, R. Mishra2, C.W. Nyuthe2;

1Assam/IN, 2IN

Last update: 09-11-2018 [Link]pm

18:00 - 18:00 189P - Efficacy of palliative chemotherapy (CTx) by lines of treatment in patients
(pts) with recurrent/metastatic esophageal squamous cell cancer (SCC):
Retrospective analysis of 103 patients in single center
E. Kim, S.R. Park, J.H. Kim, Y.-H. Kim, H.R. Kim, S.-B. Kim; KR

18:00 - 18:00 190P - Metastatic to negative lymph node ratio - can it used as a prognostic
indicator in squamous cell carcinoma esophagus
G. M.s, IN

18:00 - 18:00 191P - Nomogram to predict cancer-specific survival in patients with pancreatic
acinar cell carcinoma: A competing risk analysis
C. He, S. Li; CN

18:00 - 18:00 192P - Use of FOLFIRINOX chemotherapy in an Australasian population of

pancreatic cancer

A. Jalali1, M. Lee2, C. Semira3, S. Banks3, H.-L. Wong1, S. Ananda1, L. Lipton1, J.

Shapiro1, P. Cooray1, K. Clarke4, M. Burge5, R. Wong1, J. Shapiro3, S.-A. McLachlan3, M.
Harris1, D. Croagh3, N. Tebbutt1, P. Gibbs1, B. Lee1; 1VIC/AU, 2ACT/AU, 3AU, 4NZ,
5QLD/AU

18:00 - 18:00 193P - Prognostic implication of inflammation-based scores in patients with

metastatic pancreatic cancer (mPC) treated with first-line nab-paclitaxel plus
gemcitabine (AG)

H.N.N. Ip1, I. Hwang2, J. Kang2, K.-P. Kim2, J.H. Jeong2, H.-M. Chang2, B.-Y. Ryoo 2, C.
Yoo2; 1HK, 2KR

18:00 - 18:00 194P - Runx1 enhancer element marks stem/ progenitor cells in pancreas and
can be an origin of cancer

H. Sato1, A. Yamamura1, J. Matsuo2, Z. Hossain2, M. Osato2, T. Naitoh1, T. Kamei1, M.

Unno3, Y. Ito2; 1JP, 2SG, 3Miyagi/JP

18:00 - 18:00 195P - Symptoms at diagnosis of (metastatic) pancreatic adenocarcinoma

([m]PAC) in routine practice and frequency variation across Europe

A. Carrato Mena1, D. Melisi2, B. Westphalen3, Å. Mellbring4, J. Taieb5, G. Prager6, T.

Macarulla Mercadé1, N. D´esquermes5, A. Ferreras5, F. de Jong7; 1ES, 2IT, 3DE, 4SE,
5FR, 6AT, 7CH

18:00 - 18:00 196P - HGCSG1403 : Phase I trial of oxaliplatin / irinotecan / S-1 (OX-IRIS) as
first line chemotherapy for unresectable pancreatic cancer.

A. Yoshikawa1, Y. Kawamoto1, S. Yuki2, S. Nakano1, K. Sawada1, T. Muranaka2, H.

Nakatsumi1, K. Harada1, Y. Kobayashi2, T. Miyagishima1, T. Saiki1, A. Ishiguro1, R.
Saito1, N. Ehira1, I. Iwanaga1, K. Hatanaka2, N. Abe1, N. Sakamoto1, Y. Sakata3, Y.
Komatsu2; 1JP, 2Hokkaido/JP, 3Aomori/JP

18:00 - 18:00 197P - Expression of p16 and KRAS in periampullary cancers

J. swain, M.T. Tewari; IN

Last update: 09-11-2018 [Link]pm

18:00 - 18:00 199P - Incidence, risk factors, and outcomes of arterial thromboembolism in
patients with pancreatic cancer following palliative chemotherapy
W.-C. Chou, Y.-Y. Chen, J.-S. Chen, C.-H. Lu, P.-H. Chang, C.-Y. Hung; TW

18:00 - 18:00 200P - Liposomal irinotecan (nal-IRI) plus 5-FU/LV in patients (pts) with
metastatic pancreatic ductal adenocarcinoma (mPDAC) progressing on
gemcitabine-based treatment: further subgroup analyses of the pivotal NAPOLI-
1 study

L.-T. Chen 1, T. Macarulla Mercadé2, K.-H. Lee3, G. Lakatos4, A. Wang-Gillam5, B.

Mirakhur6, F. de Jong7; 1TW, 2ES, 3KR, 4HU, 5MO/US, 6US, 7CH

18:00 - 18:00 201P - Three-dimensional remnant pancreatic volumetry as an indicator of poor

prognosis in pancreatic cancer patients after pancreatoduodenectomy
R. Miyamoto, N. Sano, M. Maeda, S. Inagawa; JP

18:00 - 18:00 202P - GLRLM feature by using CT texture analysis is prognostic factor ,
Evaluation of pancreatic cancer heterogeneity
H.S. Kim, J.S. Park, Y.J. Kim, K.G. Kim; KR

18:00 - 18:00 204P - Prognostic impact of progression type by RECIST criteria in patients with
metastatic pancreatic cancer who received 1st line gemcitabine based
chemotherapy
J. Lee, M.A. Lee, I.-H. Kim; KR

18:00 - 18:00 205P - Trends in the Incidence, Prevalence, and Survival Outcomes of
Appendiceal Adenocarcinoma
W. Xiang, G. Cai; CN

18:00 - 18:00 206P - Incidence of catheter-related thrombosis in patients with long-term

indwelling central venous catheter who received chemotherapies for
unresectable advanced digestive cancers
H. Tanioka, M. Asano, K. Kawasaki, R. Yoshida, N. Waki, F. Uno, M. Ishizaki, K.
Yamashita, Y. Morishita, Y. Katata, T. Nagasaka; JP

18:00 - 18:00 207TiP - A phase I/II Trial of CRISPR-Cas9-mediated PD-1 knockout Epstein-
Barr Virus cytotoxic lymphocytes (EBV-CTLs) for advanced stage EBV associated
malignancies

B. Liu1, J. Yan1, S. Su1, J. Shao1, Y. Zhao1, Q. Xu1, Y. Yang1, Z. Zou1, X. Huang1, J. Wei2;
1CN, 2Jiangsu Province/CN

18:00 - 18:00 208TiP - A randomized, phase 2, multicenter, open-label study of trastuzumab

deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer

K. Shitara1, Y.-J. Bang2, D. Sakai3, H. Yasui3, Y. Kawaguchi3, M. Sugihara3, K. Saito3, R.

Dalal4, K. Yamaguchi3; 1Chiba/JP, 2KR, 3JP, 4US

Last update: 09-11-2018 [Link]pm

18:00 - 18:00 209TiP - CA209-9DX: Phase 3, Randomized, Double-Blind Study of Adjuvant
Nivolumab vs Placebo for Patients with Hepatocellular Carcinoma (HCC) at High
Risk of Recurrence after Curative Resection or Ablation

M.J. Jimenez Exposito1, M. Akce2, J. Alvarez3, E. Assenat4, L. Balart5, A. Baron6, T.

Decaens4, A. Heurgue-Berlot4, A. Martin3, S. Paik7, V. Poulart8, A. Sehbai9, M.
Shimada10, N. Takemura10, J.-H. Yoon7; 1US, 2GA/US, 3ES, 4FR, 5LA/US, 6CA/US, 7KR,
8BE, 9AL/US, 10JP

18:00 - 18:00 210TiP - IMbrave150: a randomised Phase III study of atezolizumab +

bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular
carcinoma

S. Qin1, A.-L. Cheng2, M. Ducreux3, P. Galle4, A. Zhu5, T.-Y. Kim 6, D.-Z. Xu1, W. Verret7, J.
Liu1, R. Finn8, M. Ikeda9; 1CN, 2TW, 3CEDEX/FR, 4DE, 5US, 6KR, 7AL/US, 8CA/US,
9Chiba/JP

18:00 - 18:00 211TiP - HALO 110-101: Phase 1b Study of PEGPH20 in Combination with
Cisplatin + Gemcitabine (PEGCISGEM) or Atezolizumab (ATEZO) + CIS + GEM
(PEGCISGEMATEZO) in Patients with Locally Advanced/Metastatic
Cholangiocarcinoma and Gallbladder Cancer

D.-Y. Oh 1, J.-O. Park1, C. Charoentum2, S. Stein3, M. Noel4, V. Chung5, W. Wu5, R. Alton5,

M. Muhsin6, M. Javle7, G. Abou-Alfa4, M. Borad8; 1KP, 2TH, 3CT/US, 4NY/US, 5CA/US,
6US, 7TX/US, 8AZ/US

18:00 - 18:00 YO11 - Hepatocellular carcinoma responding to sequential radioembolization

and external radiotherapy: A successful salvage?
A. Ahmed, QA

18:00 - 18:00 YO12 - Solid Pseudopapillary Tumor of Pancreas: A Case Report

S. m, G. Ushashree, N. Rao, R. Reddy; IN

18:00 - 18:00 YO13 - Synchronous adenocarcinoma and gastrointestinal stromal tumors in the
stomach
H. Ubaydullaeva, UZ

18:00 - 18:00 YO14 - Gastrointestinal perforation caused from colonofiberscopy to lung

adenocarcinoma with metastasises small intestine ; a case report
N. Haruta, Y. Haruta, M. Matsuo, K. Murase; JP

18:00 - 18:00 YO15 - A case of Obstructive Jaundice in Hepatocellular Carcinoma Treated with
Stereotactic Body Radiation Therapy
A. Giselvania, A. Munandar, G.B. Prajogi, S.M. Sekarutami, S. Gondhowiardjo; ID

18:00 - 18:00 Genitourinary tumours, prostate

Last update: 09-11-2018 [Link]pm

18:00 - 18:00 215P - Comparison between robot-assisted radical prostatectomy and minimum
incision endoscopic radical prostatectomy for high-risk prostate cancer
following neoadjuvant therapy : A propensity score-matched analysis
A. Imai, H. Yamamoto, S. Hatakeyama, T. Yoneyama, Y. Hashimoto, C. Ohyama; JP

18:00 - 18:00 216P - The impact of different treatment modalities on toxicity and quality of life
for prostate cancer - a real-world study based on WeChat in China
X. Qi, H. Li, S. Gao; CN

18:00 - 18:00 217P - HoxB13 expression in prostate cancer: clinicopathologic characteristics

and role as potential diagnostic marker
Y.A. Cho, C.K. Park, N.H. Cho; KR

18:00 - 18:00 218P - Stereotactic body radiotherapy (SBRT) versus conventional fractionated
intensity-modulated radiotherapy (CF-IMRT) for Asian patients with early-stage
localized prostate cancer: acute toxicity results from a prospective randomized
phase II study

D. Poon1, D. Lam1, K. Wong1, F. Mok2, F. Mo1, C.M. Chu1, A.C.F. Ng1, J. Suen1, A. Chan1;
1HK, 2Kowloon/HK

18:00 - 18:00 219P - The linear-quadratic (LQ) model is inappropriate for high doses per
fraction owing to α/β ratio is not a constant: evidence deduced from
radiotherapy outcomes of 16367 prostate cancer patients.
M. Cui, S. Gao; CN

18:00 - 18:00 220P - Examining skeletal-related events in Australian men with castration-
resistant prostate cancer (CRPC)

A. Anton1, S. Wong2, P. Parente2, A. Azad2, J. Shapiro1, A. Weickhardt2, J. Torres2, F.

Parnis3, J. Goh4, C. Semira1, P. Gibbs2, B. Tran1, C. Pezaro2; 1AU, 2VIC/AU, 3SA/AU,
4QLD/AU

18:00 - 18:00 221P - Prognostic impact of pT3a subclassification based on extent of

extraprostatic extension after robot-assisted radical prostatectomy.
K. Kanao, M. Sugie, S. Morinaga, H. Muramatsu, K. Kajikawa, I. Kobayashi, G.
Nishikawa, M. Watanabe, K. Zennami, K. Nakamura, M. Sumitomo; JP

18:00 - 18:00 222P - Immunotherapy with dendritic cells derived from bone marrow
hematopoietic stems cells inhibited tumor growth on a TRAMP-C1 syngeneic
mouse model of prostate cancer
Y. Kim, B.-M. Kim, C.-S. Kim, H. Kim, S.Y. Choi, H. Lee; KR

18:00 - 18:00 223P - Using PSMA PET/CT to assess response in metastatic prostate cancer
(mPC) patients (pts) receiving upfront chemohormonal therapy.

A. Anton1, Z. Ballok1, P. Bowden2, T. Costello3, L. Harewood3, N. Corcoran3, P. Dundee3,

J. Peters3, N. Lawrentschuk3, A. Troy3, D. Webb3, Y. Chan3, A. See3, S. Siva3, D. Murphy3,
M. Hofman3, B. Tran1; 1AU, 2ACT/AU, 3VIC/AU

Last update: 09-11-2018 [Link]pm

18:00 - 18:00 224P - A new novel gene ABCC5 promotes castration-resistant prostate cancer
progression through ERK carcinogenic pathway
G. Ji, CN

18:00 - 18:00 225P - Docetaxel versus Abiraterone in Newly Diagnosed Metastatic Prostate
Cancer : Study from Tertiary Care Cancer Centre in a Developing Country
S. Hussain, G. Gautam, P. Ahluwalia, A. Punnakal, H. Chaturvedi, A. Gupta; IN

18:00 - 18:00 226P - Aldo-keto-reductase 1C3 expression in prostate cancer

Y. Hashimoto, A. Imai, H. Yamamoto, S. Hatakeyama, T. Yoneyama, C. Ohyama; JP

18:00 - 18:00 227P - LOCALISED CARCINOMA PROSTATE: Intensity Modulated Radiotherapy

(IMRT) Followed By Stereotactic Body Radiotherapy (SBRT) Boost: A Feasibility
Study For Acute Toxicity.
G. Deepthi, N. Kumar, S. Kumar, B. Yadav, P. Gupta; IN

18:00 - 18:00 228P - Upfront Chemotherapy for High Volume HSPC, Single Institute
Experience of Southern Taiwan
C.-M. Tsai, J.-T. Lin, C.-C. Yu, T. Wu, I.-H. Cheng, M.-X. He; TW

18:00 - 18:00 229P - Predictability of intra-fractional prostate motion

K. Perumal, M. Potharaju; IN

18:00 - 18:00 230P - Utility of Gallium-68 PSMA PET/CT Scan for Staging and Treatment of
Prostate Cancer in Contemporary Era: Study from Tertiary Care Cancer Centre in
a Developing Country
A. Gupta, S. Hussain, P. Ahluwalia, G. Gautam, A. Punnakal, H. Chaturvedi, A. Rajput, J.
Bal, P. Dougall; IN

18:00 - 18:00 231P - Prognostic and predictive clinical factors for progression to castration
refractory prostate cancer in patients with hormone sensitive prostate cancer.
M. Watanabe, K. Kanao, M. Sugie, S. Morinaga, H. Muramatsu, I. Kobayashi, K. Kajikawa,
G. Nishikawa, K. Zennami, K. Nakamura, M. Sumitomo; JP

18:00 - 18:00 Genitourinary tumours, non-prostate

18:00 - 18:00 234P - Quantitative proteomic analysis identifies AHNAK as a novel candidate
biomarker for bladder urothelial carcinoma diagnosis
C. hyun, M.S. Park; KR

18:00 - 18:00 235P - Comparison of Cisplatin versus Carboplatin Chemotherapy for Metastatic
Urothelial Carcinoma in Patients with Stage 3 Chronic Kidney Disease
C.-C. Wu, K.-M. Rau, M.-C. Hsieh, Y.-L. Su; TW

Last update: 09-11-2018 [Link]pm

18:00 - 18:00 236P - The relationship between preoperative stage 3B chronic kidney disease
and post-surgical oncological outcomes in patients with urothelial carcinoma
S. Hatakeyama, H. Yamamoto, A. Imai, T. Yoneyama, Y. Hashimoto, T. Koie, C. Ohyama; JP

18:00 - 18:00 237P - High expression of sushi domain containing 2 (SUSD2) promote cell
proliferation in bladder cancer and was associated poor survival outcome.
C. Wang, TW

18:00 - 18:00 238P - Role of Post Lasix FDG PETCT in Recurrent Carcinoma Bladder
S. Malapure, R. Kumar, P. Sharma; IN

18:00 - 18:00 239P - Correlation of DNA damage and urinary cotinine levels in cases of
carcinoma urinary bladder.
T. Singh, S. Gupta, P. Garg; IN

18:00 - 18:00 240P - Determine cisplatin or carboplatin in first-line chemotherapy for elderly
patients with metastatic urothelial carcinoma: Does age preclude cisplatin
eligibility?
S.Y. Huang, Y.-L. Su, M.-C. Hsieh, K.-M. Rau; TW

18:00 - 18:00 241P - Does neoadjuvant chemotherapy promote chemoresistance after

recurrence in patients with muscle-invasive bladder cancer?
S. Hatakeyama, H. Kodama, S. Konishi, K. Okita, H. Yamamoto, A. Imai, T. Yoneyama, Y.
Hashimoto, T. Koie, C. Ohyama; JP

18:00 - 18:00 242P - A Novel Cost-effective Method for Diagnosis of Bladder Cancer by
Detecting ErbB3 Expression in Urine
X. Chen, S. Wang, C. Liu, J. Chen, D. Wang, M. Huang, J. Song, S. Cai, S. Qiu; CN

18:00 - 18:00 243P - Node-positive bladder cancer after neoadjuvant chemotherapy followed by
radical cystectomy: a single-center retrospective study
J.H. Cho, J. Lee, Y. Kim, S. Park, S.E. Yoon, K.K. Lee, J.Y. Hur, S.J. Lee, S.H. Park; KR

18:00 - 18:00 244P - Lipid cell change in urothelial carcinoma - Signs of tumor aggression and
the worst prognosis among the variants -
T. Hayashi, G. Kimura, Y. Kondo; JP

18:00 - 18:00 245P - comparison of partial nephrectomy and percutaneous radiofrequency

ablation for small renal mass in the manner of PADUA classification
W.-T. Kuo, TW

18:00 - 18:00 246P - Patient characteristics, patterns of care and survival outcome in patients
with Adult testicular granulosa cell tumor: an individual patient data meta-
analysis

S. Thambi1, R. Benson2, L. Haridas1; 1IN, 2Delhi/IN

Last update: 09-11-2018 [Link]pm

18:00 - 18:00 247P - Clinicopathological and survival analysis of endometrial carcinoma: a
single center experience in Pakistan
Z. Samoon, S. Ahmed, S. Jehangir, S. Rizvi, S. Sawani; PK

18:00 - 18:00 249P - The gap of frailty value from a community-dwelling population predict
oncological outcomes in patients with urological cancers
S. Hatakeyama, S. Konishi, K. Okita, O. Soma, T. Matsumoto, T. Yoneyama, Y. Hashimoto,
T. Koie, C. Ohyama; JP

18:00 - 18:20 YO16 - Urothelial carcinoma of the kidney in a patient with ovarian and breast
cancer
F.V. Que, PH

18:20 - 18:20 YO17 - Induction Chemoradiation Therapy in Recurrent Locally Advanced

Urachal Cancer
T. Dajsakdipon, S. Worawichawong, C. Leenanupunth, P. Phichai Chansriwong; TH

18:20 - 18:20 Gynaecological cancers

A.M. Poveda Velasco1, J.-W. Kim 2, E. Pujade-Lauraine3, H.Y.-S. Ngan4, C. Scott5; 1ES,
2KR, 3CEDEX 4/FR, 4HK, 5AU

18:20 - 18:20 257P - Correlation between Knowledge and Attitudes of Female High School
Students Regarding Cervical Cancer in Denpasar, Bali
R. Martianus, R. Putri, A. Satyarsa, Y. Brahmantya, A. Abdulhadi; ID

18:20 - 18:20 258P - Screening Program for cervical cancer among rural women by Visual
Inspection with Acetic Acid (VIA): A Camp approach in Eastern India
I. Mandal, J. Basak, A. Mukhopadhyay, C. Bose; IN

18:20 - 18:20 259P - Neoadjuvant chemotherapy in locally advanced cervical cancer: two
randomized studies
Z. Olimova, UZ

18:20 - 18:20 260P - Neoadjuvant intraarterial chemotherapy and chemoembolization in

locally advanced cervix cancer
O. Akhmedov, N. Zakhirova, N. Umarova; UZ

18:20 - 18:20 261P - Concurrent Chemoradiation with Nano- Paclitaxel and Carboplatin in
Locally Advanced Cervical cancer - A Study at Quaternary Care Medical Center

P. Eswaran1, S. Kalyan2, J. Crystal2; 1Tamil Nadu/IN, 2IN

18:20 - 18:20 262P - Is Bone Marrow sparing Intensity modulated radiotherapy better than 3-
Dimensional Conformal radiotherapy in reducing haematological toxicities
during pelvic irradiation in locally advanced carcinoma cervix?: A prospective
study.
A. Elangovan, A. Bahl, F. Patel, C.B. DRACHAM, B. Rai, G. Trivedi; IN

Last update: 09-11-2018 [Link]pm

18:20 - 18:20 263P - Pelvic plastic reconstruction results after small pelvis exenteration
M. Tillashaykhov, N. Zakhirova, O. Ahmedov, Y. Ten, S. Djanklich; UZ

18:20 - 18:20 264P - Development of the surgery method of pelvic floor reconstruction in
locally advanced cervical cancer after exenteration
N. Zakhirova, M. Tillyashaykhov, O. Akhmedov, S. Djanklich, Y. Ten; UZ

18:20 - 18:20 265P - Life after cervical cancer: Bowel dysfunction , Urinary dysfunction and
quality of life in long-term survivors of carcinoma uterine cervix among Indian
women.
N. Sethi, A. Shankar, J. Patil, K. Mandrelle, A. Luther; IN

18:20 - 18:20 266P - Efficacy of Multimodality Treatment in Survival Patterns among Patients
with Endometrial Carcinoma Stage III
R. Elemam, I. Uthman, A. Yahya, N. Mohamed, A. Shaltout; EG

18:20 - 18:20 267P - HPV E6/E7 oncoprotein promotes cervical cancer by promoting miR-466
expression via P53 pathway
Y. Shen, Q.-X. Xu; CN

18:20 - 18:20 269P - miRNA-96 might serve as potential biomarkers for cervical cancer
J.-M. Gong, CN

18:20 - 18:20 271P - Prevalence of BRCA and VUS Mutations in Patients with Ovarian Cancer
Treated at Oncosalud - AUNA
C. Flores, P. Carrion Calderon; PE

18:20 - 18:20 272P - Clinical background and outcomes of risk-reducing salpingo-

oophorectomy for patients with hereditary breast and ovarian cancer in Japan
H. Nomura, M. Sekine, S. Yokoyama, N. Takeshima, M. Arai, S. Nakamura; JP

18:20 - 18:20 273P - Olaparib maintenance treatment, the Royal Marsden experience
C. Orbegoso Aguilar, L. Dumas, E. Davies, M. Gore, A. George, S. Banerjee; GB

18:20 - 18:20 274P - Real-world experience of olaparib maintenance in high grade serous
recurrent ovarian cancer patients with BRCA 1/2 mutation
E.S. Paik, J. Kim, T.-J. Kim, C.H. Choi, J.-W. Lee, D.-S. Bae, B.-G. Kim; KR

18:20 - 18:20 275P - Efficacy and tolerability of Olaparib in Asian patients with recurrent
ovarian, primary peritoneal or fallopian tube carcinoma: the National University
Cancer Institute, Singapore experience.
V. Heong, Y.W. Lim, S.C. Lee, S. Ow, S.E. Lim, P.Y. Ong, J. Low, J. Ng, A. Ilancheran, P.
Tong, D. Lim, D. Tan; SG

18:20 - 18:20 276P - Overexpression of HER3 and the survival of ovarian cancer

Last update: 09-11-2018 [Link]pm

 S. Kim, J.Y. Song; KR

18:20 - 18:20 277P - Investigation of the role of transforming growth factor beta in the
development and progression of granulosa cell tumours of the ovary
A. Muthukaruppan, S.K. Arora, C. Blenkiron, A. Shelling; NZ

18:20 - 18:20 278P - Predicting CA-125 Status and Ovarian Cancer Survival Using Artificial
Neural Networks
M. Osman, EG

18:20 - 18:20 279P - PET/CT in recurrent carcinoma ovary: Contrast enhanced CT (CECT)
versus non enhanced low-dose CT (NECT)
A. Vyas, A. Tiwary, A. Aggarwal; IN

18:20 - 18:20 280TiP - GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized,

phase 3 trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC)
chemotherapy in ≥2 line recurrent or metastatic cervical cancer

K. Tewari1, I. Vergote2, A. Oaknin3, E. Alvarez1, S. Gaillard4, S. Lheureux5, D. Rischin6,

A. Santin7, M. Feng4, M. Mathias8, M. Fury8, I. Lowy8, B. Monk9; 1US, 2BE, 3ES, 4AL/US,
5AB/CA, 6ACT/AU, 7CT/US, 8NY/US, 9AZ/US

18:20 - 18:20 YO18 - Ovotesticular mixed germ cell tumor in a 46,XY/46,XX hermaphrodite: a
case report
R. So, I. Orolfo-Real, J.A. Toral, S. Paloyo, E.M. Cutiongco-Dela Paz; PH

18:20 - 18:20 YO19 - Recurrent Intracranial Hemorrhage in a Patient with Metastatic

Choriocarcinoma to the Brain Mimicking as Vasculitis
A. Gerodias, E. Esposo, J. Datukan; PH

18:20 - 18:20 Haematological malignancies

18:20 - 18:20 281P - Significance of PARP1 Expression levels in patients with Acute Myeloid
Leukemia
H. Pashaiefar, M. Yaghmaie, J. Tavakkoly-Bazzaz, S.H. Ghaffari, K. Alimoghaddam, M.
Momeny, M. Izadifard, A. Kasaeian, A. Ghavamzadeh; IR

18:20 - 18:20 282P - Efficacy and safety of Single-agent Arsenic trioxide (ATO) as an Induction
regimen in the treatment of newly diagnosed Acute promyelocytic leukemia
(APL): A prospective single arm phase II study from South India.

P. simha1, D. Lokanatha1, K. Govind Babu1, L. Jacob1, M. Suresh Babu1, K.N. Lokesh2, A.

Rudresha2, L. Rajeev1, S. Smitha1, G. Giri1; 1IN, 2Karnatka/IN

18:20 - 18:20 283P - High Dose Methotrexate in Acute Lymphoblastic Leukemia without
monitoring drug levels: Indain Experience

Last update: 09-11-2018 [Link]pm

 D. Yadlapalli1, P. Ankur1, V. Gumdal2, M. Renu1, S. Runu1, B. Ankit1, P. Chitalkar2; 1IN,
2MP/IN

18:20 - 18:20 285P - Karyotype Complexity and characterization of childhood acute myeloid
leukemia (AML) in Pakistan

Z. Ahmed1, M. Shaiakh2, T. Moatter2, A. Nasir2; 1Sindh/PK, 2PK

18:20 - 18:20 286P - First China-Manufactured Proposed MabThera® Biosimilar Met Primary
Efficacy and Safety Endpoints in CD20-Positive Diffuse Large B-Cell Lymphoma
Y. Shi, Q. Zhang, X. Han, Y. Song, Y. Qin, X. Hong, X. Ke, J. Feng, D. Wang, W. Li, H. Su, Y.
Zhang, H. Zhang, J. Yang, L. Liu, X. Zhang, E. Liu, W. Jiang, S. Liu, A. LUK; CN

18:20 - 18:20 287P - Peripheral blood neutrophil-to-lymphocyte ratio in NK/T-cell lymphoma -

prognostic significance and correlation with tumor transcriptomic profiles

T. Khee Ming1, B. Chia1, J.Q. Lim1, L.P. Khoo1, C.L. Cheng1, L. Tan1, J.Y. Chan1, E.Y.L.
Poon1, N. Somasundaram1, M. Farid1, T.P.L. Tang1, M. Tao1, D.M.Z. Cheah1, Y.
Laurensia1, J.W.L. Pang1, S.J. Kim2, W.S. Kim2, C.K. Ong1, S.T. Lim1, T. Song1; 1SG, 2KR

18:20 - 18:20 288P - Combination of chemotherapy and radiation improve the prognosis of
primary diffuse large B-cell lymphoma of the tonsil.
S. Ko, S.-N. Lim, B.S. Sohn; KR

18:20 - 18:20 289P - Safety and efficacy of pralatrexate in patients with relapsed or refractory
peripheral t-cell lymphoma from China

Y. Song1, X. Hong1, H. Huang1, B. Bai1, H. Zhang1, X. Ke1, Y. Shi1, J. Zhu1, G. Lu1, S.

Liebscher2, C. Cai1; 1CN, 2DE

18:20 - 18:20 290P - Extranodal NK/T Cell Lymphoma- Nasal type: Experience from an Indian
regional cancer centre

S. Saldanha1, K. Govind Babu2, D. Lokanatha2, L. Jacob2, M. Suresh Babu2, K.N. Lokesh1,

A. Rudresha1, L. Rajeev2, G. Giri2, P. Khandare2; 1Karnatka/IN, 2IN

18:20 - 18:20 291P - Clinicopathologic features of breast lymphoma in core needle biopsy
R. Shui, J. Rao, X. Li, W. Yang; CN

18:20 - 18:20 292P - Erectile dysfunction among male lymphoma survivors in a developing
country
G. Gan, D. Ng, Y. Leong; MY

18:20 - 18:20 293P - An Attempt to Predict Double Expresser DLBCL Based on Cell of origin
and Proliferative Index (Ki-67): A Prospective Study from India

V. Asati1, C. Premalata1, K. Govind Babu1, K. Lakshmaiah1, D. Lokanath1, L. Jacob1, M.

Suresh Babu1, K.N. Lokesh2, A. Rudresha2, L. Rajeev1, S. Smitha1, G. Giri1, D. Koppaka1,
T. Chaudhuri1, A. Anand1, R. Chethan1, A. Goyal1, R. Patidar1; 1IN, 2Karnatka/IN

Last update: 09-11-2018 [Link]pm

18:20 - 18:20 294P - A Prospective Study to Determine Survival Outcome to CHOP-based
therapy in patients with Double Expresser DLBCL: Single Centre Experience
from India

V. Asati1, K. Lakshmaiah1, K. Govind Babu1, D. Lokanath1, L. Jacob1, M. Suresh Babu1,

K.N. Lokesh2, L. Rajeev1, A. Rudresha2, S. Smitha1, G. Giri1, D. Koppaka1, A. Anand1, R.
Chethan1, T. Chaudhuri1, R. Patidar1, A. Goyal1, C. Premalata1; 1IN, 2Karnatka/IN

18:20 - 18:20 295P - A Strategy of Stringent Control of Side-effects prevent the incidence of
methotrexate related lymphoproliferative disorders in rheumatoid arthritis
Y. URATA, JP

18:20 - 18:20 296P - Is fusion of a baseline PET really necessary in radiation treatment
planning of early stage Lymphomas?? Or will a baseline CT suffices??
M. Muddabhaktuni, B. Yadav, N. Kumar, G. Prakash, B. Mittal, S. Goshal; IN

18:20 - 18:20 297P - Chemotherapy versus Combined Chemoradiotherapy: Survival Patterns

among Patients with early stage classical Hodgkin lymphoma
L. Omar, E. Ali, A. Abd Elbaset; EG

18:20 - 18:20 298P - The prognostic significance of baseline serum Ferritin in patients with
malignant Lymphoma
D. El-Habashy, E. Tawfik, S. Alhassanin, A. El-Desoky, A. Shehata; EG

18:20 - 18:20 299P - Efficacy of salvage therapy of Helicobacter pylori-positive gastric mucosa-
associated lymphoid tissue lymphoma
S.-N. Lim, S. Ko, B.S. Sohn, S.Y. Oh; KR

18:20 - 18:20 301TiP - A phase 3 randomized study of gilteritinib versus salvage chemotherapy
in FLT3 mutation-positive subjects with relapsed or refractory acute myeloid
leukemia

J. Wang1, J. Li1, A. Tantiworawit2, S. Izuka3, S. Yamada3, J. Hill4, E. Shima Rich5, E.

Bahceci4; 1CN, 2TH, 3JP, 4IL/US, 5AL/US

18:20 - 18:20 302TiP - Safety and Efficacy of Midostaurin in Patients With Newly Diagnosed
FLT3-Mutated AML

P.-N. Wang1, A.Y.H. Leung2, J.H. Jang3, S. Voloshin4, L. O'Sullivan-Djentuh5, K. Suzuki6, S.

Ifrah7, G. Le Gouadec7, T. Kakizume6, H. Kitagawa6, K. Malek5, Y. Miyazaki6; 1TW, 2CN,
3KR, 4RU, 5CH, 6JP, 7FR

18:20 - 18:20 YO20 - Dyspnoea on Anti CD 38 directed IgG1k monoclonal Antibody - A Case
Report
R. Arora, IN

18:20 - 18:20 YO21 - NK/T Cell Lymphoma, Nasal Type in a Filipino Male
A.T. Gerona, PH

Last update: 09-11-2018 [Link]pm

18:20 - 18:20 YO22 - Chemotherapy in Bulky Neck Mass DLBCL with Massive Gastrointestinal
Bleeding Due to Erosive Gastritis and Myelodysplasia Syndrome : A Case Report
Y. Putra, M. Hardianti; ID

18:20 - 18:20 Head and neck cancer, excluding thyroid

18:20 - 18:20 308P - Prophylactic percutaneous endoscopic gastrostomy in patients with

nasopharyngeal carcinoma receiving concurrent chemoradiotherapy
T. Dechaphunkul, N. Ngamphaiboon, P. Danchaivijitr, R. Jiratrachu, A. Dechaphunkul; TH

18:20 - 18:20 309P - To evaluate Oncological and Quality of life outcomes between Robotic and
open neck dissection for oral cavity cancers: A prospective trial.
K. Gupta, S. Dabas; IN

18:20 - 18:20 310P - Analgesic efficacy in Head and neck cancer patients using tapentadol vs.
tramadol plus paracetamol
R. Narayanasamy, S. Thiagarajan, K. Perumal; IN

18:20 - 18:20 311P - Efficacy of controlled-release oxycodone for reducing pain due to oral
mucositis in nasopharyngeal carcinoma patients treated with concurrent
chemoradiotherapy: a prospective clinical trial.

X. Hua1, L. Chen1, Q. Zhu1, W. Hu1, C. Lin1, Z. Long1, W. Wen1, X. Sun1, Z. Lu1, Q. Chen1,
D. Luo1, R. Sun1, H. Mo1, L. Tang1, W. Zhang1, Z. He1, H. Mai1, H. Lin1, L. Guo2; 1CN,
2Guangdong/CN

18:20 - 18:20 312P - Weight loss during Radiation Therapy in Patients of Head &&
S. Das, D. Lahiri, S. Mandal, P. Biswas; IN

18:20 - 18:20 313P - Study of the cellular immunity in children and adolescents with
nasopharyngeal cancer
N. Karimova, D. Polatova, A. Ismailova, I. Iskandarova, M. Boboev; UZ

18:20 - 18:20 314P - Association of immune-related adverse events and efficacy in Japanese
patients with squamous cell carcinoma of the head and neck treated with
nivolumab
T. Otsuka, K. Fujiishi, K. Matsumoto, T. Kimura, R. Koike, H. Cho, A. Hasegawa, M.
Nishio, S. Otozai, T. Yoshii, T. Kudo, F. Fujisawa, N. Sugimoto, T. Yagi, F. Imamura, T. Fujii;
JP

18:20 - 18:20 315P - Induction chemotherapy in locoregionally advanced nasopharyngeal

carcinoma in adults: Results from a non-endemic cohort of South India
T. Chaudhuri, K.C. Lakshmaiah, K.G. Babu, L. Dasappa, L. Jacob, M.C.S. Babu, K.N.
Lokesh, A.H. Rudresha, L.K. Rajeev, R. Patidar, V. Asati, R. Chethan, D. Koppaka, A.
Anand; IN

Last update: 09-11-2018 [Link]pm

18:20 - 18:20 317P - Nasopharyngeal carcinoma in children and adolescent: A 10-year review
in Sarawak General Hospital, Malaysia.
N.I. Mohd Naseri, R.-Y. Lee, U. Nagaswara, C.K. Tan, V. Pei Jye; MY

18:20 - 18:20 318P - Induction chemotherapy with docetaxel plus cisplatin followed by
concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma:8-
year follow-up
A. Al-Humiqani, A. Maklad,, A. Alyamany, K. Taher, R. Akasha, M. Alsenosy, M. Omran, H.
Alhussain, H. Bakhribah, A. Alzahrani, A. Marie, S. Aldahri, K. Al-Qahtani, R. Mohamed,
Y. Bayoumi,; SA

18:20 - 18:20 319P - Oral tegafur-uracil as metronomic therapy following concurrent

chemoradiotherapy in non-distant metastatic stage IV of nasopharyngeal
carcinoma
J.-H. Chen, TW

18:20 - 18:20 320P - Weekly Docetaxel Concurrent Chemoradiotherapy Versus Cisplatin in

Locorgionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched
Analysis
J. Liao, CN

18:20 - 18:20 321P - The Efficacy of Induction Chemotherapy in Stage II Nasopharyngeal

Carcinoma in IMRT Era
P.-J. Li, CN

18:20 - 18:20 322P - Gender differences in risk of developing Nasopharyngeal Cancer (NPC) in
one of the highest NPC ethnic in the world.
C.K. Tan, S.P. Beh, R.-Y. Lee, V. Pei Jye, S. Damoderam, N.I. Mohd Naseri, U. Nagaswara,
G.G. Yeo; MY

18:20 - 18:20 323P - Strong family history of nasopharyngeal carcinoma (NPC) in Bidayuh, a
local native group in Sarawak, Malaysia.
G.G. Yeo, S.P. Beh, C.K. Tan, V. Pei Jye; MY

18:20 - 18:20 324P - Neoadjuvant Chemotherapy + Concurrent Chemoradiotherapy versus

Concurrent Chemoradiotherapy ± Adjuvant Chemotherapy for Locoregionally
Advanced NPC: an Update Meta-analysis and Efficacy-toxicity Joint Analysis.
S. LIU, D. Xie, S. Zhou, C. Xu, Z. Ye, S. Liu, G. Wang, S. Ding, Y. Xia; CN

18:20 - 18:20 325P - Comparing different normal tissue complication probability (NTCP)
models of radiation-induced temporal lobe injury after intensity-modulated
radiation therapy for nasopharyngeal carcinoma
L. Zeng, CN

18:20 - 18:20 326P - A curative-intent endoscopic surgery for postradiation nasopharyngeal

necrosis in patients with nasopharyngeal carcinoma

X. Zou1, M. Chen2, Y.-P. Liu1, S.-L. Wang1; 1CN, 2Guangdong/CN

Last update: 09-11-2018 [Link]pm

18:20 - 18:20 327P - Two miRNA signatures for identifying nasopharyngeal carcinoma from
head-neck tumors and the normal
W. Wen, CN

18:20 - 18:20 328P - Unlocking the potential of saliva-based test to detect HPV-driven
oropharyngeal cancer.

K.D. Tang1, C. Punyadeera2; 1AU, 2QLD/AU

18:20 - 18:20 329P - Function Preservation with Trimodality Therapy in Locally Advanced Oral
Tongue Squamous Cell Carcinoma

U. Khaleeq1, A. Rashid1, T. Abbas1, S. Rasheed1, A. Raza1, M. Khan1, H. Mahmood1, Y.

Hameed2, R. Hussain1, A. Jamshed3; 1PK, 2TN/US, 3Punjab/PK

18:20 - 18:20 330P - Outcomes in T4 Oral cancers undergoing upfront surgery compared to
Neo-Adjuvant Chemotherapy followed by surgery: A Matched Pair analysis.
H. Dhar, S. Thiagarajan; IN

18:20 - 18:20 331P - The role of ultrasound and ultrasound guided Fine needle aspiration
cytology in detection and management of neck node metastases in clinically N0
patients with carcinoma of upper aero-digestive tract in remote part of
underdeveloped country.
M. Gubhaju, A. Bajracharya; NP

18:20 - 18:20 332P - A study to assess the supportive care needs of post operative patients
with oral cancer in B.R.A I.R.C.H, AIIMS, New Delhi.
N. Paulose, IN

18:20 - 18:20 333P - Different treatment response in several head and neck squamous cell
carcinoma cell lines possibly reflecting underlying molecular signatures
J.P. Chen, J.-Y. Chang, R.-L. Hong; TW

18:20 - 18:20 334P - Surgery versus combined radiotherapy and chemotherapy: survival
patterns among patients with laryngeal squamous cell carcinoma stage III and
IV
A. Abobkr, A. Shaltout, R. Elghareeb, N. Mohamed, I. Uthman; EG

18:20 - 18:20 335P - Safety and efficacy of Carboplatin, Capecitabine plus Cetuximab biweekly
regimen in the first-line treatment of patients with recurrent/metastatic head
and neck cancer (R/MSCCHN)
R.R. Ganta, S. Nasaka; Andhra Pradesh/IN

18:20 - 18:20 336P - Cys144Arg &&

S. Yadav1, D. Parmar2; 1Uttar Pradesh/IN, 2IN

18:20 - 18:20 338P - Palliative Chemotherapy (CT) with or without Cetuximab (CTX) in
Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M
SCCHN): An Indian Retrospective Analysis

Last update: 09-11-2018 [Link]pm

 A. Bahl, K. Bhatia, P. Choudhary, S. Singhla, G. Shrivastava, J. Bal, A.K. Anand, H.
Chaturvedi; IN

18:20 - 18:20 339P - Decreased expression of NDRG2 predicts poor clinical outcome in
patients with oral squamous cell carcinoma.
H.-J. Yoon, H.-W. Shim, W.-J. Shin, J.-H. Kim; KR

18:20 - 18:20 340P - Differential approach to the bone tumors of the maxillofacial region
according to computed tomography signs
A. Almanova, M. Khodjibekov; UZ

18:20 - 18:20 341P - Human Papillomavirus (HPV) associated oral cavity and oropharyngeal
cancers: cross-sectional follow-up study in south Asian country, Sri Lanka.
P.K.D.P. Alahakoon, K.A. Perera, W.S. Pannala; LK

18:20 - 18:20 342P - Survival predictors of Major Salivary Gland Cancer

K.M. Elhusseiny1, F.A.-E. Abd-Elhay1, M.G. Kamel1, H.H. Abd El Hamid Hassan1, H.H.
Muhammad El Tanany1, H.T. Hong2, T.M. Tieu3, S.K. Low4, V. Hou3, M. Dibas5, N.T.
Huy6; 1EG, 2VN, 3CA, 4MY, 5SA, 6JP

18:20 - 18:20 343P - Histopathologic diagnosis of tumors in the external auditory canal:
Recent 7-year experience from a single center in Daegu, Korea
Y.-H. Kim, KR

18:20 - 18:20 344P - Evaluation of oral cancer trends in Pakistan during the period 2010 to
2016.
N. Malkani, A. Mahmood; PK

18:20 - 18:20 YO23 - Nivolumab Induced Immune Thrombocytopenia in a patient with

Relapsed Carcinoma of Tongue
A. Sreevatsa, M. Kamath; IN

18:20 - 18:20 YO24 - Extra Skeletal Myxoid Chondrosarcoma of Buccal Mucosa – A Case
Report.
S. m, H. Manchala, S. Kumari; IN

18:20 - 18:20 YO25 - Primary Neuroendocrine Tumor of the Maxilla: A Case Report
C.D. Uy, C.C. Esplana, G. Fernando; PH

18:20 - 18:20 Melanoma and other skin tumours

C. Robert, FR

18:20 - 18:20 348P - Interim analysis of prospective observational study on the efficacy of
nivolumab for Japanese advanced melanoma patients (CREATIVE study)
Y. Nakamura, A. Takahashi, K. Namikawa, T. Takenouchi, S. Kitano, T. Fujita, K. Kubota, T.
Yamanaka, Y. Kawakami, N. Yamazaki; JP

Last update: 09-11-2018 [Link]pm

18:20 - 18:40 349P - Dynamics of clinical biomarkers as predictors of immunotherapy (IT)
benefit in metastatic melanoma (MM) patients (pts) treated in reference
institution.
A. Hernando, R. Dienstmann, C. Ortiz Velez, G. Villacampa, F.J. Ros Montañá, J.F. Grau
Béjar, A. Garcia-Alvarez, P. Nuciforo, A. Gros, V. Garcia-Patos, D. Bodet, B. Ferrer
Fabrega, J. Recio, E. Muñoz-Couselo; ES

18:40 - 18:40 350P - Single-institute, retrospective study of metastatic uveal melanoma in the
immune check point inhibitor era
S. kazuhiro, K. Sugiyama, K. Nozawa, Y. Funahashi, Y. Kogure, C. Kitagawa, S. Ichihara,
R. Nishimura, T. Kubota, H. Saka; JP

18:40 - 18:40 351P - Clinicopathological and prognostic significance of Programmed death

ligand 1 expression in Korean melanoma patients
S. Yun, K. Lee, Y. Park, S. Moon, H.S. Lee, G. Choe, K.S. Lee; KR

18:40 - 18:40 352P - Early safety from a phase 1, multicenter, open-label, dose de-escalation
study of talimogene laherparepvec (T-VEC) in Japanese patients (pts) with
unresectable stage IIIB-IV melanoma (MEL)

N. Yamazaki1, H. Koga1, T. Kojima1, A. Tsutsumida1, K. Namikawa1, M. Yi2, K. Mera1, C.

Pickett-Gies2; 1JP, 2CA/US

18:40 - 18:40 353P - Clinical and laboratory markers as predictors of Time to Treatment
Failure (TTF) and Overall Survival (OS) in patients (pts) with mucosal melanoma
(MM).
F.J. Ros Montañá, I. Baraibar Argota, C. Ortiz Velez, J.F. Grau Béjar, G. Villacampa, V.
Garcia-Patos, D. Bodet, C. Fernandez-Pulido, R. Dienstmann, E. Muñoz-Couselo; ES

18:40 - 18:40 354P - 5HT3 receptor antagonists selectively kill melanoma cells
A. Barzegar Fallah, H. Alimoradi, S. Baird; NZ

18:40 - 18:40 355P - Efficacy and safety of weekly docetaxel regimen for advanced
extramammary Paget’s disease: retrospective single institute analysis.
Y. Nakamura, I. Hirai, M. Ishii, Y. Kawakami, K. Tanese, T. Funakoshi; JP

18:40 - 18:40 356P - Knowledge, attitudes, and behaviors toward skin cancer among Marine
Fisheries students of Udayana University, Bali
S.A. Suryantari, A. Satyarsa, I.G.A. Indriani, P. Sudarsa, L.M. Rusyati, M. Adiguna; ID

18:40 - 18:40 357P - Location of malignant melanoma in distal extremity draining to popliteal
or epitrochlear sentinel lymph nodes
S. jinnai, K. Namikawa, E. Nakano, A. Takahashi, N. Yamazaki; JP

18:40 - 18:40 YO26 - Local disease control of nasal malignant melanoma achieved by
administration of nivolumab followed by palliative radiation: a case report
T. Yamazaki, JP

Last update: 09-11-2018 [Link]pm

18:40 - 18:40 YO27 - Complete response of BRAF-mutated metastatic melanoma treated with
dabrafenib and trametinib in a super-elderly patient: a case report
S.B. Oh, K.-O. Park, J.-J. Kim, S.-Y. Oh; KR

18:40 - 18:40 YO28 - Malignant Melanoma of the Palate: Report of a Metastatic Case
M.V. Cruz-Ordinario, C.A. Boado, A. Gorospe; PH

18:40 - 18:40 YO29 - Excellent response of nivolumab in patient with metastatic malignant
melanoma of vagina: a case report
A. Maisrikrod, A. Dechaphunkul; TH

18:40 - 18:40 Palliative care

18:40 - 18:40 359P - A prospective study about the nutritional status of cancer patients in the
southern of Tunisia
W. Ben Kridis, W. Karray, G. Marrekechi, A. Khanfir, M. Frikha; TN

18:40 - 18:40 360P - Patterns of practice for bone metastases in Japan – use of questionnaires
to promote a multidisciplinary approach

N. Nakamura1, Y. Sakai1, N. Matsubara2, K. Kakutani1, T. Akisue1, N. Kiyota3, H.

Minami3; 1JP, 2Chiba/JP, 3Hyogo/JP

18:40 - 18:40 361P - Aloe Vera:A multifaceted Ayurvedic herb use in palliative care of oral
cancer patients
J. Acharya, S. Beniwal, S. Jakhar, N. Mohta; IN

18:40 - 18:40 362P - Retrospective analysis of efficacy and safety of Cell-free and Concentrated
Ascites Reinfusion Therapy in pancreatic cancer patients with malignant ascites

K. Harada1, Y. Kobayashi2, S. Nozawa1, K. Sakurai1, K. Suto1, A. Yoshikawa1, R. Sasaki1,

R. Abiko1, H. Ebata1, I. Sano1, H. Oda1, T. Miyagishima1; 1JP, 2Hokkaido/JP

18:40 - 18:40 363P - A Randomized Controlled Trial of Mindfulness Breathing Exercise in

Patients with Advanced Lung Cancer
C.S. Chai, S.-B. Tan, D. Ng, C.K. Liam, Y.K. Pang; MY

18:40 - 18:40 364P - An Estimation of the Population-based Survival Benefit of First-course

Chemotherapy for Advanced Incurable Cancer
V. Do, W. Ng, S. Jacob, G. Delaney, M. Barton; NSW/AU

18:40 - 18:40 365P - Palliative care as a part of national cancer control plan in Uzbekistan –
first steps towards the solution
Y. Ziyaev, M. Tillyashaykhov, A. Yusupbekov, S. Abdujapparov, D. Egamberdiev, Y. Ten, H.
Islamov; UZ

Last update: 09-11-2018 [Link]pm

18:40 - 18:40 366P - Socioeconomic status and demographic assessment of advanced cancer
patients in Palliative care department of a tertiary care centre : Observational
study
G. Kumar, West Bengal/IN

18:40 - 18:40 Precision medicine

18:40 - 18:40 370P - Shaheenah Dawood MD1, Maroun Khoury2, Faraz Khan2, Falah Khatib1,
Milicent Bello3, Annette Hamadi3, Houriya Kazim3, Rania Khoury4, Georges
Nasioulas5, Aparna Dhar6

R. Khoury1, S. Dawood2, M. Khoury2, F. Khan2, F. Al Khatib2, M. Bello2, A. Hamadi2, H.

Kazim2, A. Dhar3, G. Nasioulas4; 1LB, 2AE, 3IN, 4GR

18:40 - 18:40 371P - Clinical and molecular characteristics of ALK-rearranged Chinese lung
cancer patients
Y. Fang, J. Shou, W. Han, H. Li, X. Zhou, D. Li, H. Cheng, H. Wang, F. Lou, S. Cao, H. Pan;
CN

18:40 - 18:40 372P - Identification and validation of a Prognostic Signature in Malignant

Pleural Mesothelioma
J.-G. Zhou, H. Ma; CN

18:40 - 18:40 373P - Cell-free DNA (cfDNA) landscape in ERBB2 (HER2)-amplified Asian
cancer patient population

J. Lee1, A. Franovic2, T. Rich2, Y. Shiotsu2, V. Raymond2, R. Lanman2; 1KR, 2US

18:40 - 18:40 374P - Are We There Yet? A Critical Reflection of Asian Medical Oncologists on
NGS-guided Precision Treatment in Asia 2018

A. Lai1, W.S. Seo Tho1, S.L. Poon1, K.T. Tan2, K. Tung2, J. Lee2; 1SG, 2TW

18:40 - 18:40 375P - Concordance study of between IBM Watson for oncology and real clinical
practice for gastric, breast and ovarian cancer
J.G. Choi, KR

18:40 - 18:40 376P - Impact of single-gene and co-occurring mutations on TMB with potential
implications for immunotherapy
T. Shou, H. Ma, F. Lan, W. Gu, W. Cui, B. Zhang, Y.-A. Dong; CN

18:40 - 18:40 377P - Application of a comprehensive platform technology for detection of

cancer-associated genomic alterations and viral DNA in liquid biopsies
Y. Choudhury, H. Chen, F. Fadhlullah, D. Tan, K. Ng, W. Phyo, M.H. Tan; SG

18:40 - 18:40 378P - Circulating cell-free DNA molecular profiling among East Asian patients
reveals activating MET alterations are common in diverse advanced cancer types

Last update: 09-11-2018 [Link]pm

 S. Ikeda1, Y. Kumaki1, T. Rich2, Y. Shiotsu2, A. Franovic2, V. Raymond2, R. Kurzrock3, R.
Lanman2, J. Lee4, T.S.K. Mok5; 1JP, 2US, 3AL/US, 4KR, 5HK

18:40 - 18:40 379P - Prevalence of pathogenic mutations in Korean hereditary breast-ovarian

cancer
G. Lee, J.H. Kim, S.N. Lee, H. Chae, J. Yoo, E. Han, W. Jang, M. KIM, Y. Kim; KR

18:40 - 18:40 380P - Establishment of a patient-derived xenograft (PDX) model with malignant
pleural effusion and its application
S. Chen, C.-P. Huang, H.-H. Lai, Y.-H. Lin, C.-T. Su, S.-J. Wu, C.-H. Chang, C.-C. Tsao, Y.-C.
Chen, S.-C. Wang, Y.-H. Liu, S.-B. Lin, T.-H. Chen; TW

18:40 - 18:40 381P - The study of RET rearrangement in advanced primary non-small cell lung
cancer and associated metastatic lesions
W.-X. Wang, C. Xu, Q.-X. Zhang, W. Zhuang, Y.-W. Tian, J. Zhang, M.-Y. Fang, Y.-P. Chen, G.
Chen, T.-F. Lv, Y. Song; CN

18:40 - 18:40 382P - comparison of tumor mutational burden and pd-l1 between 2797 primary
and metastatic breast cancer samples

S. Dawood1, K. Schuster2, R. Fedlman3; 1AE, 2CH, 3US

18:40 - 18:40 383P - Whether pericarcinomatous tissue of non-small cell lung cancer can serve
as genetic background filter in next-generation sequencing analysis
Y. Zhang, L. Zhang, L. Chang, Y. Yang, W. Fang, Y. Guan, X. Xia, X. Yi; CN

18:40 - 18:40 384P - Incidence of Germline BRCA1 and BRCA2 mutations among Filipinos
F.V. Que, D. Ang, J.J. Andal, M. Madrid, R. Lo, M.S. Imasa, M.L. Enriquez, F. Tria Iv, L.K.
Cabral, R. Dimalibot, R. Li; PH

18:40 - 18:40 385P - Clinical feasibility of pancreaticoduodenectomy in different ages

Z. Wei, T. Qing, D. Wei; CN

18:40 - 18:40 386P - TP53 GOF mutations predict good response and prolonged survival to
bevacizumab treatment in metastatic colorectal cancer
Y.-L. Hsieh, Y. Liu, N. Lapke, H.-C. Hsu, H.-C. Chen, S.-J. Chen, K.T. Tan; TW

18:40 - 18:40 387P - Radiation dose to contralateral parotid during treatment of carcinoma
buccal mucosa
R. Narayanasamy, S. Thiagarajan, S. P, K. Perumal; IN

18:40 - 18:40 388P - ALK rearrangent in pulmonary sarcomatoid carcinoma: a retrospective

study of the real world
Y.-C. Zhu, C. Xu, W.-X. Wang, M.-Y. Fang, W. Zhuang, Q.-X. Zhang, Z. Gong, Y.-P. Chen, G.
Chen, T.-F. Lv, Y. Song; CN

Last update: 09-11-2018 [Link]pm

18:40 - 18:40 389P - Risk factors of nivolumab-induced pneumonitis in patients with solid
tumors

T. Yamaguchi1, T. Hasegawa1, N. Hanai1, Y. Inaba1, K. Muro2, T. Hida1; 1JP, 2Aichi/JP

18:40 - 18:40 390P - Analysis of RET rearrangement non-small cell lung cancer cell blocks
from pleural effusion
C. Xu, W.-X. Wang, Q.-X. Zhang, W. Zhuang, Y.-W. Tian, J.-P. Xu, M.-Y. Fang, Y.-P. Chen, G.
Chen, T.-F. Lv, Y. Song; CN

18:40 - 18:40 391P - Mismatch repair deficiency testing for immunotherapy in metastatic
cancers: a single centre study from India

T. Sood1, A. Rauthan1, P. Patil1, S. Kulkarni1, S.P. Somashekhar1, S. Zaveri2; 1IN,

2Karnataka/IN

18:40 - 18:40 392P - Candidate markers of homologous recombination deficiency for triple
negative breast cancer

K. Havrysh1, G. Mukhametshina2, S. Petrov2, S. Safina2, R. Kiyamova2; 1UA, 2RU

18:40 - 18:40 393P - The landscape and genomic characteristics in BRAF V600E wild type
papillary thyroid carcinoma
M.-Y. Fang , C. Xu, W.-X. Wang, M.-J. Wu, G. Chen, M.-H. Ge; CN

18:40 - 18:40 394P - Development of the immuno-wall device for rapid detection of ALK and
ROS1 fusions in lung cancer.
N. Yogo, T. Hase, T. Kasama, T. Hatta, N. OZAWA, M. Sato, N. Kaji, M. Tokeshi, Y. Baba, Y.
Hasegawa; JP

18:40 - 18:40 395P - A study of efficacy and safety with apatinib therapy in advanced
neuroendocrine carcinoma patients
C. Chen, X. Liu, C. Han; CN

18:40 - 18:40 Public policy

18:40 - 18:40 400P - Do Time, distance and economic factors influence stage of presentation
of malignancies?? Experience from a Regional cancer center in India
N. Ballari, T. Jindia, L. Annam, R. Miriyala, S. Ghoshal; IN

18:40 - 18:40 401P - Survey of Diet and Physical Activity in New Cases of Young Breast Cancer
Patients in Taiwan
H. Feng, H.-C. Chen, I.-C. Chen, C.-H. Lin, Y.-S. Lu, W.-H. Kuo, M.-Y. Wang, C.-S. Huang,
A.-L. Cheng, W.-W. Chen, P.-R. Chen; TW

18:40 - 18:40 402P - Retrospective analysis of risk factor of injection site reaction induced by
infusion of cisplatin plus vinorelbine

Last update: 09-11-2018 [Link]pm

 N. OZAWA, T. Hase, T. Hatta, A. Sagara, K. Ichikawa, M. Miyazaki, M. Ando, K. Yamada,
Y. Hasegawa; JP

18:40 - 18:40 403P - Knowledge and Attitudes of Productive Age Women About Visual
Inspection with Acetic Acid (VIA) Test in Early Screening of Cervical Cancer in
Tihingan village, Klungkung, Bali
R. Putri, A. Satyarsa, L. Marina Wirahartato, L.P. Virayanti, K. Wiswa Mitra Kenwa, P.
Adiputra, I.W. Sudarsa; ID

18:40 - 18:40 404P - Clinical spectrum and treatment outcomes of HIV associated cancers in a
tertiary care center in South India
S. Elumalai, K. Kannan, R. Gopal, S. Sundararajan; IN

18:40 - 18:40 405P - The Impact of Awareness Program on the Knowledge, Attitude and
Practice of Breast self examination among Female Healthcare workers in a
Tertiary Hospital: An Interventional Study
S.R.A. Kwak, PH

18:40 - 18:40 Sarcoma

R. Quek1, H. Loong2; 1SG, 2HK

18:40 - 18:40 409P - Prognostic factors for post-progression survival after trabectedin
treatment in patients with advanced soft tissue sarcoma
S. Iwata, K. Yonemori, A. Arakawa, A. Maejima, F. Nakatani, E. Kobayashi, T. Mori, K.
Sudo, E. Noguchi, T. Hirose, S. Komatsubara, H. Fujimoto, C. Ogawa, K. Tamura, A.
Kawai; JP

18:40 - 18:40 410P - FUS-NFATc2 sarcoma of bone, a novel molecular entity with aggressive
behavior: clinical and molecular pathology findings of two cases

M. Lacambra1, H. Loong1, K.F. To1, X. Feng2, G. Taylor2, E. Pleasance2, J. Laskin2, M.

Marra2, J. Griffith1, H.Y.M. Yeung1, K.-C. Wong1, C. Chow1, S. Kumta1, W.H.A. Ng1, T.
Tse1, C. Tong1, T. Ng2; 1HK, 2BC/CA

18:40 - 18:40 411P - Molecular-genetic markers and remote results in osteosarcoma treatment
D. Polatova, M. Gafur-Akhunov, K. Abdikarimov, U. Islamov, S. Urunbaev, B. Sultonov, R.
Davletov; UZ

18:40 - 18:40 412P - Comprehensive mRNA-based screen for tyrosine kinase fusions and a de
novo alternative transcription initiation site in soft tissue sarcomas
Y. Suehara, S. Kohsaka, A. Kurisaki, K. Akaike, T. Hayashi, K. Mogushi, T. Okubo, Y. Kim,
S. Sato, E. Kobayashi, K. Kaneko, H. Mano, T. Saito; JP

18:40 - 18:40 413P - Clinical benefits of later line trabectedin and eribulin treatment for soft
tissue sarcoma (STS) after pazopanib treatment from Nishinomiya Sarcoma
Cohort Study (NSCS)

H. Narahara1, M. Morimoto2, E. Tanaka2, S. Ueda2, Y. Yasunaga2, Y. Inui2, K. Takahashi2,

S. Kawata2; 1Hyogo/JP, 2JP

Last update: 09-11-2018 [Link]pm

18:40 - 18:40 414P - Treatment outcomes of adult osteosarcoma in Srinagarind Hospital

P. Eiamprapaporn1, A. Sookprasert2, K. Wirasorn2, P. Ungarereevittaya1, J.

Chindaprasirt2; 1TH, 2Mueang Khon Kaen District/TH

18:40 - 18:40 415P - A clinical outcome of dedifferentiated Low-grade osteosarcoma based on

molecular pathological confirmation
E. Kobayashi, S. Toki, A. Yoshida, A. Kawai; JP

18:40 - 18:40 416P - Ewing Sarcoma in Adults: Demystifying Experience from a Developing
Nation

R. Ambalathandi1, S. Gundeti1, B. Stalin2, M. Konatam1, N. Palukuri1, R. Yedla1; 1IN,

2Andhra Pradesh/IN

18:40 - 18:40 417P - Oncological outcome of extremity synovial sarcomas treated with
multimodality management
A. Gulia, A. Puri, S. Laskar, B. Rekhi; IN

18:40 - 18:40 418P - Oxidized low density lipoprotein receptor 1 promotes lung metastases in
osteosarcoma through regulating the epithelial-to-mesenchymal transition

J. Dylan1, S. Jiang2, H. Long2, Q. Luo2; 1Guangdong/CN, 2CN

18:40 - 18:40 419P - Outcomes of gemcitabine-docetaxel as second-line chemotherapy in

patients of advanced soft tissue sarcoma: a retropsective analysis
K. Gupta, S. Parthiban, S. Kumar, S. Srinivas, D. Vallathol, R. Chanana, G. Grewal, N.
Rathnasamy, A. Goel, J. Bajpai; IN

18:40 - 18:40 YO30 - Extra-Gastrointestinal stromal tumor and tumor lysis syndrome, A case-
report

T. Sanlung1, K. Wirasorn2; 1TH, 2Mueang Khon Kaen District/TH

18:40 - 18:40 YO31 - Reduced and re-escalated dose of sunitinib was adequately effective
against gastrointestinal stromal tumor of the small intestine: a case report

M. Ogata1, H. Satake2, T. Ogata1, Y. Hatachi1, H. Yasui1; 1JP, 2Hyogo/JP

18:40 - 18:40 YO32 - A Case Report: Life-threatening giant cell tumor of bone with coexisting
primary hyperparathyroidism initially misdiagnosed as brown tumor treated with
denosumab.
A. Phongphithakchai, S. Sakdejayont; TH

18:40 - 18:40 YO33 - Dermatofibrosarcoma Protuberans of Thigh: A Case Report

S. m, G. Usha Shree, N. Rao, R. Reddy; IN

18:40 - 18:40 Supportive care

D. Keefe1, K. Lee2, C. Steer3; 1SA/AU, 2NSW/HK, 3VIC/AU

Last update: 09-11-2018 [Link]pm

18:40 - 18:40 424P - Clinical Factors associated with satisfaction of cancer patients for the
treatment of opioid-induced constipation: A post hoc analysis utilizing outcomes
of naldemedine Phase 3 study
H. Ishiki, E. Satomi, Y. Tada, T. Yokota, H. Sato, M. Okamoto, I. Osaka; JP

18:40 - 18:40 425P - Opioid-induced Constipation in Patients with Cancer Pain in Japan (OIC-J
Study): Patients’ Self-Assessment of the Symptoms and the Impact

T. Noriyuki1, H. Imai1, S. Fumita1, T. Harada1, M. Gamoh2, Y. Akashi1, H. Sato1, Y.

Kizawa1, A. Tokoro1; 1JP, 2Miyagi/JP

18:40 - 18:40 426P - Nutritional supplement ONCOXIN to maintain appetite, body mass and
quality of life in patients with advanced cancer on chemotherapy

M. Kopp1, I. Koroleva1, E. Bilan1, E. Sanz2, F. Petrovskiy1; 1RU, 2ES

18:40 - 18:40 427P - Association between dietary patterns with disease recurrence in Thai
colorectal cancer patients
V. Kunnavuttivanich, P. Pramyothin, S. Ithimakin; TH

18:40 - 18:40 428P - Efficacy of single dose NEPA, a fixed combination of netupitant and
palonosetron, versus a 3-day regimen of aprepitant/granisetron (APR/GRAN) for
prevention of nausea in patients receiving high dose cisplatin

A. Dechaphunkul1, S. Lu2, S. Olivari3, L. Zhang2; 1TH, 2CN, 3CH

18:40 - 18:40 429P - A Randomized, Double Blind, Placebo-Controlled Study Evaluating

Efficacy of Combination Olanzapine, Ondansetron and Dexamethasone for
Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving
Doxorubicin plus Cyclophosphamide
W. Nipondhkit, TH

18:40 - 18:40 430P - The Prospective Multicenter Study of Relation between 5-HIAA /
Substance P plasma Concentration Transition and Nausea / Vomiting in Patients
with Gastrointestinal Cancer Receiving Moderately Emetogenic Chemotherapy
(MEC).

K. Sawada1, Y. Komatsu2, T. Muranaka2, S. Nakano1, Y. Kawamoto1, H. Nakatsumi1, S.

Yuki2, M. Dazai2, T. Saiki1, A. Ishiguro1, M. Tateyama1, K. Ono1, S. Ohnishi1, N.
Sakamoto1; 1JP, 2Hokkaido/JP

18:40 - 18:40 431P - A randomized study comparing two different training programs
A. Bellens, B. Sabbe, P. van Dam; BE

18:40 - 18:40 432P - Resilience in adult cancer care: A review and concept analysis

D. Luo1, M. Eicher2, K. White3; 1AU, 2CH, 3ACT/AU

18:40 - 18:40 433P - A pilot study of exercise intervention during chemotherapy in patients
with metastatic cancer

Last update: 09-11-2018 [Link]pm

 H.K. Ahn, Y.S. Kim, E.Y. Kim, K.D. Park, I. Park, S.J. Sym, S.H. Park, D.B. Shin; KR

18:40 - 18:40 434P - A phase II study to assess the immunogenicity and optimal timing of 13-
valent pneumococcal conjugated vaccination during adjuvant chemotherapy
W.K. Bae, KR

18:40 - 18:40 435P - Title: Primary Prophylaxis For Febrile Neutropenia - Is It Really Required
For AC Chemoregimen In Breast Cancer Patients?
N. Palukuri, IN

18:40 - 18:40 436P - Identifying predictive factors for severe anemia in cancer patients treated
with cytotoxic chemotherapy
B. Mofid, A. Razzaghdoust, P. Peyghambarlou; IR

18:40 - 18:40 437P - Cost simulation for the US of febrile neutropenia hospitalization due to
pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim
and daily injections with reference and biosimilar filgrastim in lung cancer

A. McBride1, A. Krendyukov2, N. Mathieson2, K. Campbell3, S. Balu3, K. MacDonald4, I.

Abraham5; 1AL/US, 2DE, 3NJ/US, 4US, 5AZ/US

18:40 - 18:40 438P - Preventive Role of Beta Blockers and Renin-Angiotensin Inhibitors in
Anthracycline-induced Cardiotoxicity among Adult Cancer Patients: A Meta-
Analysis
D.B. Sacdalan, M.D. Tiongson, K.A. Mondragon, L. Abrahan, Iv, J. Añonuevo, G. Fernando,
F.E. Punzalan; PH

18:40 - 18:40 439P - Pain control among cancer patients receiving strong opioids and their
perspective towards opioids in a developing country with a diverse multicultural
background
D. Lee, D. Kiu, V. Pei Jye; MY

18:40 - 18:40 440P - A multicenter prospective study on the efficacy and safety of denosumab
in gastrointestinal cancer patients receiving short-term periodic steroid
premedication for prevention of chemotherapy-induced nausea and vomiting.
(ESPRESSO-02/HGCSG1602)

M. Nakamura1, T. Muranaka2, M. Yagisawa1, Y. Kawamoto1, S. Yuki2, A. Ishiguro1, M.

Dazai2, S. Sogabe1, K. Harada1, Y. Kobayashi2, T. Miyagishima1, N. Okamura1, Y. Tsuji2,
S. Terae1, K. Ono1, Y. Komatsu2; 1JP, 2Hokkaido/JP

18:40 - 18:40 441P - The Efficacy of Scalp-Cooling System for the Prevention of
Chemotherapy-induced Hair Loss in Metastatic Breast Cancer Patients Treated
with Erubrin.
M. Kato, JP

18:40 - 18:40 442P - CGA directed interventions in Asian geriatric oncology patients
M. Wang, F. Ho, Y.S. Ng, B.C. Tai, W.C. Yong, S.L.A. Pang; SG

Last update: 09-11-2018 [Link]pm

18:40 - 18:40 443P - Safety and efficacy of direct oral anticoagulants vs. warfarin for Japanese
lung cancer patients with thromboembolism in real world settings.

T. Oguri1, M. Hiraide2, T. Shiga2, C. Yasuda2, M. Nishio2, S. Takahashi2; 1Aichi/JP, 2JP

18:40 - 18:40 444P - Alteration of muscle mass after chemotherapy in patients with newly
diagnosed multiple myeloma
S. Nakamura, H. Miki, Y. Okamoto, K. Sogabe, M. Oura, M. Takahashi, M. Iwasa, T.
Harada, S. Fujii, K. Kagawa, M. Abe; JP

18:40 - 18:40 445P - Correlation between Lymphocyte-Monocyte Ratio and Hand Grip Strength
in Breast Cancer Patients before Chemotherapy
A. Kurniawan, R. Hatma, A. Adisasmita, N. Soetandyo, F. Witjaksono, H. Putri, D. Widjaja;
ID

18:40 - 18:40 446P - What do oncologists think patients with incurable cancer should be told
about their prognosis?

A. Vasista1, M. Stockler2, A. Martin2, N. Lawrence2, B. Kiely2; 1AU, 2NSW/AU

18:40 - 18:40 447P - Herbal product and dietary supplement intake among patients at the
Philippine General Hospital (PGH) medical oncology clinic: a cross-sectional
survey.
R.E. King, D. Sacdalan, R.R. Angeles; PH

18:40 - 18:40 448P - Can we estimate the risk of chemotherapy toxicity in Indian Geriatric
patient population and utility of CRASH (Chemotherapy risk assessment scale
for high age patients) score?
A. Mittal, A. Agarwal, R. Rangaraju, S. Batra, C. Gouda D, S. Qureshi; IN

18:40 - 18:40 449P - A Study of Adherence to oral temozolomide chemotherapy in central

nervous system tumors
S. VALLATHOL, IN

18:40 - 18:40 450P - Prescreening of immune-related adverse events in our institute

T. Sone, T. Murai, K. Itaya, Y. Koike, Y. Ono, M. Nakamura; JP

18:40 - 18:40 451P - Epidemiology of AYA(adolescents and young adults) cancer in National
Institute of Cancer Research and Hospital(NICRH),Dhaka, Bangladesh.
A.A.M. Khan, P.S. Akthar; BD

18:40 - 18:40 452TiP - A feasibility study of edoxaban for the cancer-associated asymptomatic
venous thromboembolism in Japanese gastrointestinal cancer patients receiving
chemotherapy. (ExCAVE study)

M. Nakamura1, M. Yagisawa1, T. Saiki1, A. Ishiguro1, K. Sawada1, S. Yuki2, T. Sasaki1, T.

Ando1, H. Ohori3, M. Kotaka4, O. Muto1, Y. Shindo1, K. Nakashima1, A. Hosokawa1, A.
Doi5, N. Izawa1, Y. Sunakawa1, A. Satoh1, K. Ono1, Y. Komatsu2; 1JP, 2Hokkaido/JP,
3Miyagi/JP, 4Hyogo/JP, 5Chiba/JP

Last update: 09-11-2018 [Link]pm

18:40 - 18:40 Thoracic tumours, early stage

18:40 - 18:40 454P - The PD-L1 expression in surgically resected lung adenocarcinoma: Its
correlations with the prognosis, driver oncogene alterations and
clinicopathological features
K. Takamochi, T. Hayashi, K. Hara, K. Suzuki; JP

18:40 - 18:40 455P - Association Between Pre-Existing Conditions and Driver Gene
Profiles/Immune Contextures in NSCLC: A Large-Sample Analysis
W. Liang, C.C. Li, Z. Wang, Y. He, J. He; CN

18:40 - 18:40 456P - Optimal Starting Age for Lung Cancer Screening with Low-dose CT: A
Population Level Analysis
C.C. Li, H. Liang, Y. Zhao, Y. Wen, G. Qiu, N. Zhong, J. He, W. Liang; CN

18:40 - 18:40 457P - Impact of FDG PET/CT in selection of patients for adjuvant chemotherapy
in resection margin negative stage IB and IIA (T2bN0) non-small cell lung
cancer
H.L. Park, I.R. Yoo, S. Park, S.H. Boo; KR

18:40 - 18:40 458P - Rate of pathological N2 nodes among patients of NSCLC with cN0/cN1
nodal status on CECT scan - A study from tertiary care hospital in India
B. Bansal, M. Gowda, V. Kumar, S. Deo, S. Bhoriwal, D. Jain, P. Malik, S. Jee Bharati, M.
Yadav, S. Kumar; IN

18:40 - 18:40 459P - Clinical outcomes and treatment strategies of sarcomatoid carcinoma of
the lung
Y. Wang, CN

18:40 - 18:40 460P - Chemotherapy versus Combined Chemoradiotherapy: Survival Patterns

among Elderly Patients with Limited Stage Small Cell Lung Cancer
S. Abdulaziz, EG

18:40 - 18:40 461P - Clinical courses of patients with small cell lung cancer after complete
resection followed by adjuvant chemotherapy
Y. Shinno, S. Kanda, J. Sato, R. Morita, Y. Matsumoto, S. Murakami, Y. Goto, H.
Horinouchi, Y. Fujiwara, N. Yamamoto, Y. Ohe; JP

18:40 - 18:40 462P - Circular RNA Profiling and Its Potential for Esophageal Squamous Cell
Cancer Diagnosis and Prognosis
Q. Cao, L. Fan, J. Zhu, J. Zhang, B. Li; CN

18:40 - 18:40 463P - Asthma and Risk of Lung Cancer: A Mendelian Randomization Study

H. Zhou1, Y. Zhang1, W. Fang1, Y. Huang1, Y. Yang1, S. Hong1, G. Chen1, S. Zhao1, J. Liu1,

H. Zhao1, Z. Li2; 1CN, 2Guangdong/CN

Last update: 09-11-2018 [Link]pm

18:40 - 18:40 YO35 - Thymic large cell neuroendocrine carcinoma- a rare and aggressive
tumor: case report
W. laosuangkool, E. Sirachainan; TH

18:40 - 18:40 YO36 - A Case of Good Syndrome: A Rare Acquired Immunodeficiency Associated
with Thymoma
S. Sakchinabut, C. Sookthon, P. Phichai Chansriwong; TH

18:40 - 18:40 Thoracic tumours, locally advanced

18:40 - 18:40 467P - Correlation between PD-L1 expression and clinicopathological

characterization in NSCLC
Y. Jin, CN

18:40 - 18:40 468P - Relationship of the level of soluble PD-L1 and its relevant proteins in
peripheral blood with the prognosis of patients with NSCLC
G. Bai, Y. Xu, M. Wang; CN

18:40 - 18:40 469P - Application of Next Generation Sequencing in Pleural Effusion Molecular
Profiling Using Oncomine™ Lung Cell-Free Total Nucleic Acid Research Assay
C. Xiang, R. Zhao, S. Ma, L. Guo, Y. Han; CN

18:40 - 18:40 470P - Clinical and Pathological Characteristics and Survival Analysis of NSCLC
Patients with Skip Metastasis in Stage pN2/III
L. Zhang, CN

18:40 - 18:40 471P - Effect of second-line ramucirumab in East Asian patients with refractory
and aggressive disease: Subgroup analysis from REVEL and JVCG trials in non-
small cell lung cancer

K. Yoh1, K. Nakagawa1, G.-C. Chang2, Y. Hosomi1, T.-C. Hsia2, T. Tamura1, R. Cheng2, R.

Varea3, S. Enatsu1, A. Hayden Zimmermann4, J.-Y. Shih 2; 1JP, 2TW, 3ES, 4AL/US

18:40 - 18:40 472P - Plasma KRAS Mutation in Indonesian Lung Cancer Patients with Smoking
History, Treated with Chemotherapy

N. Masykura1, S. Andarini2, E. Syahruddin Spp K1, J. Zaini1, A. Hudoyo1, Y. Santoso1, A.

Mirandari3, A.R. Utomo1; 1ID, 2DKI Jakarta/ID, 3GB

18:40 - 18:40 473P - ASTRIS global real world study of osimertinib in patients (pts) with EGFR
T790M non-small cell lung cancer (NSCLC): subpopulation analyses by poor
performance status (PS), elderly, uncommon EGFR mutations

M. Provencio1, P. Cheema2, J. Vansteenkiste3, B.C. Cho4, C. Zhou5, J. Yu5, C. Martin6, K.

Park4, Y. He5, Y. Hu5, D. Vicente1, M. Miranda7, J. Rigas8, F. de Marinis9; 1ES, 2CA, 3BE,
4KR, 5CN, 6AR, 7GB, 8MD/US, 9IT

Last update: 09-11-2018 [Link]pm

18:40 - 18:40 474P - Afatinib in chemotherapy pre-treated EGFR mutation-positive NSCLC

S. Thongprasert1, S. Geater1, D. Clement2, A. Abdelaziz3, J. Reyes-Igama4, D. Jovanovic5,

A. Alexandru2, M. Schenker2, V. Sriuranpong1, P. Serwatowski6, S. Suresh7, A. Cseh8, R.
Gaafar3; 1TH, 2RO, 3EG, 4PH, 5RS, 6PL, 7SG, 8AT

18:40 - 18:40 475P - Radiotherapy With Continued EGFR-TKIs for Oligoprogressive Disease in
Non-Small Cell Lung Cancer: A Real-World Study

F. Wu1, S. Wu2, H. Hu2; 1Hunan/CN, 2CN

18:40 - 18:40 476P - Clinicopathological Features of ALK Protein in 9889 Non-small-cell Lung
Cancer Specimens and Genomic Rearrangement Identified by Capture-based
Next-generation Sequencing: a Chinese Retrospective Analysis
R. Zhao, J. Zhang, Y. Han, J. Shao, L. Zhu, C. Xiang, Q. Zhang, H. Teng, G. Qin, L. Zhao,
M. Ye, J. Zhao, W. Ding; CN

18:40 - 18:40 477P - Meta-analysis comparing incidence of Grade 3/4 neutropenia with ALK
inhibitors and chemotherapy, in patients with NSCLC

A. Krendyukov1, R. Arani2, N. Mathieson1, B. Rapoport3; 1DE, 2NJ/US, 3ZA

18:40 - 18:40 478P - A Large-scale Retrospective Study on ROS1 Fusion in Lung Carcinoma in
Chinese Population.
Q. Zhang, Y. Han, J. Zhang, J. Shao, L. Zhu, R. Zhao; CN

18:40 - 18:40 479P - Bevacizumab-Induced Radiosenitzation in Small Cell Lung Cancer

J. Bonner1, H. Trummell2; 1US, 2AL/US

18:40 - 18:40 480P - Tracheal adenoid cystic carcinoma: A systematic review and Meta-analysis
S. Mallick, P. Giridhar, G. Rath; IN

18:40 - 18:40 481P - The effectiveness of CRT combined with esophagectomy for cT4b
esophageal SCC
S. Hamasu, D. Manaka; JP

18:40 - 18:40 482P - treatment experience of thymoma & thymic carcinoma in teritiary cancer
institute in india

V. Tirumala1, M. Suresh Babu1, K. Govind Babu1, D. Lokanatha1, L. Jacob1, K.N. Lokesh2,

A. Rudresha2, L. Rajeev1, S. Saldanha2, G. Giri1; 1IN, 2Karnatka/IN

18:40 - 18:40 YO37 - The usefulness of radiotherapy for intubated patients with squamous cell
carcinoma of the lung.
S. Hiraoka, K. Ogura, Y. Kosaka, T. Imagumbai, T. Hattori, T. Ogata, M. Kokubo; JP

18:40 - 18:40 Thoracic tumours, metastatic

Last update: 09-11-2018 [Link]pm

18:40 - 18:40 494P - Hippo-YAP Pathway Mediated Resistance to Crizotinib in ROS1-Positive
Lung Cancer
P. Sun, H. Gao; CN

18:40 - 18:40 495P - Serum EGFR1 and EGFR2 expression in Non Small Cell Lung Cancer
patients.
M.M.A. Beg, IN

18:40 - 18:40 496P - Clinical application of plasma mitochondrial DNA content in lung cancer
patients
L. Zhang, CN

18:40 - 18:40 497P - Neutrophil Extracellular Traps Promote Lung Cancer Invasion and
Migration In Response to Severe Infection
L. Zhang, CN

18:40 - 18:40 498P - Retrospective evaluation of PD-L1 Expression in Tumor Tissue of Patients
with Lung Carcinoma and Correlation with clinical and demographical data from
a tertiary care institute of northern India.
K. Domadia, U. Batra, P. Jain, M. Sharma, S. Gupta, S. Bothra, S. Pasricha, K. Chaudhari,
G. Vishwakarma; IN

18:40 - 18:40 499P - Mutation status and targeted therapeutic efficacy of advanced non-small
cell lung cancer: A real-world study of NSCLC in China (preCAPTRA-LUNG)
H. Liang, X. Song, Y. Zhang, S. Zhang, F. li, J. Fang, J. li, L. Liang, L. Nie, K. Ma, L. Zhang,
X. Wang, W. Zhong, J. Zhao, Y. Xu, M. Chen, M. Wang; CN

18:40 - 18:40 500P - Efficacy of Icotinib in Advanced Lung Squamous Cell Carcinoma
S. Liang, M. Wang, Y. Xu, F. Tan, L. Ding, Y. Ma; CN

18:40 - 18:40 501P - Phase Ⅱ study of Nedaplatin plus Amrubicin in patients with untreated,
advanced or relapsed Squamous cell lung cancer
T. Suyama, H. Taniguchi, T. Ikeda, H. Yamaguchi, T. Kitazaki, H. Soda, K. Nakatomi, A.
Kinosita, M. Fukuda, H. Mukae; JP

18:40 - 18:40 502P - Apatinib plus S-1 as Second-Line or Laterline Treatment for Advanced
Squamous Cell Lung Carcinoma

Q. Shi1, L. Xia1, J. Zhou1, Z. Wang1, L. Sheng1, G. Wang1, L. Wang1, X. Cheng1, F. Wang1,

F. Kong2, F. Zhao1, X. Li1, B. Ye1, L. Mei1, Y. Liu1, L. Pan1, J. Xie1, G. Cheng1, X. Li1; 1CN,
2CX

18:40 - 18:40 503P - Clinical experiences of cytotoxic chemotherapy in patients with lung
cancer complicated by interstitial pneumonia who were treated with pirfenidone
simultaneously: A retrospective observational study in single institution
Y. Yano, K. Nishida, M. Ishijima, T. Uenami, Y. Akazawa, T. Yamaguchi, M. Mori; JP

Last update: 09-11-2018 [Link]pm

18:40 - 18:40 504P - Association of Systemic Inflammation With Survival in EGFR wild-type
lung cancer
X. Chen, L. Zhang, X. Liu; CN

18:40 - 18:40 505P - Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced
Non-small Cell Lung Cancer (NSCLC) (NCT02780778)
Z. Pan, C. Wang, G. Xie, D. Liu, Z. Yan, Y. Li, Z. Jiang, B. Wang, L. Li; CN

18:40 - 18:40 506P - Efficacy of local therapy for patients with oligometastatic non-small cell
lung cancer
Y. Sato, D. Fujimoto, K. Hosoya, H. Kawachi, H. Hamakawa, Y. Takahashi, M. Kokubo, S.
Hara, K. Tomii; JP

18:40 - 18:40 507P - Investigating Tumour Evolution in a Single Patient with Disseminated
Cancer
T. Robb, C. Blenkiron, P. Tsai, K. Parker, A. Drummond, M. Black, A. Gavryushkin, B.
Woodhouse, P. Houseman, E. Coats, P. Shields, S. Fitzgerald, D. Wright, R. Tse, N.
Kramer, C. Barker, Y. Triggs, S. Stables, B. Lawrence, C. Print; NZ

18:40 - 18:40 508P - Oncogenic driver mutation analysis in lung adenocarcinoma: a single
center study in India

S. Kulkarni1, A. Rauthan1, P. Patil1, T. Sood1, S. Somashekhar1, S. Zaveri2; 1IN,

2Karnataka/IN

18:40 - 18:40 509P - Treatment (Tx) patterns in patients (pts) with lung cancer starting 1st or
2nd generation (1G/2G) EGFR-TKI: a US insurance claims database analysis

J. Gray1, B. Thakrar2, P. Sun2, S. Maclachlan2, N. Chehab3, D. Potter2; 1FL/US, 2GB, 3US

18:40 - 18:40 510P - Characteristics and outcome of small cell lung cancer patients (SCLC)
transformed from adenocarcinoma after tyrosine kinase inhibitors treatment
B. Zhang, J. Xu, S. Wang, Y. Zhang, J. Qian, R. Qiao, J. Lu, L. Zhang, Y. Zhao, B. Han; CN

18:40 - 18:40 511P - AURA17 study of osimertinib in Asia-Pacific patients (pts) with EGFR
T790M-positive advanced non-small cell lung cancer (NSCLC): updated PhII
results including overall survival (OS)

C. Zhou1, M. Wang1, Y. Cheng2, Y. Chen3, Y. Zhao1, Y.-K. Shi1, M.-J. Ahn4, Y. Lu5, M. Shi1,
J.-Y. Han 4, S.-W. Kim 4, H.-L. Zhang1, G. Chen1, H. Li1, J. Wang1, Y.-L. Wu1; 1CN, 2Jilin/CN,
3Hubei/CN, 4KR, 5Sichuan/CN

18:40 - 18:40 512P - Osimertinib in advanced or metastatic non-small cell lung cancer patients
with EGFR T790M mutation after treatment with EGFR-TKI: interim analysis of
China cohort from the single-arm, open-label, international, multi-center real-
world ASTRIS study
Q. Zhou, H. Zhang, L. Jiang, Y. Shi, Y. Chen, J. Yu, C. Zhou, Y. He, Y. Hu, Z.-A. Liang, Y.
Pan, W. Zhuo, Y. Song, G. Wu, G. Chen, Y. Lu, Y. Cheng, S. Lu, J. Wang, Y. Wu; CN

Last update: 09-11-2018 [Link]pm

18:40 - 18:40 513P - Preventing and treating brain metastases with three first-line EGFR-
tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced
non-small cell lung cancer
P.-L. Su, Y.-L. Wu, W.-Y. Chang, W.-C. Su, S.-C. Yang, C.-C. Lin; TW

18:40 - 18:40 514P - Co-occurring Alterations in Driver Genes Impact on EGFR-Targeted

Therapy Among Patients With EGFR-Mutant Advanced Non–Small Cell Lung
Cancer
C. Lu, J. Kang, H.-J. Chen, H.-Y. Tu, Q. Zhou, J.-Y. Ye, Y.-L. Wu, J.-J. Yang; CN

18:40 - 18:40 515P - Tepotinib + gefitinib (TEP+GEF) in MET+/epidermal growth factor

receptor (EGFR)-mutant non-small lung cancer (NSCLC): phase 2 data

Y.-L. Wu1, J. Zhou2, S. Lu2, Y. Zhang3, J. Zhao2, H. Pan2, Y.-M. Chen4, C.-F. Chian5, R.
Bruns6, A. Johne6, J. Scheele6, Y. Cheng7; 1Guangdong/CN, 2CN, 3Zhejiang/CN, 4TW, 5,
6DE, 7Jilin/CN

18:40 - 18:40 516P - Phase II Trial of Afatinib in Elderly Patients over 75 Years of Age with
EGFR mutation positive NSCLC
Y. Nakahara, S. Oizumi, H. Mizugaki, Y. Fujita, T. Harada, T. Takashina, R. Ko, K.
Watanabe, T. Hotta, H. Minemura, S. Saeki, S. Yagishita, A. Hamada; JP

18:40 - 18:40 517P - A real world study of osimertinib: ASTRIS 2nd DCO Korean subgroup
analysis

J.-S. Lee1, B.C. Cho2, D.-W. Kim 2, K. Park2, J.H. Kang2, S.S. Yoo2, S.Y. Lee2, C.H. Kim2,
S.H. Jang2, Y.C. Kim2, H.-K. Yoon2, S.-W. Kim 2; 1Gyeonggi-do/KR, 2KR

18:40 - 18:40 518P - Outcomes of EGFR-TKIs for patients with non-small cell lung cancer
harboring EGFR mutations with poor performance status
K. Hashimoto, Y. Okuma, T. Hakozaki, K. Watanabe, Y. Hosomi; JP

18:40 - 18:40 519P - Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) -
Tyrosine Kinase Inhibitors (TKI) in Elderly Patients With EGFR Mutation-
Positive Non-Small Cell Lung Cancer (NSCLC)
Y. Takeyasu, Y. Goto, R. Morita, J. Sato, S. Murakami, H. Horinouchi, Y. Fujiwara, S.
Kanda, N. Yamamoto, Y. Ohe; JP

18:40 - 18:40 520P - Brain surgery for epidermal growth factor receptor-mutant non-small-cell
lung cancer with brain metastases
H.H. Lee, M.-Y. Huang; TW

18:40 - 18:40 521P - Real World Data of EGFR minor mutated NSCLC treated with EGFR-TKI:
Comparative analysis including compound mutation and de novo T790M
mutation.

K. Tanaka1, N. Inui1, K. Asada1, T. Abe1, O. Hataji1, S. Hayai1, K. Ito1, K. Imaizumi1, T.

Kimura2, A. Kubo1, E. Kunii1, K. Murotani1, M. Okuno1, Y. Oya1, J. Shindoh1, H.
Taniguchi1, T. Tsuda1, T. Yamaguchi1, T. Hida1, T. Suda1; 1JP, 2Aichi Prefecture/JP

Last update: 09-11-2018 [Link]pm

18:40 - 18:40 523P - Real World Data on Epidermal Growth Factor Receptor (EGFR) Tyrosine
Kinase Inhibitors (TKI) use in Advanced/Metastatic Non-Small Cell Lung Cancer
(NSCLC) with EGFR mutations in Singapore
B. Chua, E.H. Tan, D. Lim, M.-K. Ang, D.S.W. Tan, Q.-S. Ng, R. Kanesvaran, A. Jain, W.-L.
Tan, C.K. Toh, T. Rajasekaran; SG

18:40 - 18:40 524P - EGFR mutation in Middle East and Africa is it really lower than in asiatic
NSCLC ?
Z. Benbrahim, H. Bedoudou, N. Mellas; MA

18:40 - 18:40 525P - Management of Brain Metastases in Epidermal Growth Factor Receptor-
Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional
Analysis
C.H. Chen, M.-Y. Huang, I.-W. Chong; TW

18:40 - 18:40 526P - Correlation between the response to critzotinib and concomitant genetic
alterations in advanced lung cancer patients with ALK rearrangement
X. Liu, M. Chen, Y. Xu, J. Zhao, W. Zhong, M. Wang; CN

18:40 - 18:40 527P - Cost-effectiveness of ceritinib in previously untreated ALK-positive

advanced non-small cell lung cancer in Hong Kong

H. Loong1, C. Wong1, L. Leung1, C.P.K. Chan1, A. Chang1, M. Gibbs2; 1HK, 2AE

18:40 - 18:40 528P - The impact of continuing ALK inhibitors beyond initial disease
progression on clinical outcome in patients with advanced ALK-positive non-
small cell lung cancer: Results of a multicenter retrospective analysis
S. Sakata, S. Saeki, Y. Sakata, K. Kawamura, K. Ichikado, M. Inaba, S. Ushijima, K.
Imamura, K. Iyonaga, T. Kumabe, R. Fujita, K. Kashiwabara, S. Fujii, T. Komatsu, O.
Sakamoto, H. Okabayashi, K. Saruwatari, Y. Tomita, T. Sakagami; JP

18:40 - 18:40 529P - The management and outcome of crizotinib resistant patients:
comparison of patients who received ceritinib to those treated with
chemotherapy or other oral TKI.
S. Majumdar, A. Agarwal, V. Noronha, A. Joshi, V. Patil, R. Kumar, K. Prabhash; IN

18:40 - 18:40 530P - Comparative efficacy of first-line ceritinib and alectinib in advanced
ALK+ NSCLC: a cross-study indirect comparison

C.P.K. Chan1, J. Li2, S. Knoll3, W. Tang4, I. Bocharova2, J. Signorovitch2; 1HK, 2MA/US,

3NJ/US, 4US

18:40 - 18:40 531P - Clinical Experience in Patients With Advanced ALK-Rearranged Non–
Small-Cell Lung Cancer and Brain Metastases in China
Y. Han, K. Ren, H. Zhang, L. Sun, X. Ren; CN

18:40 - 18:40 532P - KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem)
and platinum vs placebo plus pem and platinum for untreated, metastatic,
nonsquamous NSCLC: does choice of platinum affect outcomes?

Last update: 09-11-2018 [Link]pm

 D. Rodriguez Abreu1, M. Garassino2, E. Esteban3, G. Speranza4, E. Felip3, M. Domine3,
M. Hochmair5, S. Powell6, S. Cheng7, H. Bischoff8, N. Peled9, R. Hui10, M. Reck8, E.
Garon11, M. Boyer12, F. Grossi2, R. Jennens13, J. Yang14, M.C. Pietanza14, S. Gadgeel15;
1Canary Islands/ES, 2IT, 3ES, 4AB/CA, 5AT, 6SD/US, 7ON/CA, 8DE, 9IL, 10NSW/AU,
11CA/US, 12ACT/AU, 13VIC/AU, 14NJ/US, 15MI/US

18:40 - 18:40 533P - PD-(L)1 Inhibitors VS. Chemotherapy VS. Their Combination in Front-line
Treatment of NSCLC
H. Liang, D. Chen, Z. Liu, J. He, W. Liang; CN

18:40 - 18:40 534P - Pre-existing antibody profiles related to immune-related adverse events
in advanced non-small-cell lung cancer patients treated with anti PD-1 antibody
Y. Toi, S. Sugawara, J. Sugisaka, H. Ono, M. Asou, K. Tsurumi, K. Suzuki, H. Shimizu, Y.
Domeki, T. Aiba, S. Kawana, R. Saito, K. Terayama, Y. Kawashima, A. Nakamura, S.
Yamanda, Y. Kimura, Y. Honda; JP

18:40 - 18:40 535P - Association of immune-related pneumonitis with the phenotypic

appearance of concurrent ILD in patients treated with anti-PD-1 antibody
R. Shibaki, S. Murakami, Y. Matsumoto, Y. Goto, S. Kanda, H. Horinouchi, Y. Fujiwara, N.
Yamamoto, Y. Ohe; JP

18:40 - 18:40 536P - Correlation of plasma exosomal microRNAs with the efficacy of
immunotherapy in EGFR/ALK wild type advanced NSCLC

P. Xiao1, R. Yu2, X. Wu3, Y. Shao2, Y.-L. Wu1, Q. Zhou1; 1CN, 2CA, 3ON/CA

18:40 - 18:40 537P - The financial toxicity of non-small lung cancer treatment: the
optimization of first and second-line therapy with immune check point inhibitors
J. Giuliani, A. Bonetti; IT

18:40 - 18:40 538P - Lung cancer vaccine – Experiences in Serbia

Z. Andric, RS

18:40 - 18:40 539P - Profiling of Immune related adverse events from nivolumab or
pembrolizumab monotherapy in advanced non-small-cell lung cancer in real
world.
M. Aso, S. Sugawara, Y. Toi, J. Sugisaka, H. Ono, K. Tsurumi, K. Suzuki, H. Shimizu, Y.
Domeki, T. Aiba, S. Kawana, R. Saito, K. Terayama, Y. Kawashima, A. Nakamura, S.
Yamanda, Y. Kimura, Y. Honda; JP

18:40 - 18:40 540P - Clinical Outcomes in Non–Small Cell Lung Cancer Patients with Ultra-
high Expression of Programmed Death Ligand-1 Treated with Pembrolizumab as
First-line Therapy: A Retrospective Multicenter Cohort Study
H. Kurebe, R. Edahiro, M. Kanazu, D. Fujimoto, M. Tamiya, A. Tamiya, H. Suzuki, K.
Hirano, T. Yokoyama, M. Morita, Y. Fukuda, J. Uchida, T. Makio; JP

18:40 - 18:40 541P - Gold fiducial tracking using Cyberknife in adrenal metastasis from Small
cell lung cancers
G. Lohith, B.S. Ajai Kumar; IN

Last update: 09-11-2018 [Link]pm

18:40 - 18:40 542P - Prophylactic cranial irradiation in patients with extensive-stage small-cell
lung cancer (ES-SCLC): an updated tertiary cancer centre experience
M. Naidoo, F. Lin, M. Jameson, K. Shelly, A. Srivastava; NZ

18:40 - 18:40 543P - Investigation and Analysis of Nutritional Status of Patients With Lung
Cancer
X. Chen, L. Zhang, X. Liu; CN

18:40 - 18:40 544P - Lung Cancer in Adolescent & Young Adults: Single Center Experience
from Eastern India
B. Biswas, D. Dabkara, S. Ganguly, J. Ghosh; IN

18:40 - 18:40 545TiP - Establishment of a prospective multicenter cohort for advanced non-
small cell lung cancer in China (CAPTRA-Lung study)
Y. Xu, L. Zhang, J. Fang, Z. Wang, J. li, L. Li, B. Ai, L. Nie, X. Mu, L. Liang, S. Zhang, Y.
Zhang, Y. Song, X. Song, Y. Wang, T. Xin, B. Jin, X. Wang, C. Ding, M. Wang; CN

18:40 - 18:40 546TiP - Tepotinib in non-small cell lung cancer (NSCLC) with MET-exon 14
skipping mutations (METex14+) and MET amplification (METamp); a phase 2
trial in progress

P. Paik1, H. Sakai2, R. Bruns3, J. Scheele3, J. Straub3, E. Felip4; 1NY/US, 2JP, 3DE, 4ES

18:40 - 18:40 YO38 - Concurrent nivolumab and radiotherapy in treatment of lung squamous
cell carcinoma

D.W. Lee1, G.F. Ho2; 1MY, 2Wilayah Persukutuan/MY

18:40 - 18:40 YO39 - Adenocarcinoma lung with sphenoidal metastasis

M. Behera1, L. Soy2, F. Ansari2, N. Panda2, L. Sarangi2; 1Delhi/IN, 2IN

18:40 - 18:40 YO40 - Osimertinib in the Treatment of Leptomeningeal Disease in T790M-

negative, EGFR-mutated NSCLC: A Case Report

L. Kasherman1, J. Chen2, H. Soudy1; 1AU, 2NSW/AU

18:40 - 18:40 YO41 - Hemodynamic instability caused by cardiac metastases of non-small cell
lung cancer- case studies
C.-I. Shen, B.-W. Hu, Y.-H. Wu, C.-H. Chiu, Y.-M. Chen, C.-L. Chiang; TW

18:40 - 18:40 YO43 - The long term survival of a 78 year old female diagnosed with Malignant
Epithelial Mesothelioma with peritoneal disease on Pembrolizumab plus
Pemetrexed and Carboplatin: a case report
K.R. Oracion, G. Cornelio; PH

18:40 - 18:40 General interest

Last update: 09-11-2018 [Link]pm

18:40 - 18:40 548P - Can we improve cost effectiveness of oncology clinical trials workflow? A
prospective RECIST 1.1 study
H. Beaumont, A. Iannessi, C. Klifa, S. Patriti; FR

18:40 - 18:40 549P - Clinical association of antibiotics in immune check point inhibitors for
advanced cancer treatment
H. Kim, I.-H. Kim; KR

18:40 - 18:40 550P - Effect of Reasons for Screen Failure (RFSF) on Standard of Care in
Cancer Patients Screened for Clinical Trials

C. Tiu1, Z. Loh1, C. Gan2, J. Hakanson2, H. Gan2, T. John2, E. Hawkes1; 1AU, 2VIC/AU

18:40 - 18:40 551P - The reporting quality of prediction models in oncology journals: a
systematic review
T. Takemura, Y. Kataoka, Y. Uneno, T. Otoshi, H. Matsumoto, Y. Tsutsumi, Y. Tsujimoto, M.
Yuasa, T. Yoshioka, H. Wada; JP

18:40 - 18:40 552P - Survival patterns of pediatric neuroblastoma at different primary sites
A. Diab, I. Uthman; EG

18:40 - 18:40 553P - Efficacy of chemotherapy for elderly patients with extrapulmonary
neuroendocrine carcinomas
C. Funasaka, O. Yasushi, Y. Kanemasa, T. Shimoyama; JP

18:40 - 18:40 554P - Rational Combinations of Active and Passive Immunotherapy Mobilize
Immune and clinical responses in terminal cancers

R. Ruan1, Q.Z. Ruan2; 1CN, 2AL/US

18:40 - 18:40 555P - Clinical Features and Outcomes of Carcinoma of Unknown Primary Site: A
single center experience

S. Gohar1, S. Al-Hassanin2, S. Soliman2; 1Menoufia Governorate/EG, 2EG

18:40 - 18:40 556P - Surgery for Nonhepatic malignancy in Cirrhotic Patients; 5 year Single
Center Experience in India
S. Galodha, S. Bains; IN

18:40 - 18:40 557P - The National Liver Disease Biobank: A Good Resource for Liver and
Associated Cancer Research

B. Yadav1, C. Bihari2; 1Rohini/IN, 2IN

Last update: 09-11-2018 [Link]pm

 25-11-2018
08:30 - 09:15 Type: Young Oncologist session Exhibition area
Title: Vesalius
09:15 - 10:00 Type: Challenge Your Expert session Hall
Title: First line treatment in a fit advanced NSCLC patient with PD-L1 404
expression of 60%
Chair: Shun Lu, CN

09:15 - 09:30 First line treatment in a fit advanced NSCLC patient with PD-L1 expression of
60%
S. Novello, IT

09:30 - 10:00 Discussion led by

S. Lu, CN

Last update: 09-11-2018 [Link]pm

09:15 - 11:15 Type: Special Session Hall 407
Title: Working together: Illustration of combined modalites
Chair: Françoise Mornex, FR; Suresh Senan, NL

09:15 - 09:30 Early stage breast cancer: Case presentation 1: What is the recommended
surgical approach?
C.W. Chan, SG

09:30 - 09:45 Early stage breast cancer: Is there a place for radiation after surgery?
F. Lim, SG

09:45 - 10:00 Lung SABR: Case presentation: Imaging and delivery techniques

10:00 - 10:15 Lung SABR: Post-SABR radiological evaluation: IASLC paper

S. Senan, NL

10:15 - 10:30 Castration-resistant prostate cancer: Case presentation: Indications for SABR,
treatment planning and delivery techniques
M.L.K. Chua, SG

10:30 - 10:45 Castration-resistant prostate cancer: Is there a need for combined medical
treatment?
R. Kanesvaran, SG

10:45 - 11:00 Esophageal and EG junction: How can the Medical Oncologist contribute?
F. Lordick, DE

11:00 - 11:15 Esophageal and EG junction: Clinical case presentation: Esophageal cancer
treatment strategy, imaging and radiation delivery techniques
T. Leong, AU

Last update: 09-11-2018 [Link]pm

09:15 - 10:15 Type: ESMO Colloquium Room
Title: ESMO COLLOQUIUM - Metastatic gastric and oeso-gastric 324
junction cancers

09:15 - 09:20 Introduction

K. Muro, Aichi/JP

09:20 - 09:30 1st line treatment options for patients without a biomarker driven option
L.-T. Chen, TW

09:30 - 09:40 Biomarker driven option in 1st line treatment options

M. Ng, SG

09:40 - 09:50 2nd and later lines of treatment: What are the options?
F. Lordick, DE

09:50 - 10:00 Is there some hope from immunotherapy in metastatic gastric cancer?
Y.-J. Bang, KR

10:00 - 10:10 What’s new in the guidelines?

K. Muro, Aichi/JP

10:10 - 10:15 Conclusions

F. Lordick, DE

09:30 - 11:00 Type: Educational session Hall 405

Title: Challenges in head and neck oncology
Chair: Christophe Le Tourneau, FR

09:30 - 09:55 Hyperprogression following immunotherapy: Myth or reality?

C. Le Tourneau, FR

09:55 - 10:20 The role of plasma EBV DNA in management of nasopharyngeal cancer
A. Chan, HK

10:20 - 10:45 Surgery for low-risk HPV positive head and neck cancer
C. Simon, CH

10:45 - 11:05 Discussion

Last update: 09-11-2018 [Link]pm

09:30 - 10:20 Type: Mini Oral session Room 311
Title: Mini Oral - Melanoma and Sarcoma
Chair: Rick L. Haas, NL; Caroline Robert, FR

09:30 - 09:35 345O - The survivorship experience of patients with metastatic melanoma on
long-term immune checkpoint inhibitors

J. Lai-Kwon1, C. Khoo2, S. Lo3, D. Milne1, M. Mohamed1, J. Raleigh1, K. Smith1, K. Lisy1,

S. Sandhu1, M. Jefford1; 1VIC/AU, 2AU, 3ACT/AU

09:35 - 09:40 346O - PD-L1 expression and clinical outcome after nivolumab monotherapy in
various subtypes of melanoma: a single-institutional retrospective study
K. Namikawa, T. Mori, Y. Muto, S. jinnai, Y. Kage, E. Nakano, A. Takahashi, N. Yamazaki;
JP

09:40 - 09:45 347O - A pilot study of intrahepatic Yttrium-90 microsphere radioembolisation in

combination with intravenous cisplatin for uveal melanoma liver-only metastases

S. Arulananda1, S. Parakh1, M. Goodwin2, M. Andrews2, J. Cebon1; 1VIC/AU, 2ACT/AU

09:45 - 09:55 Discussion led by moderators

09:55 - 10:00 406O - Multimodality, aggressive and sustainable care in metastatic

osteosarcoma: A tertiary care cancer experience from India
J. Bajpai, V. Simha, A. Chandrashekharan, J. Ghosh, B. Rekhi, T. Vora, S. Banavali, S.
Gupta; IN

10:00 - 10:05 407O - Clinicopathological features of wild-type GISTs based on multiple-gene

panel analysis
T. Nishida, Y. Naito, T. Takahashi, Y. Honma, T. Saito, H. Ichikawa, S. Hirota; JP

10:05 - 10:10 408O - Can fairer sex, febrile neutropenia & compliance influence surviving
probability in non-metastatic osteosarcoma: Experience over two decades from
India
J. Bajpai, V. Simha, A. Chandrashekharan, J. Ghosh, B. Rekhi, T. Vora, S. Banavali, S.
Gupta; IN

10:10 - 10:20 Discussion led by moderators

10:15 - 11:15 Type: Mini Oral session Hall 404

Title: Mini Oral - Thoracic cancers
Chair: Silvia Novello, IT; Masahiro Tsuboi, JP; Yasushi Yatabe, JP

10:15 - 10:20 453O - Quality of life in the CHISEL randomized trial of stereotactic ablative
radiotherapy (SABR) versus standard radiotherapy for stage I non-small cell
lung cancer (Trans Tasman Radiation Oncology Group 09.02).

Last update: 09-11-2018 [Link]pm

 D. Ball1, G.T. Mai2, S. Vinod3, S. Babington4, J. Ruben1, T. Kron1, B. Chesson1, A.
Herschtal1, M. Vanevski1, A. Rezo5, C. Elder4, M. Skala5, A. Wirth1, G. Wheeler1, A. Lim1,
M. Shaw1, P. Schofield1, L. Irving1, B. Solomon1; 1VIC/AU, 2QLD/AU, 3NSW/AU, 4NZ,
5ACT/AU

10:20 - 10:25 466O - ASTRIS real world study of osimertinib in patients (pts) with EGFR
T790M NSCLC: efficacy analysis by tissue or plasma T790M test

H. Freitas1, K. Park2, D.-W. Kim 2, M. Tiseo3, M. Hochmair4, G.-C. Chang5, Y.-K. Shi6, T.
Moran7, Y. Chen5, J. Laskin8, B. Solomon9, M. Miranda10, J. Rigas11, P. Cheema12, S.-W.
Kim2; 1SP/BR, 2KR, 3IT, 4AT, 5TW, 6CN, 7ES, 8British Columbia/CA, 9VIC/AU, 10GB,
11MD/US, 12CA

10:25 - 10:30 489O - Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in
patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-
progression outcomes

D. Planchard1, M. Boyer2, J.-S. Lee3, A. Dechaphunkul4, P. Cheema5, T. Takahashi6, A.

Todd7, A. McKeown7, Y. Rukazenkov7, Y. Ohe6; 1FR, 2ACT/AU, 3KR, 4TH, 5AB/CA, 6JP, 7GB

10:30 - 10:35 490O - Primary resistance mechanisms revealed in Asian TKI-sensitizing EGFR
mutations NSCLC patient populations
Q.-X. Zhang, C. Xu, W.-X. Wang, W. Zhuang, Z.-B. Song, Y.-C. Zhu, Y.-P. Chen, G. Chen, M.-
Y. Fang, T.-F. Lv, Y. Song; CN

10:35 - 10:40 491O - Carboplatin-paclitaxel/nab-paclitaxel with or without pembrolizumab in

first-line metastatic squamous NSCLC: results from the KEYNOTE-407 East Asia
subgroup

T. Kato1, S. Lee2, Y. Cheng3, G.-W. Lee 2, K. Lee2, A. Luft4, J. Trigo5, R. Hui6, B. Balint7, A.
Robinson8, I. Okamoto1, G. Gerstner9, L. Paz-Ares5, X. Li10, Y. Shentu10, B. Piperdi10, A.
Tafreshi11; 1JP, 2KR, 3CN, 4RU, 5ES, 6ACT/AU, 7HU, 8ON/CA, 9IL/US, 10NJ/US, 11AU

10:40 - 10:45 492O - Osimertinib for patients (pts) with leptomeningeal metastases (LM)
associated with EGFRm advanced NSCLC

M.-J. Ahn1, C.-H. Chiu2, Y. Cheng3, J.-Y. Han 1, S.B. Goldberg4, A. Greystoke5, J.
Crawford4, Y. Zhao6, X. Huang5, M. Johnson5, K. Vishwanathan4, A. Mendoza-Naranjo5,
T. Mok6; 1KR, 2TW, 3Jilin/CN, 4AL/US, 5GB, 6CN

10:45 - 10:50 493O - Tepotinib in patients with advanced non-small lung cancer (NSCLC) and
MET exon 14-skipping mutations: phase 2 data

H. Sakai1, E. Felip2, A. Cortot3, R. Veillon3, F. Griesinger4, J. Patel5, L. Horn6, J.

Mazieres3, J. De Castro Carpeno2, M. Morise7, T. Sakamoto1, R. Bruns4, J. Scheele4, J.
Straub4, P. Paik8; 1JP, 2ES, 3FR, 4DE, 5IL/US, 6TN/US, 7Aichi/JP, 8NY/US

10:50 - 11:10 Discusion led by moderators

Last update: 09-11-2018 [Link]pm

10:30 - 11:15 Type: Challenge Your Expert session Room
Title: Immunotherapy vs. targeted therapy in first-line treatment of 324
mutation positive metastatic melanomas: How does one choose?
Chair: Caroline Robert, FR

10:30 - 10:45 Immunotherapy vs. targeted therapy in first-line treatment of mutation positive
metastatic melanomas: How does one choose?
J. Guo, CN

10:45 - 11:15 Discussion led by

C. Robert, FR

10:30 - 11:15 Type: Challenge Your Expert session Room 311

Title: Molecular biology and treatment of HCC
Chair: Takuji Okusaka, JP

10:30 - 10:45 Molecular biology and treatment of HCC

L.-T. Chen, TW

10:45 - 11:15 Discussion led by

11:30 - 12:30 Type: Industry Satellite Symposium Hall 405

Title: Industry Satellite Symposium
11:30 - 12:30 Type: Industry Satellite Symposium Hall 404
Title: Industry Satellite Symposium
11:30 - 12:30 Type: Industry Satellite Symposium Hall 407
Title: Industry Satellite Symposium
11:30 - 12:30 Type: Industry Satellite Symposium Room 311
Title: Industry Satellite Symposium

Last update: 09-11-2018 [Link]pm

12:45 - 14:15 Type: Proffered Paper session Hall 405
Title: Proffered Paper session 3

12:45 - 12:57 148O - Assessment of Tumor Response, Alpha-Fetoprotein (AFP) Response, and
Time to Progression (TTP) in the Phase 3 CELESTIAL Trial of Cabozantinib (C)
versus Placebo (P) in Advanced Hepatocellular Carcinoma (HCC)

T. Yau1, P. Merle2, L. Rimassa3, B.-Y. Ryoo 4, I. Cicin5, W. Harris6, E. Banu7, D. Sarker8, B.

Tan9, H. van Vlierberghe10, S. Sen11, C. Love11, A.-L. Cheng12, T. Meyer8, R. Kelley11, G.
Abou-Alfa13; 1CN, 2FR, 3(MI)/IT, 4KR, 5, 6WA/US, 7RO, 8GB, 9MO/US, 10BE, 11CA/US,
12TW, 13NY/US

12:57 - 13:09 152O - Efficacy and safety of the Met inhibitor tepotinib in patients (pts) with
advanced Met+ hepatocellular carcinoma (HCC) previously treated with
sorafenib

T. Decaens1, C. Barone2, E. Assenat1, M. Wermke3, A. Fasolo2, P. Merle1, J.-F. Blanc1, V.

Grando1, R. Bruns3, J. Straub3, C. Zhao4, S. Faivre1; 1FR, 2IT, 3DE, 4MA/US

13:09 - 13:19 Invited discussant

S. Chan, HK

13:19 - 13:31 149O - Efficacy and safety of ramucirumab (RAM) in Asian and non-Asian
patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-
fetoprotein (AFP): Subgroup analysis from two randomized studies.

Y.-K. Kang1, M. Kudo2, H.-Y. Lim 1, C.-H. Hsu3, A. Vogel4, G. Brandi5, R. Cheng3, I.
Carton6, P. Abada7, Y. Hsu7, A. Zhu8, C.-J. Yen3; 1KR, 2JP, 3TW, 4DE, 5IT, 6BE, 7AL/US, 8US

13:31 - 13:43 150O - Atezolizumab + bevacizumab in hepatocellular carcinoma (HCC): safety

and clinical activity results from a Phase Ib study

K.-H. Lee1, C.-H. Hsu2, M. Lee3, B.-Y. Ryoo 1, W. Verret4, A.R. He5, A. Kwan6, B. Liu6, K.
Iizuka6, S. Stein7; 1KR, 2TW, 3NC/US, 4AL/US, 5DC/US, 6CA/US, 7CT/US

13:43 - 13:55 151O - Practice Patterns, Radiologic Tumor Response, and Deterioration of Liver
Function after Transarterial Chemoembolization (TACE): Final Analysis of
OPTIMIS in Korea and Other Regions

J. Heo1, A.-L. Cheng2, J.-L. Raoul3, M. Peck-Radosavljevic4, M. Kudo5, K. Nakajima6, I.

Bayh7, S.-M. Lin2, H.C. Lee1; 1KR, 2TW, 3FR, 4AT, 5JP, 6NJ/US, 7DE

13:55 - 14:05 Invited discussant

Last update: 09-11-2018 [Link]pm

12:45 - 14:15 Type: Joint Symposium Hall 404
Title: ESMO-AACR: ALK gene fusions: From discovery to clinical use
Chair: Tony S.K. Mok, HK

12:45 - 12:50 Introduction

T.S.K. Mok, HK

12:50 - 13:10 Talk on basic science discovery of ALK/EML4 translocation

T. Bivona, US

13:10 - 13:30 Incidence and distribution of ALK translocation in human tumours and pre-
clinical evidence

13:30 - 13:50 Early-phase clinical development and identification of second and third
generation of ALK inhibitors
B. Solomon, VIC/AU

13:50 - 14:10 Present indication and therapeutic strategies of ALK inhibitors in lung cancer
T.S.K. Mok, HK

14:10 - 14:15 Conclusions

12:45 - 14:15 Type: Educational session Hall 407

Title: Advances in targeted therapy in gynaecological cancer
Chair: Keiichi Fujiwara, JP; Andres Maria Poveda Velasco, ES

12:45 - 13:10 Anti-angiogenic therapy in ovarian and endometrial cancer

D. Lorusso, IT

13:10 - 13:35 PARP inhibitors and synthetic lethality in ovarian cancer

E. Pujade-Lauraine, CEDEX 4/FR

13:35 - 14:00 Targeted therapy for treatment of cervical cancer

S. Gupta, IN

14:00 - 14:15 Discussion

Last update: 09-11-2018 [Link]pm

12:45 - 14:15 Type: Multidisciplinary tumour board Room 324
Title: Locally advanced nasopharyngeal carcinoma
Chair: Brigette Ma, HK; Zhang Li, CN; Melvin Lee Kiang Chua, SG; Mingyuan Chen, CN

12:45 - 12:55 Presentation of case/condition

B. Ma, HK

12:55 - 13:15 Timing of chemotherapy in nasopharyngeal cancer

Z. Li, Guangdong/CN

13:15 - 13:35 IMRT or proton therapy

M.L.K. Chua, SG

13:35 - 13:55 The role of surgery in the treatment of NPC

M. Chen, Guangdong/CN

13:55 - 14:15 General discussion

12:45 - 14:15 Type: Special Session Room

Title: Integrating BRCA testing into routine cancer care in Asia – how 311
can it be done?
Chair: Angela George, GB; Sook Yee Yoon, MY

12:45 - 12:50 Introduction

A. George, GB

12:50 - 13:10 Barriers to BRCA testing in Asia

T. Enomoto, JP

13:10 - 13:30 Mainstreaming cancer genetics – BRCA testing in oncology clinics

A. George, GB

13:30 - 13:50 Expanding BRCA testing through Malaysia – the MaGiC trial
S.Y. Yoon, MY

13:50 - 14:10 Overcoming distance – BRCA telephone counselling programmes

A. Trainer, AU

14:10 - 14:15 Conclusions

S.Y. Yoon, MY

Last update: 09-11-2018 [Link]pm

14:30 - 16:00 Type: Special Session Hall 405
Title: Beyond panel based mutation profiling
Chair: Miguel Quintela-Fandino, ES; Daniel Shao Weng Tan, SG

14:30 - 14:50 The maximal potential of precision medicine needs to go beyond genomic
sequencing
L. Siu, Ontario/CA

14:50 - 15:10 Emerging therapeutic opportunities in the non coding genome

D.S.W. Tan, SG

15:10 - 15:30 Unravelling resistance to multitargeted agents based on high-throughput

phosphoproteomics
M. Quintela-Fandino, ES

15:30 - 15:50 Utilizing mutational signatures to inform treatment decisions

H. Davies, GB

15:50 - 16:00 The evolving role of molecular tumour boards

14:30 - 16:00 Type: Multidisciplinary tumour board Hall 404

Title: Management of HER2 positive early breast cancer
Chair: Giuseppe Curigliano, IT; Fatima Cardoso, PT; Masakazu Toi, JP; Wonshik Han, KR

14:30 - 14:35 Presentation of case/condition

G. Curigliano, IT

14:35 - 14:55 Emerging strategies in neoadjuvant treatment of patients with HER2 early
breast cancer
F. Cardoso, PT

14:55 - 15:15 Adjuvant treatment of patient with HER2+ breast cancer following neo-adjuvant
chemo
M. Toi, JP

15:15 - 15:35 Optimal surgical intervention after neoadjuvant chemotherapy

W. Han, KR

15:35 - 16:00 General discussion

Last update: 09-11-2018 [Link]pm

14:30 - 16:00 Type: Special Session Hall
Title: ESMO-FACO Joint Symposium: Bridging clinical research and 407
practice between Europe and Asia
Chair: Fortunato Ciardiello, IT; Hideo Baba, JP

14:30 - 14:35 Introduction

F. Ciardiello, IT

14:35 - 14:55 Guidelines adaptation: Principles and achievements to date

G. Pentheroudakis, GR

14:55 - 15:15 The European-Asian contribution of practice-changing in adjuvant

chemotherapy of colon cancer: The IDEA study
C.-H. Koehne, DE

15:15 - 15:35 How may clinical research on gastric cancer in Asia contribute to European
management?
H. Baba, JP

15:35 - 15:55 The challenge of defining oligometastasis for breast cancer in Europe and Asia
Y.-H. Im, KR

15:55 - 16:00 Conclusions

H. Baba, JP

14:30 - 16:00 Type: Educational session Room 324

Title: Multidisciplinary management of retroperitoneal sarcomas
Chair: Axel Le Cesne, FR; Akira Kawai, JP

14:30 - 14:55 The role of surgery in retroperitoneal sarcomas

M. Fiore, IT

14:55 - 15:20 The role of radiotherapy in retroperitoneal sarcomas

R.L. Haas, NL

15:20 - 15:45 The role of systemic therapy in retroperitoneal sarcomas

H. Loong, HK

15:45 - 16:00 Discussion

Last update: 09-11-2018 [Link]pm

14:30 - 16:30 Type: Special Session Room
Title: Rare cancers: A call to advancing partnerships between Asia and 311
Europe
Chair: Paolo G. Casali, IT

14:30 - 14:35 Introduction

P.G. Casali, IT

14:35 - 14:50 What can we do on rare cancers: Lessons learned from “Rare Cancers Europe”,
10 years on
P.G. Casali, IT

14:50 - 15:05 Incidence of rare cancers: Results of an epidemiological comparison effort

between Asia and Europe
A. Trama, IT

15:05 - 15:20 Which cancers are really rare in Asia?

Y.-J. Won, KR

15:20 - 15:35 The epidemiological/biological enigma of nasopharyngeal carcinoma from a

European perspective
L. Licitra, IT

15:35 - 15:50 How to address the research questions on nasopharyngeal carcinoma: The case
for an Asian/European partnership
A. Chan, HK

15:50 - 16:05 A clinical-pathologic web Sarcoma Tumor Board between Asia and Europe
A.P. Dei Tos, IT

16:05 - 16:20 Discussion

16:20 - 16:30 Conclusions: Towards “Rare Cancers Asia”

R. Quek, SG

Last update: 09-11-2018 [Link]pm